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ABSTRACT
Acute kidney injury (AKI) is a common and 
dreaded complication to severe illness and 
major surgery, with major impact on mor-
bidity and mortality. The aim of this doc-
toral thesis was to increase the knowledge 
on renal pathophysiology and to explore 
potential interventions for treatment and 
prevention of AKI after cardiac surgery, 
liver transplantation and in early clinical 
septic shock.
Patients and methods: Patients were stud-
ied in the intensive care unit (ICU) imme-
diately after surgery, and in septic shock 
patients within 24 hours from admission 
to ICU. We studied the renal effects of a 
crystalloid (Ringers-acetate®) and a col-
loid (Venofundin®) fluid as plasma volume 
expanders after uncomplicated cardiac 
surgery (paper I, n=30), renal pathophysi-
ology and the renal effects of target mean 
arterial pressure (tMAP) after liver trans-
plantation (paper II n=12, and II, respec-
tively, n=10), and renal pathophysiology in 
early clinical septic shock (paper IV, n=8). 
Renal blood flow (RBF) and glomerular fil-
tration rate (GFR) were measured by renal 
vein thermodilution and renal extraction 
of 51Cr-EDTA, respectively. In paper IV, RBF 
was measured by infusion clearance for 
para-aminohippurate (PAH).
Results: RBF is increased by both crystal-
loid and colloid fluid when used as plasma 
volume expander after cardiac surgery, but 
due to hemodilution, neither of the fluids 
increases renal oxygen delivery (RDO2). 
The crystalloid-induced increase in GFR 
is associated with impaired renal oxygen-
ation, which is not seen with the colloid. 
After liver transplantation, vasodilation of 
the efferent arterioles causes a renal va-
sodilation and a fall in GFR. Renal oxygen 
consumption (RVO2) is considerably in-
creased early after liver transplantation, 
despite the lower GFR. The increased RBF 
seen after liver transplantation is not suf-
ficient to meet the increased RVO2, result-
ing in an impaired renal oxygenation. Ear-
ly after liver transplantation, a tMAP of 75 
mmHg, compared to 60 mmHg, improves 
RBF and GFR without impairing renal ox-
ygenation. In early clinical septic shock, 
there is a fall in GFR and RDO2 caused by a 
constriction of renal afferent arterioles, ac-
companied by a sodium reabsorption at a 
high oxygen cost, which together with the 
reduced RDO2 impairs renal oxygenation, 
causing renal tubular injury.
Conclusions: Treatment of hypovolemia 
with a bolus dose of crystalloid fluid im-
pairs renal oxygenation after uncomplicat-
ed cardiac surgery. In liver transplant re-
cipients, renal function is severely reduced 
and renal oxygenation is impaired due to a 
high RVO2 not matched by a proportional 
increase in RDO2.  In liver recipients, RBF 
and GFR are pressure-dependent due to 
the loss of renal autoregulation at a MAP 
< 75 mmHg. In early clinical septic shock, 
GFR and RDO2 are reduced because of re-
nal vasoconstriction, causing impaired re-
nal oxygenation and a tubular injury. 
Keywords: Acute kidney injury, glomeru-
lar filtration rate, renal oxygenation, liver 
transplantation, septic shock. 
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SAMMANFATTNING PÅ SVENSKA
Akut njursvikt drabbar upp till ca 65% av in-
tensivvårdskrävande patienter, med ökad 
sjuklighet och dödlighet som följd.  Död-
ligheten för IVA-patienter utan njursvikt 
är 8%, att jämföra med en dödlighet på upp 
mot hela 60% för patienter som utvecklar 
njursvikt i samband med svår sjuka eller 
efter stora operationer. 
Den vanligaste orsaken till njursvikt inom 
intensivvården är blodförgiftning, men 
njursvikt är också en vanlig komplikation 
efter stor kirurgi som tex hjärtkirurgi och 
levertransplantation. 
Lågt blodflöde till njuren, pga tex blodför-
lust under operationer, anses vara en av 
orsakerna till njursvikt. Det råder delade 
meningar om hur blodförlusten ska ersät-
tas. Det finns risker med blodtransfusioner, 
varför man helst ersätter blodförlust med 
vanliga dropp. Vilket dropp som är minst 
skadligt för njuren har orsakat en stor in-
ternationell diskussion utan att forskarna 
har kunnat enas om hur blodförlusten bäst 
ersätts för att undvika njurskada. En annan 
orsak till njursvikt har antagits vara syre-
brist, och flera olika teorier till syrebristen 
har diskuterats utan att man har kunnat 
enas. 
Studier av njurarna är mycket svåra att göra 
på människa, varför de i huvudsak sker på 
djur. Djuren kan dock inte fås att efterlikna 
den speciella situation människan utsätts 
för vid blodförgiftning och leversvikt, el-
ler efter stora operationer. Vår forsknings-
grupp har en unik metod med vilken vi kan 
undersöka njuren på människa, vilket kan 
bidra till att förstå njurarnas situation i den 
sjuka kroppen.
Den här avhandlingen har undersökt dels 
hur njurarna fungerar vid blodförgiftning 
och efter levertransplantation, dels vad 
man kan göra för att förbättra njurarnas 
förutsättningar vid blodförgiftning, lever-
transplantation och efter hjärtkirurgi. Vi 
har kommit fram till att det finns fördelar 
med att använda en viss typ av dropp fram-
för en annan för att ersätta måttlig blodför-
lust vid hjärtkirurgi, att det finns en undre 
gräns för blodtrycket för att njurarna ska 
må bra efter levertransplantation, att vid 
blodförgiftning och levertransplantation 
så leder kroppen blodet, dvs syrgasen, iväg 
från njurarna, och att det vid så stora på-
frestningar också kostar mer syrgas för 
njurarna bara att fungera. 
Kombinationen av mindre syrgas till nju-
rarna och ökad syrgaskostnad för samma 
arbete bidrar till njursvikten vid blodför-
giftning och i samband med levertrans-
plantation. Den nyvunna kunskapen att val 
av vätska efter stor kirurgi, och val av blod-
trycksnivå efter levertransplantation, kan 
minska belastningen på njurarna, bidrar 
till att bättre kunna förebygga njursvikt vid 
blodförgiftning, i samband med blodförlust 
vid hjärtkirurgi samt vid levertransplanta-
tion. 
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ABBREVIATIONS
AKI Acute kidney injury
ANOVA Analysis of variance
CI Cardiac index
CVP Central venous pressure
51Cr-EDTA Chromium ethylene diamine tetraacetic acid
eGFR estimated glomerular filtration rate according to the MDRD formula
FF Filtration fraction
GFR Glomerular filtration rate
ICU Intensive care unit
MAP Mean arterial pressure
MDRD Modification of diet in renal disease, calculation of GFR
mGFR Measured GFR
NO Nitric oxide
PBow Hydrostatic pressure in the capsule of Bowman
Pglom Hydrostatic pressure in the glomeruli
PAH Paraaminohippuric acid
PCWP Pulmonary capillary wedge pressure
πBow Osmotic pressure in the capsule of Bowman
πglom Osmotic pressure in the glomeruli
RASS Richmond agitation-sedation scale
RAVO2-diff Arterial–renal vein oxygen content difference
RBF Renal blood flow
RBFIC Renal blood flow, infusion clearance technique
RBFTD Renal blood flow, thermodilution technique
RDO2 Renal oxygen delivery
RO2Ex Renal oxygen extraction
RPF Renal plasma flow
RVO2 Renal oxygen consumption
RVR Renal vascular resistance
SAS Statistical Analysis Software
SD Standard deviation
SPSS Statistical packages for the social sciences
SVI Stroke volume index
SVRI Systemic vascular resistance index
DEFINITIONS IN SHORT
Acute Kidney Injury, AKI According to KDIGO (Kidney Disease: Improving Global 
Outcomes); 
Increase in SCr by 0.3 mg/dl (26.5 mmol/l) within 48 
hours
or 
Increase in SCr to 1.5 times baseline, which is known or 
presumed to have occurred within the prior 7 days 
or 
Urine volume of 0.5 ml/kg/h for 6 hours. 
Child-Pugh score 1- and 2-year survival in liver disease
It contains five variables including serum levels of biliru-
bin and albumin, prothrombin time, ascites, and enceph-
alopathy. CPS divides patients class A, intermediate (class 
B), and poor (class C)
MELD score 3-months mortality for liver disease
The difficulties and interobserver variability for the 
subjective parameters in the CPS classification led to the 
development of the “model for end stage liver disease” 
(MELD) score based on laboratory values only, which 
should be more objective and accurate than CPS.
MELD = 3.78×ln[serum bilirubin (mg/dL)] + 11.2×ln[INR] + 
9.57×ln[serum creatinine (mg/dL)] + 6.43
”Educating the mind
without educating the
heart is no education
at all”
Aristotle
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INTRODUCTION
1.1 Definition of AKI
Acute kidney injury (AKI) is defined 
as an abrupt decrease in renal func-
tion. It is a common and deleterious 
complication after major surgery and 
in critical illness. The epidemiology of 
AKI has up until recently been hard to 
assess since a uniform definition has 
been lacking. This rendered a collabo-
rating group, the Acute Dialysis Qual-
ity Initiative (ADQI), to present the RI-
FLE criteria for the definition of AKI [1]. 
Based on the increase in serum creat-
inine level and/or the duration of ol-
iguria, this definition presented three 
stages of AKI, namely Risk, Injury, and 
Failure. Moreover, the RIFLE defini-
tion identified Loss of kidney func-
tion and End-stage kidney disease as 
outcome criteria. In 2004, Lassnig et 
al found that even a small increase in 
SCr had a negative impact on survival 
after cardiac surgery [2], hence it be-
came obvious that it was the change, 
and not only the absolute number, of 
SCr that mattered. The RIFLE crite-
ria was therefore modified by the AKI 
Network (AKIN) group, presenting the 
AKIN criteria in 2007, adding an abso-
lute value for the raise in SCr [3]. The 
advantage of the AKIN criteria over 
the RIFLE criteria is that it enables an 
AKI diagnosis based on small absolute 
changes in SCr. In 2012, the Kidney 
disease: Improving Global Outcomes 
(KDIGO) unified the definition of AKI 
by combining the RIFLE and AKIN cri-
teria, resulting in the KDIGO classifi-
cation, defining the time frame of SCr 
changes, and adding the need for re-
nal replacements therapy as a staging 
parameter [4]. The KDIGO criteria is 
evaluated as the most accurate diag-
nostic tool to use in patients with liver 
cirrhosis, in whom SCr is a very poor 
tool for evaluation of renal function, 
and where the urinary output mea-
sure is not applicable [5, 6]. Pereira et 
al recently found that, among septic 
patients, using the RIFLE and KDIGO 
criteria diagnosed AKI more often 
than the use of AKIN, but the in-hos-
pital mortality did not differ between 
the different diagnostic criteria [7].
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Table 1: Definitions of AKI. Urine output <0.5 ml/kg/h >6 h.
RIFLE (2004) AKIN (2007) KDIGO (2012)
S-Creatinine 
increase
≥1.5 times baseline 
within 7 days
≥1.5 times baseline
or 
0.3 mg/dl (26 µmol/L) 
within 48 hrs 
1.5-1.9 times baseline 
known or presumed 
to have occurred 
within the prior 7 days
or 
0.3 mg/dl (26 µmol/L) 
within 48 hrs
1.2 Epidemiology and conse-
quences of AKI
AKI have an extraordinary negative 
impact on morbidity, i.e. chronic kid-
ney disease (CKD) with the need for 
renal replacement therapy (RRT), and 
furthermore on both mortality and so-
ciety costs [8-10]. As recently reported 
in an epidemiological multicenter in-
ternational study, over 60% of the pa-
tients admitted to the intensive care 
unit (ICU) develop AKI according to 
the KDIGO criteria, the most common 
causes being sepsis and hypovole-
mia [9]. AKI has been found to occur 
in 37-84 % of septic ICU patients. The 
higher the stage of AKI, the higher 
the mortality risk. For AKI stage 2 and 
3, mortality is reported to be 3.9 and 
7.2 times higher, respectively, than in 
septic shock without AKI [7, 9, 11, 12]. 
Cardiac surgery is associated with 
an AKI incidence of up to 40%, and 
mortality is independently increased 
for up to ten years after surgery [13-
15]. AKI needing renal replacement 
therapy (RRT) after cardiac surgery is 
uncommon, but associated with an 
almost eight-fold increase in mortal-
ity [13]. Liver transplantation without 
postoperative AKI carries a mortality 
of 2-6%, to be compared to a mortality 
of 47-55% in the case of postoperative 
AKI [16, 17]. Even a minimal increase 
in SCr is associated not only with a 
higher mortality, but also with a short-
er graft survival, resulting in severe 
consequences for both the individu-
al patient, patients on the waiting list 
for liver transplantation and society 
[18-20]. Moreover, hospital costs have 
been found to be almost 60% high-
er for patients with AKI compared to 
those without [10].
1.3 Risk factors for AKI after 
cardiac surgery, liver trans-
plantation and in septic shock
The female sex is a risk factor for de-
veloping AKI after cardiac surgery, liv-
er transplantation and in septic shock 
[21-24]. 
In cardiac surgery with cardiopulmo-
nary bypass, the major risk factors in-
clude left ventricular ejection fraction 
<40%, diabetes mellitus, preoperative 
use of an intraaortic balloon pump, 
emergency surgery and an elevated 
preoperative serum creatinine [21, 22]. 
Preoperative risk factors for AKI after 
liver transplantation includes obesity, 
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severe liver failure defined as a high 
Child-Pugh score, diabetes mellitus, 
renal failure, liver graft dysfunction 
and cold and warm ischemic time 
for the liver graft. Perioperative risk 
factors associated with postopera-
tive AKI are the amount of required 
transfusions, intraoperative blood loss 
and occurrence of postreperfusion 
syndrome (PRS), defined as a 30% re-
duction in MAP lasting for > 1 minute 
within 5 minutes after peroperative 
reperfusion of the liver graft [18, 20, 
23-27].
Patients at risk for AKI in association 
with septic shock are older, have more 
co-morbidities, have a higher severi-
ty of illness score and are more often 
admitted to the ICU for non-surgical 
medical disease, than patients with 
septic shock that do not develop AKI. 
Moreover, the more unstable the re-
spiratory and hemodynamic situation 
is for the septic patient, the greater the 
risk for development of AKI [28].
1.4 Renal physiology at a 
glance
Filtration of fluid and waste products 
from the blood into the renal tubular 
system occurs in the glomerular capil-
laries. The ultrafiltrate enters the Bow-
man’s capsule and the glomerular fil-
tration rate (GFR) is determined by the 
permeability of the filtration barrier 
(ultrafiltration coefficient Kuf), and by 
the Starling forces, such as the hydro-
static (Pglom) and mean colloid osmotic 
(πglom) pressure in the glomerular cap-
illaries, and in Bowman’s capsule (PBow 
and πBow, respectively), according to 
the formula:
GFR = Kuf  x ((Pglom + πBow) – (PBow + πglom))
From this formula, one can under-
stand that there are two forces; Pglom 
and πBow promoting, and PBow + πglom 
opposing, filtration.
The glomeruli are supplied by a single 
afferent arteriole, which divides into 
glomerular capillaries, and converge 
in an efferent arteriole. The hydrostat-
ic pressure in the glomerular capil-
laries is dependent on the tone of the 
afferent and the efferent arterioles. Va-
soconstriction of the afferent arteriole 
lowers the flow through and pressure 
in the capillaries and hence GFR is re-
duced. On the contrary, if the efferent 
arteriole is constricted, blood flow is 
decreased, while the pressure in the 
capillaries is increased, leading to an 
augmentation of GFR.
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Fig 1: The nephron is the functional unit of the kidney. The glomerulus and convoluted tubules of the 
nephron are located in the cortex of the kidney, while the collecting ducts are located in the pyramids of 
the kidney’s medulla. 
Reproduced from Boundless learning, CC permission.
GFR is also, to some extent, dependent 
on glomerular plasma flow, because of 
flow-dependent changes in capillary 
protein concentration. Lowering RBF, 
the glomerular transit time for plasma 
increases, leaving more time for filtra-
tion. The more plasma that is filtrated 
per time unit, the higher the colloid 
osmotic pressure in the glomerulus 
(?glom), and hence the lower the GFR. 
Increasing RBF causes the opposite 
situation [29]. 
It is important that the elimination 
of water and waste products, and the 
regulation of the salt and water con-
tent of the body, is kept constant in-
dependently of the strains the body is 
subjected to. Systemic extrinsic ways 
to maintain homeostasis includes 
activation of hormones (renin-an-
giotensin system and natriuretic pep-
tides) and of the sympathetic nervous 
system in cases of e.g. extreme fluid 
loss. Furthermore, RBF and GFR is kept 
constant by intrinsic autoregulatory 
mechanisms affecting the afferent ar-
teriole:
1. Myogenic mechanism
 At a higher blood pressure, sensed 
by the afferent arteriole as an 
increase in transmural pressure, 
the afferent arteriole constricts, 
maintaining RBF and GFR con-
stant, despite the higher blood 
pressure. This is the faster of the 
two mechanisms.   
2. Tubuloglomerular feedback 
mechanism (TGF)
 At higher blood pressure, GFR and 
sodium filtration increases due 
to increased tubular flow, result-
ing in a higher concentration of 
NaCl in the early distal tubule. The 
concentration of NaCl is sensed 
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by chemoreceptors in the macu-
la densa, which is a collection of 
epithelial cells in the distal tubule, 
situated adjacent to the affer-
ent and efferent arterioles. At an 
increased concentration of NaCl 
in the filtrate reaching the mac-
ula densa, the afferent arteriole 
vasoconstricts, adjusting flow and 
keeping GFR unaffected by the 
variations in blood pressure.
The range within which renal auto-
regulation operates in humans is not 
well understood, but in the literature it 
has been assumed to be in the range 
of 80-130 mmHg. The lower limit for 
renal autoregulation has been shown 
to be a mean arterial pressure (MAP) 
of >75 mmHg in patients with septic 
shock [30, 31]. 
After the filtration of the primary urine 
into Bowman’s capsule, the renal tu-
bules have the task to reabsorb and 
concentrate the primary urine from 
approximately 180 L/day to 1-2 L/day. 
This is done in the tubular system, 
extending from the Bowman’s cap-
sule, situated in the renal cortex, via 
the proximal tubule, further on to the 
loop of Henle, the distal tubule, and 
ending in the collecting duct. Water 
and sodium is filtered into the Bow-
man’s capsule, and then reabsorbed to 
99% in the tubular system according 
to the current needs of the body. So-
dium molecules enter the tubuli cells 
by passive diffusion, but are then ac-
tively pumped through the basolateral 
membrane into the interstitium by a 
Na+/K+-ATPas. From the interstitium, 
sodium is passively diffusing into the 
peritubular capillaries. Intercellular 
apical tight junctions in the tubular 
cells hinder sodium from reentering 
the tubular lumen from the intersti-
tium. While the filtration process is a 
passive process, the reabsorption of 
sodium is an active and energy and 
oxygen consuming process. A great 
part of the renal oxygen consumption 
is used for tubular sodium reabsorp-
tion.
Fig 2: Sodium passively diffuses through the apical membrane into the tubuli cells due to a concentration 
gradient. It is then actively pumped into the interstitium, from where it is absorbed into the peritubular 
capillaries, drawn by the intravasal colloid osmotic pressure. Tight junctions between the tubuli cells 
hinder the sodium from leaking back into the tubular lumen. 
Reprinted with permission from B. Redfors.
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The kidney receives 20-25% of the total 
cardiac output (CO). This redundant 
blood supply is necessary to main-
tain a high GFR. RBF is however not 
evenly distributed in the kidney; the 
renal cortex receives ≈80%, the outer 
medulla ≈20% and the inner medulla 
receives ≈1-2% of the RBF. This distri-
bution of RBF is necessary to optimize 
GFR in the cortex, and to maintain the 
osmotic gradient for concentration of 
urine in the medulla. Oxygen tension 
is 6-7 kPa in the cortex compared to 
only 1.5-2.5 kPa in the medulla [32]. 
The low tissue pO2 in the medulla is 
caused by the relatively low medullary 
blood flow [33] and by the high levels 
of renal oxygen consumption of the 
medullary thick ascending limbs of 
Henle’s loop, which reabsorb a large 
proportion of the filtered sodium by 
active, O2 - demanding transport. As 
almost 99% of the glomerular filtrate 
is reabsorbed, the renal oxygen con-
sumption (RVO2) is high, second only 
to the heart [34].
The uneven distribution of RBF and 
oxygen consumption between the 
various parts of the kidney affects 
the local balance between renal oxy-
gen delivery (RDO2) and consumption 
(RVO2). This balance is crucial for local 
renal oxygenation. The renal medulla, 
particularly the outer portion, is sus-
ceptible to hypoxia. The global renal 
oxygen supply/demand relationship 
can be expressed as renal oxygen ex-
traction (RO2Ex). An increase in RVO2 
that is not met by a proportional in-
crease in RDO2, results in an increased 
RO2Ex, i.e. renal oxygenation is im-
paired and vice versa.
Fig 3: Blood supply and partial pressure of oxygen (pO2) of the renal cortex and medulla. 
Reproduced with permission from Brezis N Engl J Med 1995, Copyright Massachusetts Medical Society
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It has been shown that there is a close 
correlation between tubular sodium 
reabsorption and RVO2 [35]. Further-
more, there are several studies show-
ing a linear relationship between GFR, 
RVO2 and renal sodium reabsorption 
in different clinical conditions [36-38]. 
Thus, in general, the major determi-
nant of RVO2 is GFR. Since an increase 
in RBF results in an increase in GFR 
and the filtered amount of sodium, 
renal oxygen consumption increas-
es as a result of the augmented renal 
blood flow and filtered sodium. Thus, 
in contrast to other organs, RVO2 is 
flow-dependent as long as RBF and 
GFR changes in parallel.
Besides the renal oxygen used for so-
dium reabsorption, there is an oxygen 
demand for renal basal metabolism. 
In a study by Redfors et al, comparing 
patients after cardiac surgery with and 
without AKI, it was found that basal 
metabolism constituted around 25% 
of the total renal oxygen consumption 
in both groups [36]. 
In conclusion, GFR is determined by 
RBF and the relationship between 
afferent and efferent arteriolar resis-
tances with direct effects on glomer-
ular filtration pressure. The kidneys 
receive a great proportion of the car-
diac output for the filtration process. 
Due to intrarenal distribution of blood 
flow in combination with the uneven 
distributed oxygen demand, the re-
nal oxygenation, i.e. the balance be-
tween oxygen supply and demand, is 
susceptible to increased oxygen con-
sumption or impaired renal oxygen 
delivery. Particularly the outer part of 
the renal medulla is vulnerable and al-
ready under normal conditions on the 
verge of hypoxia.
1.5 AKI – pathophysiologic 
theories
It is beyond all doubt that the ethiol-
ogy of AKI is multifactorial and com-
plex. It has been stressed that due to 
the limited understanding of renal 
pathophysiology, our possibilities to 
prevent and treat AKI is limited, and 
that further understanding of the 
mechanisms behind the renal dys-
function in AKI is needed [39, 40]. Our 
knowledge on renal pathophysiology 
in AKI is based on experimental isch-
emia-reperfusion models, usually in 
the rat, induced by renal artery occlu-
sion. Depending on the time of occlu-
sion, an extensive tubular necrosis is 
seen, in striking contrast to the very 
limited necrosis seen in biopsies of 
patients with AKI [41, 42]. Thus, this 
experimental model used to better 
understand the pathophysiology of 
AKI has been questioned [42]. New 
radiological non-invasive imaging 
techniques have been suggested for 
the study of the renal pathophysiolo-
gy of clinical AKI [43, 44]. These tech-
niques are, however, less suited for the 
critically ill patient requiring extensive 
treatment for multiple organ support, 
as the patients need to be transported 
to a scanner for e.g. magnetic reso-
nance imaging (MRI) and the need 
for removal of any invasive device not 
compatible with MRI.
1.5.1 Septic AKI
Based on large animal experimental 
models of early sepsis, it has been sug-
gested that renal dysfunction, i.e. a fall 
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in GFR, may occur in spite of hyper-
dynamic circulation with an increase 
in RBF [45, 46]. The reason for this is, 
up to the present, unknown. One the-
ory is that the increase in RBF in early 
sepsis is mainly due to a vasodilation 
of the efferent arterioles, resulting in 
a decreased pressure over glomeruli 
and hence a lower GFR. Another the-
ory is that there is an shunting mech-
anism, redistributing the intrarenal 
blood flow from the medulla to the 
cortex, causing a mismatch in local 
renal oxygen supply/demand balance, 
and hence a hypoxic state in the me-
dulla [47]. 
An increased production of nitric ox-
ide (NO) has been demonstrated to 
result in a systemic vasodilation and 
hypotension in both clinical and ex-
perimental sepsis [48-51]. Hypoten-
sion in sepsis elicits a baroreflex-me-
diated activation of the sympathetic 
nervous system, including the renal 
sympathetic nerves, as demonstrated 
in animal models of sepsis [52, 53] and 
in clinical sepsis as an elevated plas-
ma norepinephrine level [54]. Thus, a 
NO-mediated renal vasodilation may 
be antagonised by the increase in 
renal sympathetic activity in sepsis. 
Ramchandra et al demonstrated, in 
conscious septic sheep, that the pre-
viously described renal vasodilatation 
[45] was accompanied by an increase 
in renal sympathetic nerve activity, 
which would promote renal vaso-
constriction [53]. They suggested that 
the profound increase in NO in septic 
shock will override this sympatheti-
cally mediated renal vasoconstriction, 
causing a net renal vasodilation and 
an increased RBF because of vaso-
dilated efferent arterioles. However, 
there is no report on RBF, GFR and re-
nal oxygenation in early clinical septic 
shock. 
1.5.2 Ischemic AKI
Ischemic/reperfusion injury (IRI) 
as a cause of AKI is common, and is 
caused by a reduced RBF and a de-
creased RDO2. The reduction in RBF 
and RDO2 is caused either by hypovo-
lemia, by an increased renal vascular 
resistance (RVR) or by alterations in 
the intrarenal microcirculation. Hy-
povolemia can be the consequence 
of a reduced circulating blood vol-
ume due to perioperative bleeding, or 
by a decreased effective intravascular 
blood volume caused by for example 
liver failure and cirrhosis [55, 56].  
Increased RVR is partly a consequence 
of a decreased production of the vaso-
dilator NO, caused by damaged endo-
thelial cells. This results in a decreased 
vasodilation [57]. Moreover, the in-
flammatory response gives rise to an 
activation of the endothelium, en-
hancing adhesion of activated leuko-
cytes to the endothelial cells. Further-
more, cytokines like TNF-α and IL-1 
disrupts cell matrix and causes cell 
debris to shed into the lumen. These 
consequences of IRI results in an in-
creased resistance in the renal micro-
circulation, and an elevated RVR [58]. 
In the maintenance and repair phases 
of ischemic AKI, the tubular cells start 
to proliferate, function and RBF is be-
ing restored. Renal blood flow, though, 
is not fully restored after an ischemic 
event, this is known as the “no-reflow” 
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phenomenon. The resulting changes 
in the vascular morphology causes an 
increased permeability of the vascular 
walls and an endothelial cell dysfunc-
tion, resulting in interstitial and cellu-
lar edema. This in turn causes further 
obstruction of renal microcirculation, 
lower oxygen delivery and promotes 
renal injury [59-62].
1.6 Plasma volume expansion 
in hypovolemia –colloid vs. 
crystalloid
To ameliorate ischemic AKI after ma-
jor surgery, crystalloid or colloid fluid 
is used for plasma volume expansion 
if serum hemoglobin and coagulation 
are within the normal range [42]. This 
restores normovolemia and renal per-
fusion, but induces a hemodilution, 
potentially resulting in little or no net 
effect on oxygen delivery. It has been 
shown in animal studies that nei-
ther colloids nor crystalloids increase 
RDO2 despite increases in cardiac 
output, and that crystalloids even can 
negatively affect renal microvascular 
oxygenation [43, 44]. In patients with 
severe sepsis, fluid resuscitation with 
the colloid hydroxyethyl starch, had 
an increased mortality and a higher 
incidence of AKI [63]. Effects of post-
operative plasma volume expansion 
with i.v. fluids on RDO2 and renal ox-
ygenation have not previously been 
studied in man. Furthermore, periop-
erative data on the effects of crystal-
loids and colloids on RBF, GFR, and re-
nal oxygenation, defined as the renal 
oxygen supply–demand relationship, 
are lacking.  
1.7 Treatment of hypotension, 
preserving autoregulation of 
RBF.
In a volume resuscitated vasodilatory 
state, as for example in septic shock 
and liver failure, the systemic vasodi-
lation results in a hypotension threat-
ening to induce hypoperfusion of vital 
organs, particularly when organ auto-
regulation of blood flow is exhausted. 
Vasodilation is most commonly treat-
ed with the vasopressor norepineph-
rine. Norepinephrine has been shown 
to induce renal vasoconstriction and 
to reduce RBF in healthy volunteers 
[64, 65]. On the other hand, there is a 
risk of pressure dependent RBF if the 
blood pressure is allowed to decrease 
below the limit of the renal autoregu-
latory capacity. Indeed, it was recent-
ly found that restoring mean arterial 
pressure from 60 to 75 mmHg in va-
sodilatory shock, by the use of norepi-
nephrine, increased both RDO2 and 
GFR with preserved renal oxygenation 
[30]. However, the effects of norepi-
nephrine-controlled target MAP on 
renal filtration, perfusion and oxygen-
ation early after liver transplantation 
have not previously been studied in 
humans. 
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AIM
1. To evaluate the differential renal 
effects of a crystalloid vs a colloid 
for plasma volume expansion 
on renal perfusion, filtration and 
oxygenation after uncomplicated 
cardiac surgery (paper I).
2. To study renal hemodynamics, 
function and oxygenation after 
liver transplantation (paper II).
3. To evaluate the effects of three 
various target levels of MAP on 
renal perfusion, function and ox-
ygenation early after liver trans-
plantation (paper III).
4. To study renal hemodynamics, 
function and oxygenation in 
volume-resuscitated norepineph-
rine-dependent early clinical 
septic shock (paper IV).
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PATIENTS AND METHODS
The Gothenburg Regional Ethical Re-
view Board approved the study pro-
tocols of all four papers included in 
this thesis. For conscious patients 
scheduled for cardiac surgery and liv-
er transplantation, respectively, writ-
ten informed consent was obtained 
at the preoperative evaluation. For the 
sedated patients with septic shock in 
paper number IV, the next of kin was 
informed prior to inclusion. 
3.1 Patients
In this thesis, three groups of patients 
were studied, namely patients under-
going uncomplicated cardiac surgery 
with cardiopulmonary bypass (CPB) 
(n=30), patients immediately after liv-
er transplantation (n=12) and patients 
in early septic shock (n=8). The pa-
tients included in each study group 
all had a normal preoperative (I, II, III) 
or premorbid (IV) serum creatinine. In 
addition, in papers II and III, the pa-
tients had normal pretransplant renal 
function, as assessed by measure-
ments of GFR while on the waiting 
list for transplantation. Notably, both 
the liver recipients in papers II and 
III, and the septic patients in paper IV, 
had MELD- and SOFA-scores in the 
lower range (14.0 and 7.9 respectively), 
i.e. the patients included in the study-
groups in papers II-IV had an expect-
ed mortality rate of less than 20% and 
were, thus, not exceptionally ill. The 
control groups in paper II (n=73) and 
IV (n=58) had earlier been included in 
pharmacological studies performed 
by our study group [37, 66-69]. These 
patients where all subjected to un-
complicated cardiac surgery, with no 
postoperative impairment of renal 
function. The baseline renal and sys-
temic data of these patients, i.e. before 
pharmacological intervention, were 
used for comparison with the studied 
patients in papers II and IV). 
3.2 Measurements of systemic 
hemodynamics
Cardiac output (CO) was measured 
in triplicates using, in paper I, con-
trol groups and parts of the patients 
in paper IV, a pulmonary artery ther-
modilution catheter (Baxter Health-
care Corporation, Irvine, CA). In the 
remaining patients, a PiCCO® cath-
eter (PULSION Ltd, Munich, Germa-
ny) for transthoracic thermodilution 
pulse contour technique, was insert-
ed in the femoral artery and used for 
CO measurement. The mean arterial 
pressure (MAP) was measured via a ra-
dial or femoral artery line. The central 
venous pressure (CVP) was measured 
via a catheter placed in vena cava su-
perior. MAP, CVP and in paper I, pul-
monary arterial pressure, was mea-
sured continuously, while pulmonary 
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artery wedge pressure (PCWP, paper 
I) was measured intermittently. Stroke 
volume (SV), systemic and pulmonary 
vascular resistance (SVR and PVR, re-
spectively) were calculated according 
to standard formulae.
3.3 Measurements of renal 
variables
All renal data were normalised to a 
body surface area of 1.73 m2. 
3.3.1 The renal vein catheter
A ball-ended 8-fr catheter for retro-
grade venous thermodilution (Web-
ster Laboratories, Baldwin Park, CA) 
was inserted into either of the renal 
veins via the right femoral vein. The 
femoral vein was identified blindly in 
paper I, and by the use of ultrasound 
in papers II-IV. After punction of the 
femoral vein, the catheter was intro-
duced into the left or right renal vein 
under fluoroscopic guidance. The tip 
of the catheter was placed in the cen-
tral part of the renal vein, it’s position 
being confirmed by venography us-
ing ultralow doses of iohexol (Omni-
paque® 300 mg I/ml, GE Healthcare, 
Stockholm, Sweden) [70]. There are 
two thermistors located at the distal 
part of the renal vein catheter, one in-
dicator and one external thermistor, 
the latter being located 2.5 cm proxi-
mal to the catheter tip.
3.3.2 Renal blood flow by continu-
ous thermodilution (papers I, II, III)
A two-channelled Wheatstone bridge, 
for measurement of changes in resis-
tance, was connected to the renal vein 
catheter. The changes in resistance 
were achieved by creating a tempera-
ture difference between the indicator 
(internal thermistor) and the renal 
vein blood (external thermistor). To 
do so, room tempered isotonic crys-
talloid solution was infused for 15-30 
seconds into the catheter at a constant 
rate of 53.7 ml/min. The infusion was 
repeated three times for each mea-
surement. The correct position of the 
renal vein catheter was defined as one 
that did not yield a variation in renal 
blood flow of more than 10% in the 
three consecutive measurements. An-
alogue signals from the Wheatstone 
bridge were stored and analysed in a 
computer, using data acquisition soft-
ware (fig 4). The proportion of cooling 
between the two thermistors was then 
used to calculate the renal blood flow 
of one kidney. To get the total renal 
blood flow, the value from the mea-
surement of RBF from one kidney was 
doubled, and urine flow was added, 
according to the formula 1.
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Fig 4: A recording of a continuous renal vein thermodilution blood flow measurement in the software. 
The upper graph reflects the temperature of the indicator (internal thermistor), and the lower reflects 
the temperature of the renal blood flow (external thermistor). A decrease in temperature causes an 
elevation of the graph. To calculate RBF, calibration signal strength (1), basal blood temperature (2) and 
temperatures at infusion (3) were used. Three measurements at the time were made, defined manually 
and then the program calculated the mean signal strength for each period and each channel separately. 
With permission from B. Redfors
3.3.3 Renal blood flow by infusion 
clearance of paraaminohippuric 
acid (paper IV)
Paraaminohippuric acid (PAH) is a 
crystalline acid administered intrave-
nously in the form of its sodium salt. 
Since PAH is completely removed 
from the blood by the kidneys by both 
glomerular filtration and tubular se-
cretion, the rate of clearance of PAH 
from the blood reflects RBFIC. An in-
travenous priming dose of PAH was 
given, followed by a constant rate in-
fusion individualized to body weight 
and serum creatinine. Serum con-
centration of PAH in arterial and re-
nal vein blood were measured using 
a spectrophotometer. RPF was calcu-
lated as the amount of infused PAH 
divided by the difference in PAH con-
centration between arterial and renal 
vein blood. RBF was then calculated 
by RPF / (1-hematocrit).
3.3.4 Glomerular filtration rate (GFR)
Renal filtration fraction is the propor-
tion of fluid reaching the tubules, i.e. 
the relationship between glomerular 
filtration rate (GFR) and renal plasma 
flow (RPF), and is, in this thesis, mea-
sured as the renal extraction of the 
filtration marker chromium ethylene-
diamine-tetraacetic acid (51Cr-EDTA). 
After blood and urine blanks were col-
lected, an intravenous priming dose 
of 51Cr-EDTA was given to all patients. 
The priming dose was followed by an 
infusion at a constant rate, individual-
ized to body weight and serum creati-
nine. Serum 51Cr-EDTA activities from 
arterial and renal vein blood were 
measured using a well counter. In 
order to eliminate errors due to high 
diuresis, the formula for calculation of 
FF was corrected taking the urine flow 
into account. GFR was then calculated 
as FF x RPF.
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3.3.5 Urine flow
All patients included in this thesis had 
a Foley catheter draining the bladder 
of urine. Measurements were made of 
urine flow, concentration of sodium, 
of creatinine and of the tubular injury 
marker N-acetyl-β-d-glucosaminidase 
(NAG).
Analysis of oxygen, sodium and he-
moglobin
Arterial blood was analyzed for the 
content of oxygen, sodium and he-
moglobin using an automated blood 
gas analyser (Siemens RAPIDPoint 
500®). Blood samples from central 
vein and pulmonary catheters, and 
from the renal vein catheter were an-
alyzed for oxygen content, using the 
same analyzer.
3.4 Experimental procedures
Written informed consent was ob-
tained from all patients in papers I, II 
and III. Informed consent from next 
of kin was obtained in paper IV. All 
patients, both in the study groups and 
in the control groups, were studied in 
the ICU, during sedation with propo-
fol and an opioid to RASS -5, and 
during mechanical ventilation to nor-
mocarbia. Infusion rates of fluids and 
drugs, other than study related, were 
not changed during the experimental 
procedures. The renal vein catheter 
was inserted in the ICU in all patients, 
and an equibrilation period of at least 
60 minutes was applied before start of 
the experimental procedures. A total 
of 5 patients in the study groups were 
excluded due to unsuccessful place-
ment or function of the renal vein 
catheter.  
Statistics: All statistical analyses have 
been performed using Statistical 
Package Social Sciences (SPSS) ver-
sion 24, except for analyses of repeat-
ed measures of creatinine in paper 
II, where Statistical Analysis System 
(SAS) was used.  Continuous data was 
checked for normal distribution using 
the Shapiro-Wilk test, in combination 
with visual assessment of Q-Q plots 
[71]. Categorical data was compared 
using Fischer’s exact test. Values are 
presented as mean and standard devi-
ation (± SD) of the mean. A probabili-
ty level (p-value) of less than 0.05 has 
been considered to indicate statistical 
significance.
3.4.1 Renal effects of plasma volume 
expansion: a randomised study on 
crystalloid vs. colloid (paper I)
30 patients were studied after un-
complicated cardiac surgery. Post-
operative hemodynamic goals were 
CVP 5-10 mmHg, MAP >70 mmHg 
and a mixed venous oxygen satu-
ration (SVO2) > 60%. Plasma volume 
expansion was achieved using Ring-
ers-Acetate® 20 ml/kg as crystal-
loid, and hydroxyethylstarch 60 mg/
ml, 130/0.62 (Venofundin®) 10 ml/kg 
as colloid. Randomization between 
crystalloid and colloid fluid was per-
formed using sealed envelopes. The 
fluid was administered during 20-30 
minutes. Thermodilution measure-
ments of RBF and CI were conducted, 
and blood and urine samples were ob-
tained, at 20, 40 and 60 minutes after 
the end of the fluid administration.
Statistics: Intragroup effects were 
analyzed using one-way ANOVA for 
repeated measurements. Mauchley’s 
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test of sphericity was used to test 
the difference in variance between 
the points of measurements. When 
sphericity was not confirmed, Green-
house-Geisser was used to report the 
p-values, instead of the otherwise 
used Sphericity assumed. Intergroup 
effects were compared by ANCOVA 
for repeated measurements, with the 
mean of baseline measurements as a 
covariate, and after linearity between 
the variables were checked.
3.4.2 Renal hemodynamics, func-
tion and oxygenation early after liv-
er transplantation (paper II)
Twelve liver recipients with pretrans-
plant normal renal function were in-
cluded in this study. Postoperative he-
modynamic goals were pulse pressure 
variation of < 12% and a MAP of 70-80 
mmHg. Hypovolemia was treated ac-
cording to routine clinical practice, 
and if there was a persistent hypoten-
sive state despite resuscitation with 
fluids, norepinephrine was used as a 
vasopressor, titrated according to the 
attending intensivist. Two 30 minutes 
urine collection periods were then 
started, and thermodilution measure-
ments of RBF and CO were conduct-
ed at the end of each urine collection 
period, followed by blood and urine 
sampling. The results from the liver 
recipients were compared to a control 
group consisting of 73 patients after 
uncomplicated cardiac surgery with 
cardiopulmonary bypass, data derived 
from previous studies conducted by 
our research team. The control group 
had normal cardiac and renal func-
tion.
Statistics: Intergroup differences were 
compared using independent-sam-
ples t-test for normally distributed 
data, consideration taken to Levene’s 
test of equality. Mann-Whitney U test 
was used for non-parametric data. 
Linear regression analyses were used 
to correlate renal oxygen consump-
tion to renal sodium reabsorption 
and GFR, respectively. A mixed model 
using SAS was performed to analyse 
within- and intergroup repeated mea-
surements of serum creatinine.
3.4.3 Renal effects of norepineph-
rine-induced changes in mean arte-
rial pressure after liver transplanta-
tion (paper III)
In this study, the same patients were 
studied as in paper II, although two 
patients were excluded after random-
ization, due to occlusion of the renal 
vein catheter, leaving 10 liver recipi-
ents with a preoperative normal renal 
function to be included in this paper. 
After an equilibration period of at 
least 60 minutes, two 30-min con-
trol periods ensued at a target MAP of 
75 mmHg. The infusion rate of nor-
epinephrine was then randomly in-
creased or decreased, in a cross-over 
design to obtain a 30-min period at a 
MAP of either 60 or 90 mmHg. A titra-
tion period of 15 min was needed for 
each new MAP level to obtain the tar-
get pressure. Randomisation was ac-
complished using sealed envelopes in 
two blocks. At each target MAP, urine 
was collected for 30 minutes. At the 
end of each period, cardiac output and 
renal thermodilution measurements 
were performed and blood samples 
were taken from radial artery and re-
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nal vein for measurements of serum 
concentrations of sodium, 51Cr-EDTA, 
hemoglobin as well as oxygen con-
tent. 
Statistics: Intragroup data from the 
two control measurements at MAP 
70-80 mmHg were pooled, and then 
compared to the two other levels of 
target MAP using repeated measure 
ANOVA in combination with LSD 
post-hoc test.
3.4.4 Renal hemodynamics, func-
tion and oxygenation in early clini-
cal septic shock (paper IV)
Eight patients with a premorbid nor-
mal serum creatinine and norepi-
nephrine-dependent septic shock 
were studied within 24 hours from 
ICU admission. Hemodynamic targets 
in the ICU were a pulse pressure varia-
tion of <12% and a MAP 70-80 mmHg. 
The data from the study group was 
compared to 58 post cardiac surgery 
patients without AKI, data derived 
from previous studies performed by 
our research group. In this study, RBF 
was measured using the technique 
of infusion clearance of PAH, instead 
of thermodilution. In addition to re-
nal and systemic hemodynamics and 
oxygenation states, urine was ana-
lysed for NAG and creatinine to get 
the U-NAG/U-creatinine ratio in the 
septic group. After the equilibration 
period, two 30 minutes urine collec-
tion periods were conducted. CO was 
measured, followed by arterial, renal 
vein and mixed venous blood sam-
pling, at the end of each urine collec-
tion period.
Statistics: IIntragroup data from the 
two 30 minutes measurements was 
pooled. Intergroup differences were 
compared using the independent 
t-test for parametric data, consider-
ation taken to Levene’s test of equality. 
The Mann-Whitney U test was used 
for analysis of non-parametric data.
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RESULTS
4.1 Renal effects of plasma 
volume expansion: a ran-
domised study on crystalloid 
vs. colloid (paper I)
To evaluate the renal effects of crys-
talloid and colloid for plasma volume 
expansion after uncomplicated cardi-
ac surgery, a total of 30 patients with 
preoperative normal cardiac and renal 
function were randomized to receive 
either crystalloid (n=15, Ringers-ac-
etate® 20 mg/kg) or colloid (n=15, 
Venofundin® 10 mg/kg) solution. Data 
obtained during the two control peri-
ods before intervention did not differ 
significantly between the groups. The 
induced plasma volume expansion 
effect, measured as effects on CI, did 
not differ, significantly between the 
groups
4.1.1 Effects of i.v. fluids on system-
ic variables 
In the crystalloid group, there was a 
peak increase in MAP, SVI and CI at 
20 minutes after the end of fluid infu-
sion, declining back to baseline at 60 
minutes after end of infusion. Using 
colloid fluid, there was a more per-
sistent rise in MAP, SVI and CI during 
the whole experimental procedure, 
the increase in CI being significantly 
greater than in the crystalloid group. 
In both groups, filling pressures in-
creased and SVRI decreased. HR was 
left unaffected by both fluids. Both 
fluids induced hemodilution with a 
consequent decrease in arterial ox-
ygen content, the effect being more 
pronounced in the colloid than in the 
crystalloid group. Despite this, there 
was no significant difference in DO2I 
between the groups.
4.1.2 Effects of i.v. fluids on renal 
variables (Table II)
RBF increased significantly in both 
groups without any intergroup statis-
tically significant difference. RBF in-
creased only transiently in the crystal-
loid group, whereas the increase was 
more consistent in the colloid group. 
Despite the increase in RBF, RDO2 was 
not statistically affected in any group, 
because of hemodilution. GFR, sodi-
um filtration, sodium reabsorption, 
FF, RVO2, RO2Ex and RAVO2-diff in-
creased only in the crystalloid group, 
with intergroup significance only for 
FF, RO2Ex and RAVO2. Renal oxygen 
extraction was increased only in the 
crystalloid group, leading to a statisti-
cal difference between the groups (fig. 
5).
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Table 2: Renal variables crystalloid vs colloid after uncomplicated cardiac surgery
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Values are mean (SD). RBF; renal blood flow, RVR renal vascular resistance, RDO2; renal oxygen delivery, GFR; glomerular filtration rate, RVO2; 
renal oxygen consumption, SrvO2; Renal vein oxygen saturation, RO2Ex; renal oxygen extraction, RAVO2-diff; Arterial-renal vein oxygen content 
difference, RBF/CI; relationship between RBF and cardiac index. ANOVA; within-group analysis of variance, ANCOVA; between-groups analysis of 
variance with baseline as a co-variate.
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Fig 5: Effects of a crystalloid (10 ml kg−1) and a colloid (20 ml kg−1) bolus on renal oxygen extraction 
after cardiac surgery. The crystalloid increased renal oxygen extraction (P<0.001) 20, 40 and 60 min after 
the bolus, in contrast to the colloid (NS), suggesting impairment of renal oxygenation. The change in 
renal oxygen extraction was significantly (P<0.05) more pronounced in the crystalloid group compared 
with the colloid group. 
4.2 Renal hemodynamics, 
function and oxygenation ear-
ly after liver transplantation 
(paper II)
To study the effects of liver transplan-
tation on renal variables early after liv-
er transplantation, we studied 12 liver 
recipients with pre-transplant GFR 
>60 ml/min, and compared the re-
sults to a control group consisting of 
73 post cardiac surgery patients with-
out AKI, previously studied by our re-
search group [66-69, 72]. 
Preoperative data on the liver recipi-
ents are presented in table 5. Notably, 
the MELD- and Child-Pugh-scores 
are in a medium range, i.e. the symp-
toms of liver failure were moderate. 
Primary sclerotic cholangitis was the 
most common diagnosis, followed by 
cirrhosis due to viral infection.
There was a significant difference be-
tween the study and the control group 
regarding preoperative serum cre-
atinine, being 14% lower in the study 
group (p=0.001), than in the control 
group. This was anticipated since liver 
failure per se lowers serum creatinine 
by a lower conversion of creatine to 
creatinine, and by the reduced mus-
cle mass in patients with liver failure. 
However, eGFR, calculated according 
to the MDRD formula, did not differ 
between the groups. Serum creatinine 
increased in the liver transplanted 
group by over 40% per day during the 
first two postoperative days and 67% of 
the patients developed AKI.
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Table 3. Preoperative individual data, liver transplant recipients 
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Data presented as mean ± SD. MELD; Model For End-Stage Liver Disease, mGFR; measured glomerular filtration rate, ASA; American Society of 
Anesthesiologists
4.2.1 Effects on systemic variables
The circulation after liver transplanta-
tion was more hyperdynamic than af-
ter cardiac surgery, with a significant 
higher CI and DO2I, but a lower SVRI, 
compared to the control group. All 
liver recipients required norepineph-
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rine at a mean dose of 0.28 ± 0.17µg/
kg/min to maintain a MAP of 70-80 
mmHg. 
4.2.2 Effects on renal variables (table 
4)
There was a 40% decline in mGFR, and 
a 24% increase in serum creatinine 
immediately after liver transplanta-
tion compared to the pretransplant 
value (fig 6). 
Compared to the control group, RVR 
was lower and RBF was higher in the 
liver transplanted group. Despite the 
renal vasodilation, the ratio between 
RBF and CI was significantly lower 
after liver transplantation than after 
cardiac surgery. GFR, FF and renal 
sodium reabsorption were all low-
er amongst liver recipients. Despite 
the lower sodium reabsorption, RVO2 
was considerably higher in the study 
group than in the control group. Thus, 
the ratio RVO2 per mmol/min of reab-
sorbed sodium was 2.7 times higher 
after liver transplantation than after 
uncomplicated surgery (fig 7). The 
higher oxygen consumption in liver 
recipients was not met by a propor-
tional increase in RDO2, resulting in a 
higher renal oxygen extraction in the 
study group than in the control group, 
i.e. impaired renal oxygenation.
Table 4: Renal data in the immediate postoperative period after liver transplantation
Variable Control group
(n=73)
Liver transplant 
recipients
(n=12)
p-value
Renal oxygen extraction 0.100 ± 0.03 0.124 ± 0.04 0.042
Urine flow (ml/min) 3.13 ± 1.7 2.54 ± 2.2 0.065
Renal blood flow (ml/min) 716 ± 209 843 ± 197 0.024
Renal blood flow /cardiac index 0.277 ± 0.08 0.202 ± 0.05 <0.001
Renal vascular resistance (mmHg/ml/min) 0.100 ± 0.03 0.085 ± 0.02 0.051
Glomerular filtration rate (ml/min) 70.9 ± 23.3 51.5 ± 30.4 0.043
Filtration fraction 0.15 ± 0.04 0.09 ± 0.06 0.006
Renal sodium filtration (mmol/min) 9.67 ± 3.2 7.63 ± 5.6 0.052
Renal sodium reabsorption (mmol/min) 9.28 ± 3.2 7. 50 ± 5.5 0.065
Fractional sodium excretion (%) 5.0 ± 4.0 2.5 ± 3.5 0.002
Renal oxygen delivery (ml/min) 103.5 ± 32.1 119.7 ± 29.7 0.048
Renal oxygen consumption (ml/min) 10.0 ± 3.2 14.4 ± 4.8 0.001
Renal oxygen consumption / renal sodium 
reabsorption (ml/mmol) 
1.15 ± 0.3 3.13 ± 2.4 <0.001
Serum creatinine day 1 (µmol/l) 75.1 ± 13.9 99.8 ± 32.7 0.025
Data are presented as mean ± SD
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Fig 6 Individual data on measured glomerular filtration rate (GFR) and serum creatinine before 
(preoperative) and early after liver transplantation (intensive care unit [26] ≤ 3 hours) (n = 12) 
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Fig 7: Relationship between renal oxygen consumption (RVO2) and renal sodium reabsorption, and 
between renal oxygen consumption and glomerular filtration rate (GFR), in the early postoperative period 
in liver recipients and after uncomplicated cardiac surgery (controls) 
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4.3 Renal effects of norepi-
nephrine-induced changes in 
mean arterial pressure after 
liver transplantation (paper III)
To study the renal effects of norepi-
nephrine-induced changes in target 
MAP, 10 liver recipients with pretrans-
plant normal renal function were in-
cluded in this paper. Target MAP was 
randomized to 60, 75 and 90 mmHg, 
and the infusion rates of norepineph-
rine to achieve these targets were 0.13 
± 0.11, 0.25 ± 0.16 and 0.38 ± 0.28 µg/
kg/min, respectively. Sixty percent of 
the patients included in this study de-
veloped AKI during the two first post-
operative days.
4.3.1 Effects on systemic variables 
(table 5)
SVRI and serum haemoglobin in-
creased significantly as the infusion 
rate of norepinephrine was adjusted 
to reach the higher target MAPs. In-
creasing MAP from 60 to 75 mmHg 
caused a significant augmentation in 
CI, SVI, and DO2I, while VO2I was left 
unaffected. Increasing target MAP 
further to 90 mmHg increased SVI in 
addition to SVRI and serum haemo-
globin with no changes in CI.
Table 5: Effects of varying doses of norepinephrine on systemic variables after liver trans-
plantation (n=10) 
60 mmHg 75 mmHg 90 mmHg
Norepinephrine (µg/kg/min) 0.13  ± 0.11 0.25  ± 0.16*** 0.38  ± 0.28##
Cardiac index (l/min/m2) 3.8  ± 1.0 4.3  ± 1.1*** 4.1  ± 1.1
Heart rate (beats/min) 72 ± 15 72 ± 16 65 ± 19##
Stroke volume index (ml/m2) 53.2  ±11.7 59.9  ± 11.6** 63.9  ± 10.9##
Central venous pressure 
(mmHg) 
7.1 ± 3.0 7.9  ± 2.8 8.4  ± 3.1
SVRI (dynes x sec/cm3/m2) 1183 ± 374 1352 ± 431** 1707 ± 474###
ScvO2 (%) 78.0  ± 6.4 81.5  ± 7.4*** 81.3  ± 7.2
Serum haemoglobin (g/l)  102.4 ± 14.2 106.6  ± 16.2*** 109.5 ± 14.5##
DO2I (ml/min/min2) 521 ± 122 614 ± 156*** 604 ± 150
VO2I (ml/min/min2) 97 ± 14 92 ± 19 93 ± 19
Body temperature 36.7  ± 0.4 36.9  ± 0.4* 36.8  ± 0.3
Data are presented as mean ± SD. 75 mmHg versus 60 mmHg *p <0.05, ** p < 0.01, *** p < 0.001; 90 mmHg versus 75 mmHg # p <0.05, ## p < 
0.01, ### p < 0.001 
SVRI, systemic vascular resistance index; ScvO2, central venous oxygen saturation 
DO2I, systemic oxygen delivery index; VO2I, systemic oxygen consumption index. 
The following data are non-parametric: heart rate.
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4.3.2 Effects on renal variables (table 
6)
Increasing MAP from 60 to 75 mmHg 
increased GFR, sodium filtration and 
reabsorption, RBF, RDO2, and RVO2, 
but left RVR and RO2Ex unaffected. 
Increasing MAP further, to 90 mmHg, 
increased RVR as the only affected re-
nal variable.
Table 6: Effects of varying doses of norepinephrine on renal variables after liver trans-
plantation (n=10) 
60 mmHg 75 mmHg 90 mmHg
Renal oxygen extraction 0.121 ± 0.05 0.120 ± 0.04 0.125 ± 0.05
Urine flow (ml/min) 1.27 ± 0.7 2.74 ± 2.5 2.52 ± 2.9
Renal blood flow (ml/min) 694 ± 243 820 ± 208* 767 ± 272
Renal blood flow /cardiac index 0.185 ± 0.06 0.200 ± 0.06 0.190 ± 0.06
Renal vascular resistance (mmHg/ml/
min) 
0.083 ± 0.03 0.087 ± 0.02 0.120 ± 0.04##
Glomerular filtration rate (ml/min) 42.6 ± 44.4 55.9 ± 38.3** 58.8 ± 58.8
Filtration fraction 0.08 ± 0.07 0.10 ± 0.05 0.11 ± 0.09
Renal sodium filtration (mmol/min) 5.84 ± 6.2 7.64 ± 5.4** 8.02 ± 8.2
Renal sodium reabsorption (mmol/min) 5.80 ± 6.2 7. 51 ± 5.4** 7.93 ± 8.2
Fractional sodium excretion (%) 2.4 ± 3.2 2.7 ± 3.8 1.6 ± 2.5#
Renal oxygen delivery (ml/min) 95.1 ± 33.8 119.0 ± 34.1** 114.3 ± 41.7
Renal oxygen consumption (ml/min) 11.4 ± 5.8 13.7 ± 4.5* 14.1 ± 7.4
Data are presented as mean ± SD. 75 mmHg versus 60 mmHg *p <0.05, ** p < 0.01, *** p < 0.001; 90 mmHg versus 75 mmHg # p <0.05, ## p < 
0.01, ### p < 0.001. 
The following data are non-parametric: urine flow, fractional sodium excretion.
4.4 Renal hemodynamics, 
function and oxygenation 
in early clinical septic shock 
(paper IV)
To evaluate renal perfusion, function and 
oxygenation in early clinical septic shock, 
we studied 8 patients within 24 hrs from 
ICU admission due to septic shock, and 
compared those data with data from 58 post 
cardiac surgery patients, previously includ-
ed in studies conducted by our research 
group. In the study group, there were 5 
cases of abdominal sepsis and 3 cases of 
septic pneumonia. Premorbid serum cre-
atinine was significantly lower, and hence 
eGFR higher, in the study group than in 
the control group (table 7). The mean SOFA 
score was 7.9 ± 2.6 at the time of the study. 
The mean serum creatinine had increased 
from 71 ± 15 (premorbid) to 91 ± 22 µumol/l 
at the time of the experimental procedure.
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Table 7: Patient characteristics; septic shock vs control group
Variable Control 
group
(n=58)
Septic 
shock
(n=8)
p-value
Gender, n (% female) 4 (7) 6 (75) <0.001
Age, mean (SD) 66 ± 10 64 ± 19 0.667
Body surface area (m2) 2.0 ± 0.2 1.8 ±0.1 0.019
Hypertension, n (%) 33 (57) 1 (8.3) 0.022
Diabetes, n (%) 6 (10) 0 (0) 0.445
Beta-adrenergic blocker, n (%) 46 (79) 1 (12.5) <0.001
ACE-inhibitor, n (%) 31 (53) 0 (0) 0.004
Calcium antagonist, n (%) 9 (16) 2 (25) 0.399
Serum creatinine (µmol/l) 83 ± 12 64 ± 13 <0.001
eGFR (MDRD) 81 ± 13 92 ± 17 0.049
Values are means ± SD, n = number of patients (%) 
ACE-inhibitor; angiotensin converting enzyme-inhibitor
4.4.1 Systemic variables in septic 
shock
Despite a mean dose of norepineph-
rine of 0.23 ± 0.17 µg/kg/min in the 
study group, MAP was slightly lower, 
but CVP was higher, than in the con-
trol group. Other systemic hemody-
namic variables did not differ between 
the groups.
4.4.2 Renal variables in septic shock 
(table 8)
GFR, sodium filtration and sodium 
reabsorption was significantly 
lower in the septic group than in 
the control group. Despite the lower 
sodium reabsorption, RVO2 did not 
differ between the groups. Thus, the 
ratio RVO2 per mmol of reabsorbed 
sodium was 45%  higher in the septic 
group (p=0.057). There was a trend 
for a lower RBF (-19%, p = 0.068) and 
a higher RVR (20%, p = 0.069), and 
the RBF/CI ratio was significantly 
lower, in the septic group than in the 
control group. However, RDO2 was 
significantly lower (-24%, p = 0.037) in 
the septic group than in the control 
group. Hence, RO2Ex was significantly 
higher in septic shock than after 
uncomplicated cardiac surgery.
Urinary NAG/creatinine ratio was 
5.4 ± 3.4 units/µmol creatinine in the 
study group. This variable was not 
measured in the control group.
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Table 8: Renal data; septic shock vs control group
Variable Control 
group
(n=58)
Septic shock
(n=8)
p-value
Renal oxygen extraction 0.097 ± 0.027 0.124 ± 0.039 0.022
Urine flow (ml/min) 3.8 ± 2.3 1.8 ± 1.0 0.007
Renal blood flow (ml/min) 858 ± 261 696 ± 166 0.068
Renal blood flow/cardiac index 0.31 ± 0.79 0.22 ± 0.67 0.003
Renal blood flow/cardiac output 0.16 ± 0.42 0.12 ± 0.43 0.028
Renal vascular resistance (mmHg/ml/
min)
0.082 ± 
0.023
0.098 ± 
0.023
0.069
Glomerular filtration rate (ml/min) 79.8 ± 24.3 54.4 ± 17.6 0.006
Filtration fraction 0.140 ± 0.033 0.120 ± 0.052 0.306
Renal sodium filtration (mmol/min) 11.0 ± 3.4 7.6 ± 2.5 0.008
Renal sodium reabsorption (mmol/min) 10.5 ± 3.3 7.5 ± 2.5 0.014
Renal oxygen delivery (ml/min) 122.3 ± 42.4 92.7 ± 23.5 0.037
Renal oxygen consumption (ml/min) 11.4 ± 3.1 11.4 ± 4.0 0.956
Renal oxygen consumption / renal 
sodium reabsorption (ml/mmol) 
1.12 ± 0.25 1.62 ± 0.71 0.057
Renal extraction of para-aminohippurate 0.84 ± 0.07 0.66 ± 0.21 0.005
Syrgasextraktionen är högre trots att GFR och natriumreabsorptionen är lägre, vilket skulle ha renderat en LÄGRE syrgasextraktion. 
Mismatchen beror på en försämrad syrgastillförsel till njuren, för syrgaskonsumtionen är ju densamma 
Trender är att RDO2 är lägre pga en afferent vasokonstriktion vilken ses här som en trend att RVR ökar, och RBF minskar, dvs en redistribution av 
blod från njuren. Varför? Ingen aning… Uppenbarligen är inte njurens blodförsörjning så extensivt tilltagen att den klarar av denna nedgång utan att 
få en negativ påverkan på GFR.
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DISCUSSION
5.1 Methodological and ex-
perimental considerations
In this thesis, the differential renal ef-
fects of crystalloid and colloid fluids 
for plasma volume expansion were 
studied after cardiac surgery with car-
diopulmonary bypass. Furthermore, 
we have studied the renal pathophys-
iology and the renal effects of three 
levels of target MAP early after liver 
transplantation, as well as, renal per-
fusion, function and oxygenation in 
early clinical septic shock. All stud-
ies were performed within 24 hours 
from ICU admission and all patients 
were sedated and mechanically ven-
tilated. Three out of four experimen-
tal procedures were performed out of 
office hours, due to the character of 
the studied procedures and circum-
stances.
5.2 Ethical issues
Some ethical considerations have 
been made during the planning of the 
studies. First of all, in paper I, plasma 
volume expansion was performed in 
patients considered haemodynam-
ically stable, according to our local 
postoperative treatment protocol. The 
reason for this approach was that we 
considered it unethical to include pa-
tients with obvious haemodynamic 
signs of hypovolemia, without treat-
ing this condition during the prepa-
ration for the experimental procedure, 
including time to reach a body tem-
perature > 36oC, time needed for se-
rum 51Cr-EDTA to reach steady state (at 
least 60 minutes) and baseline mea-
surements (60 minutes) before start of 
the plasma volume expansion. How-
ever, over 80% of the patients studied 
in paper I did respond to the given 
volume with an increase in CI. This 
is fundamental to our belief that the 
renal results of plasma volume expan-
sion with colloid and crystalloid fluid 
reported in our study are valid also 
for hypovolemic patients after major 
surgery. Second, the septic patients in 
paper IV were not included after in-
formed consent, but rather approval 
from the next of kin since the septic 
patients all were already sedated and 
mechanically ventilated at inclusion. 
This approach was approved by the 
ethical committee before inclusion of 
the first patient.
5.3 Study population
In two of the papers included in this 
thesis (Papers II and IV), we have in-
cluded uncomplicated postoperative 
patients with no renal impairment (no 
AKI) from earlier studies by our group, 
as controls. The baseline systemic and 
renal data of these patients were used 
for comparison with the liver recip-
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ients and the septic patients, respec-
tively. Factors shared by the patients 
in the control and the study groups 
are that they are all sedated and me-
chanically ventilated, and all are in an 
inflammatory state of different sever-
ity, the patients included in the con-
trol groups being studied after cardiac 
surgery with CPB. One major differ-
ence between the control groups and 
the study groups, is the distribution 
with regard to gender. In the control 
groups, the proportion of women is 
below 15% in all studies, compared 
to over 50% among liver recipients 
and patients with septic shock. This 
is simply caused by the distribution 
of gender in the Swedish population 
undergoing cardiac surgery, where 
women constitutes only 19% [73].
One common limitation in the stud-
ies included in this thesis, is the rela-
tively low sample size of liver recipi-
ents and patients with septic shock 
(Paper II and IV). Even though sepsis 
is a common diagnosis among ICU 
patients, the severity of the septic dis-
ease at ICU admission has increased 
over the years, resulting in early initi-
ation of RRT in many of these patients 
in the ICU, which together with strict 
inclusion and exclusion criteria, limit-
ed the number of patients eligible for 
inclusion. Moreover, it proved to be 
challenging to include, get informed 
consent from the next of kin, perform 
catheterisation of the pulmonary ar-
tery and the renal vein and achieve 
a steady state of PAH and 51Cr-EDTA 
within 24 hrs after arrival to the ICU. 
The strength of the study on septic 
patients, was the large control group 
made up by post-cardiac surgery pa-
tients with CPB, and hence also in a 
state of systemic inflammatory re-
sponse syndrome (SIRS) [74, 75]. An-
other reason is that many patients 
were eligible only off-hours.
In paper II, we did not assess whether 
or not there was a structural tubular 
cell injury in the early postoperative 
period in this group, as we did not 
measure tubular injury markers. How-
ever, the incidence of AKI in the
present study was high (67%), when 
compared to previous studies on tu-
bular injury markers after liver trans-
plantation (38–46%) [28, 29], and it is 
likely that release of tubular injury 
markers occurred also in the present 
study.
In paper III, it could be argued that 
changes in systemic and renal vari-
ables induced by varying infusion 
rates of norepinephrine, to obtain 
pre-determined levels of MAP, was 
caused by time-dependent sponta-
neous fluctuations and not to norepi-
nephrine itself. Thus, a time-control 
group is lacking in paper III. One way 
to circumvent this problem was to 
change the infusion rates of norepi-
nephrine to achieve the target MAP:s 
in a random fashion. Furthermore, 
the measured variables did not differ 
significantly between the two control 
values separated by 30 minutes, indi-
cating stability over time. 
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5.4 Measurement of renal 
blood flow (RBF), filtration 
fraction (FF) and GFR
5.4.1 RBF by thermodilution
Using a renal vein catheter for ther-
modilution measurement of RBF, ei-
ther by a bolus or by a continuous in-
fusion, has previously been described 
and validated [76-78]. The most crucial 
factor for successful measurements of 
RBF using the renal vein catheter, is 
to find the correct position and then 
to retain that position throughout the 
experimental procedure. The possi-
bility to estimate RBF repeatedly and 
without the need of a steady state or 
urine collection, makes it possible to 
bedside detect rapid fluctuations in 
RBF using the renal vein catheter and 
the retrograde thermodilution tech-
nique. 
Assumptions made for accurate ther-
modilution measurements of RBF are 
that there is only one renal vein at the 
site for measurement, that the renal 
blood flow is equal in both kidneys, 
that admixture of blood from other 
adjacent vessels like spermatic, ovari-
an or adrenal veins are negligible, and 
that the injectate mixes completely 
with the renal vein blood. The tech-
nique of thermodilution measure-
ment of renal blood flow is validated 
against the standard technique for RBF 
measurement using urinary clearance 
of PAH, and was initially found to pro-
duce a repeatability comparable to the 
PAH technique [76]. The repeatability 
was found to have improved when it 
was reevaluated ten years later, and 
the coefficient of variation of repeat-
ed estimations was 5.2% in a material 
presented by Bragadottir et al [68, 69].
5.4.2 RBF by infusion clearance of 
paraaminohippurate (PAH)
PAH is eliminated to approximately 
90% by the kidneys [79] and have an ex-
tra-renal elimination of 15% in patients 
after major surgery [30, 76]. There are 
some limitations to the golden stan-
dard of RBF measurement using the 
urinary clearance technique correct-
ed for by extraction of PAH. Swärd et 
al have compared the within-method 
error of infusion clearance for PAH to 
that of the urinary clearance of PAH 
and found that the within-method er-
ror was 16% and 33%, respectively [76]. 
The collection of urine is probably the 
main source of error using the uri-
nary clearance technique, despite the 
use of urine catheters. By the use of 
the infusion clearance technique for 
PAH, urine collection can be avoided, 
but it requires that PAH is not metab-
olized and that there is an equilibrium 
between the rate of infusion and ex-
cretion of PAH, and that the volume of 
distribution of PAH is constant during 
the measurement. PAH extraction has 
repeatedly been found to be 0.67- 0.95 
in patients after uncomplicated cardi-
ac surgery [30, 76]. However, Brenner 
et al found that PAH extraction was de-
creased in patients with septic shock 
and acute renal impairment, some-
thing that was also demonstrated in 
patients with AKI after cardiac surgery 
by Redfors et al several years later [30, 
77]. This would severely underesti-
mate RBF in critically ill patients, if not 
renal vein concentration of PAH was 
measured and taken into account in 
calculating RBF in patients with sep-
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tic shock. Redfors et al described that 
the half time of PAH in critically ill pa-
tients is four times longer than in un-
complicated postoperative patients, 
and hence it was concluded that the 
infusion clearance of PAH-technique 
was inappropriate for estimations of 
dynamic changes in RBF in critically 
sick patients (unpublished data pre-
sented in the thesis “Prevention and 
treatment of acute kidney injury after 
cardiac surgery”).
In paper IV, the arterial concentra-
tion of PAH did not differ between the 
two measurement periods, neither in 
the septic nor in the control group, 
indicating that steady state, required 
for measurement of RBF by infusion 
clearance of PAH, was achieved. Since 
the study on septic patients did not 
contain any intervention after start of 
infusion and baseline measurements, 
there were no dynamic changes to be 
expected.
5.4.3 Estimation of GFR by filtration 
fraction (FF) and by renal plasma 
flow (RPF) 
In 1951, Homer W. Smith published 
the textbook ‘The Kidney: Structure 
and Function in Health and Disease’, 
in which it was stated that glomerular 
filtration rate (GFR) was the best evalu-
ation of renal function. Assessment of 
GFR by infusion or urinary clearance 
of a filtration marker, such as 51CrEDTA, 
is by many considered to be the meth-
od of choice for clinical assessment 
of renal function [80, 81]. 51CrEDTA 
is an isotope undergoing glomerular 
filtration, is not reabsorbed or secret-
ed by the tubules and the extra-renal 
elimination is under 5%. It has recent-
ly been found that the repeatability of 
infusion clearance of 51CrEDTA is high 
with a low with-in method error and a 
low coefficient of variation in critical-
ly ill patients, confirming it to be the 
method of choice also in the ICU set-
ting [82]. However, the 51CrEDTA infu-
sion and urinary clearance techniques 
for estimation of GFR require equilib-
rium between rate of infusion and rate 
of excretion, i.e. steady state. However, 
repeated estimations of GFR at short 
intervals, can be performed by the 
renal vein thermodilution technique 
for measurement of the renal ex-
traction fraction of 51CrEDTA and RPF, 
[(RPF=RBF x (1-hematocrit)], without 
the requirement of a steady state. Thus, 
this technique allows instant and cor-
rect measurements of renal function. 
One issue with measurement of FF, 
using the renal extraction technique, 
is that the production of urine induc-
es a hemoconcentration affecting also 
the concentration of 51CrEDTA in the 
renal vein. This becomes incorrectly 
high, and the FF and GFR are therefore 
underestimated. To evade this error, 
the renal extraction of 51CrEDTA has 
been corrected for the differences in 
renal vein hemoconcentration caused 
by diuresis. 
5.4.4 Estimated GFR (eGFR)
To compare basal preoperative renal 
function between patients with liver 
failure waiting for liver transplanta-
tion, and the patients prior to cardi-
ac surgery constituting the control 
group, we used the MDRD formula 
(Modification of Diet in Renal disease) 
to calculate eGFR [83]. This formula 
was found to best correspond to mea-
sured GFR in cirrhotic patients [84], 
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and is based on age, gender, ethnic 
origin and serum creatinine. Creati-
nine is a molecule derived from cre-
atine. Creatine is produced in the liver 
and stored in muscle mass. Hence, 
the limitations of serum creatinine 
as a filtration marker in liver failure 
is mainly based on the reduced pro-
duction of creatine and the decreased 
muscle mass in patients with liver fail-
ure [85, 86]. Hence, creatinine based 
formulae tends to overestimate eGFR 
in patients with cirrhosis, especially 
in patients with GFR < 60 ml/min [85]. 
The preoperative measured GFR was > 
80 ml/min and there was no signifi-
cant difference between the measured 
and the estimated GFR among the liv-
er transplant recipients presented in 
this thesis (papers II and III).
5.5 Renal physiology in vaso-
dilatory shock 
We have studied renal hemodynam-
ics, function and oxygenation in two 
different vasodilatory states, namely 
early after liver transplantation and 
in patients with early septic shock 
(papers II and IV). In both studies, 
the vasopressor norepinephrine was 
needed also after fluid resuscitation to 
evade the vasodilation and to be able 
to maintain a target MAP of 75 mmHg.
A common strength between the two 
studies discussed in this part, is the 
large control groups that were used in 
both studies. The control groups con-
sists of patients after uncomplicated 
cardiac surgery and with uncompro-
mised renal function. Several parame-
ters are in common between the con-
trol and the studied groups, namely 
the presence of an inflammatory state, 
and moreover that all patients are se-
dation and mechanical ventilated in 
the ICU [74, 75].
5.5.1 Renal hemodynamics in vaso-
dilatory shock 
Even though liver transplantation and 
septic shock share the common path 
of a hyperdynamic circulation with a 
pronounced vasodilatation, our re-
sults bear witness that the renal he-
modynamics contributing to the fall 
in GFR differs between these two con-
ditions. GFR is partly controlled by the 
pressure across the glomeruli created 
by the balance in vascular tone of the 
afferent and the efferent arterioles. If 
the reduction in GFR is accompanied 
by a reduction in RBF, the most ten-
tative cause would be a vasoconstric-
tion of the afferent arteriole. On the 
contrary, if the reduction in GFR is ac-
companied by an increase in RBF, the 
cause would be assumed to be a vaso-
dilation of the efferent arteriole. 
RBF is increased, and GFR is de-
creased, after liver transplantation. 
This is presumably a result of a va-
sodilation of the efferent arteriole. In 
septic shock, on the other hand, the 
lower GFR is combined with, if any-
thing, a reduced RBF and hence most 
likely due to a vasoconstriction of the 
afferent arteriole. These findings are 
both in contrast with previously as-
sumed theories that the reduction in 
GFR in patients with liver failure is due 
to a vasoconstrictive reduction in RBF 
and an increase in RVR as presumed 
in HRS [87], and that AKI in septic 
shock is due to increased renal vaso-
dilation and an increased RBF [45]. On 
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the contrary, the findings regarding 
septic AKI in this thesis are in line with 
other previously described tentative 
mechanisms of septic AKI, where RBF 
is hypothesized to be low due to renal 
vasoconstriction [88, 89]. 
Activation of the renal sympathetic 
nerve activity has been shown to cause 
a reduction in both RBF and GFR, sug-
gesting an effect on preferentially the 
afferent arterioles [90], which could 
explain the increased renal vascular 
resistance in septic shock as shown in 
paper IV. Another explanation could 
be an activation of the tubulo-glo-
merular feedback (TGF) mechanism, 
caused by tubular dysfunction. This 
would reduce sodium reabsorption 
of individual tubules, increasing the 
sodium delivery to the macula densa, 
activating the TGF response, induc-
ing afferent arteriolar vasoconstriction 
with a decrease in both RBF and GFR 
[88, 91]. This hypothesis is supported 
by the finding that renal extraction of 
PAH, an indicator of tubular function, 
was significantly lower in septic shock 
patients than in the control group in 
paper IV. We find the early fall in GFR, 
in this study unlikely to be caused by 
shedding of tubular cells causing tu-
bular obstruction[88], as postmortal 
histopathological findings in septic 
AKI shows limited tubular injury [41], 
suggesting that the early fall in GFR 
in clinical sepsis is functional rather 
than structural in nature. It is not like-
ly, however, that TGF plays any major 
role in the mechanism causing the fall 
in GFR after liver transplantation, since 
RVR was lower and RBF higher when 
compared to the control group.
An interesting renal hemodynam-
ic variable in the two hyperdynamic 
states of post liver transplantation and 
septic shock, is the ratio between RBF 
and cardiac index, i.e. the relationship 
between systemic and renal blood 
flow. This ratio, RBF/CI, is reduced in 
the states of vasodilatory shock studied 
here, indicating that blood flow is di-
rected away from the kidneys in vaso-
dilatory shock. In septic shock, CI did 
not differ between the study and the 
control group, and the reduced RBF/
CI could be caused by the afferent ar-
teriolar vasoconstriction mediated by 
an increase in renal sympathetic nerve 
activity and/or TGF, resulting in the re-
duced RBF. In liver recipients, on the 
other hand, both CI and RBF were in-
creased compared to the control group, 
hence the reduced RBF/CI is more like-
ly caused by the greater increase in CI 
than in RBF. This could be the result of 
altered renal haemodynamics seen in 
liver failure, i.e. an increased renal va-
soconstriction as a result of splanchnic 
vasodilation, and a neurohormonal 
response resulting in renal vasocon-
striction, without which RBF might 
have increased enough not to cause a 
reduction in RBF/CI (fig 8). Since the 
patients in both studied groups were 
treated with norepinephrine to treat 
the vasodilatory shock state, and since 
norepinephrine has been shown to 
decrease RBF in healthy volunteers 
[64, 65], one could argue that the nor-
epinephrine could be at least partly 
responsible for the redistribution of 
blood away from the kidneys. Howev-
er, it has been proven that GFR, renal 
oxygen delivery and renal oxygenation 
are improved by restoring MAP to 75 
mmHg by the use of norepinephrine 
in vasodilatory shock [30]. 
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Fig 8. Mechanisms leading to hyperdynamic circulation in hepatic failure. Two hypotheses are advanced 
to explain the mechanism leading to hyperdynamic circulation: The humoral includes an overproduction 
of circulating vasodilators (intestinal or systemic); vasodilators escaping the degradation in the diseased 
liver or bypassing the liver through the porto-systemic shunts; a reduction in vasoconstrictors, and 
an increase in vasodilators. Porto-systemic vessels allow gut-derived humoral substances, such as 
glucagon, bile acid and calcitonin gene-related peptide to enter into the systemic circulation. The neural 
dysregulation hypothesis suggests that chemoreceptors and baroreceptors of the mesenteric area are 
activated by PH, and signals are related to central cardiovascular-regulatory nuclei via afferent nerves. 
(CBV: central blood volume; HVPG: hepatic vein portal gradient; CO: cardiac output ; HR: heart rate; PV: 
plasma volume; BV: blood volumes; RVR: renal vascular resistance; RBF: renal blood flow; SVR: systemic 
vascular resistance; MAP: mean arterial blood pressure; SNS: sympathetic nervous system; RAAS: renin–
angiotensin–aldosterone system; AVP: arginine vasopressin; ET: endothelin). 
Reprinted from European Journal of Internal Medicine, Vol 25, Pages 795-802, 2014,  by Licata et al, “Clinical implications of the hyperdynamic 
syndrome in cirrhosis”, with permission from Elsevier
5.5.2 Renal oxygenation in vasodil-
atory shock
The kidneys have a high energy de-
mand and oxygen requirements, 
particularly the outer portion of the 
medulla, due to the reabsorptive pro-
cesses. In addition, this region has, 
relative to the cortex, a low blood 
supply. Thus, the medulla is on the 
verge of being ischaemic already un-
der normal conditions. This makes 
the kidneys sensitive to hypoxaemic 
injury. Renal oxygenation is the bal-
ance between renal oxygen supply 
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and demand. Renal oxygen supply 
is dependent on RBF and arterial ox-
ygen content, while RVO2, to a large 
extent (60-80%), is dependent on tu-
bular reabsorption of sodium. There is 
a verified close relationship between 
GFR, tubular sodium reabsorption and 
RVO2, both in postoperative patients 
and, as shown previously by our study 
group and now in paper II in this the-
sis, after liver transplantation [36, 37, 
69, 92]. The higher the glomerular fil-
tration of sodium, the higher the tu-
bular sodium reabsorption and RVO2. 
Thus, GFR is in general the major de-
terminant of RVO2. 
In this thesis, there was a disconnec-
tion between renal function (GFR) 
and oxygen consumption, with an 
increased RVO2 despite a decreased 
GFR and sodium reabsorption, with 
a resulting mismatch in renal oxygen 
supply/demand relationship, both af-
ter liver transplantation and in septic 
shock. This results in an increased 
renal oxygen extraction, a direct mea-
sure of renal oxygen supply/demand 
relationship and hence an impaired 
renal oxygenation in these two va-
sodilatory states. However, after liver 
transplantation, the pathophysiology 
of the impaired oxygenation seems to 
be of a different nature than in septic 
shock, since renal oxygen consump-
tion was increased which was not 
seen in septic shock. Moreover, there 
was a significant increase of 2.7 times 
in renal oxygen consumption per re-
absorbed molecule of sodium in liver 
recipients. This could either be caused 
by a tubular injury and a subsequent 
inefficient tubular sodium transport, 
as demonstrated by our group in a 
previous study on renal effects in early 
ischemic AKI [36], or by an increased 
oxygen requirement for basal renal 
metabolism. This latter explanation 
is plausible since extrapolation of the 
regression lines in fig 7 shows that 
the presumed oxygen consumption 
at GFR of 0 ml/min is increased after 
liver transplantation compared to af-
ter cardiac surgery. The explanation to 
this is unclear, however it is not likely 
to be a generalized systemic increase 
in oxygen requirements since sys-
temic oxygen consumption was equal 
between the groups. The ensuing 
impairment in renal oxygenation, in 
turn, most likely gives rise to an isch-
emic tubular injury, presumably orig-
inating from the renal medulla where 
oxygen tension is low even under 
normal conditions, since it has previ-
ously been shown that tubular injury 
markers are elevated early after liver 
transplantation [93-95]
The impaired renal oxygenation in 
patients with septic vasodilated shock 
seems to have another explanation 
than after liver transplantation. Since 
there was no difference between the 
septic and the control group regard-
ing renal oxygen consumption, but 
instead a significant and pronounced 
reduction in RBF/CI and hence in renal 
oxygen delivery in the septic group, 
the main cause of the impaired renal 
oxygenation in septic shock seems to 
be due to renal vasoconstriction and 
a redistribution of blood flow away 
from the kidneys. In septic shock, hy-
potension is caused by an increased 
production of nitric oxide (NO) [48-
51]. Based on animal studies, it has 
been suggested that the hypotension 
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elicits an elevation of plasma norepi-
nephrine levels and an increase in re-
nal sympathetic nerve activity, which 
however has been suggested to be 
overridden by the profound increase 
in NO, resulting in a net renal vaso-
dilation [52-54].  The redistribution 
of renal blood flow presented in this 
thesis in patients with clinical sepsis, 
is most likely due to an increased tone 
of the afferent arteriole, since there is 
a reduction in both RBF and GFR. This 
is most likely caused by an increase in 
renal sympathetic nerve activity over-
riding the NO-induced vasodilation, 
resulting in a renal vasoconstriction. 
These findings and the interpreta-
tion presented in Paper IV is hence in 
contrast to the previously described 
pathophysiology in experimental sep-
tic AKI. Another tentative explanation 
to the renal afferent vasoconstriction 
could be a tubular dysfunction, result-
ing in a reduced sodium reabsorption 
and a subsequent activation of TGF 
causing a vasoconstriction of the renal 
afferent arteriole [88, 96]. This hypoth-
esis is supported by the finding that 
renal extraction of PAH, an indicator 
of tubular function, was lower among 
patients with septic shock than in the 
control group. Moreover, we found 
that urinary N-acetyl-β-D-glucos-
aminidase (NAG)/creatinine, a marker 
for tubular injury, was elevated in early 
clinical septic shock compared to the 
urinary NAG/creatinine in anesthe-
tized mechanically ventilated patients 
with normal renal function [97], sug-
gesting tubular injury in early clinical 
septic shock.
There is an impairment of tubular 
oxygen utilization, manifested as an 
increased oxygen consumption per 
mmol reabsorbed sodium, both in 
septic shock and after liver transplan-
tation. There could be several expla-
nations to the impaired renal oxygen 
utilization in vasodilatory shock. One 
explanation could be a hypoxia-in-
duced loss of epithelial cell polar-
ization and tight junction integrity, 
leading to a possible leakage of sodi-
um back to the tubuli. Another expla-
nation could be a reduced renal pro-
duction of NO that would cause an 
increase in RVO2, although this theory 
is less likely in septic shock since there 
was no difference in RVO2 between 
the groups. Yet another explanation 
to the impaired oxygen utilization in 
septic shock and after liver transplan-
tation could be a reaction to oxida-
tive stress, giving rise to an increased 
mitochondrial oxygen consumption. 
The increased oxygen consumption 
for basal renal metabolism seen after 
liver transplantation could be a reac-
tion to reactive oxygen species (ROS) 
that are released at reperfusion of the 
liver graft, causing an oxidative stress 
known to increase mitochondrial ox-
ygen consumption [98]
5.6 Measures to minimize the 
risk of renal harm in vasodila-
tory states
Impaired oxygenation is thus a ma-
jor cause of renal failure after major 
surgery and in septic shock. Since 
oxygenation is dependent on oxygen 
delivery and consumption, one could 
try either to increase oxygen delivery, 
or to decrease oxygen consumption to 
58 JENNY SKYTTE LARSSON
improve renal oxygenation. Postoper-
ative hypovolemia is commonly treat-
ed with i.v. fluids, such as colloids and 
crystalloids, as a measure to preserve 
organ perfusion, and hence oxygen 
delivery, despite perioperative blood 
loss.  
5.6.1 Renal oxygen delivery by plas-
ma volume expansion
Plasma volume expansion with fluids 
increases cardiac output and RBF, but 
at the same time i.v. fluids can cause a 
haemodilution and a decreased arteri-
al oxygen content that could counter-
act the positive effect on renal oxygen 
delivery. This has been demonstrat-
ed in several animal studies [99, 100], 
and this was also the case in paper I, 
where plasma volume expansion with 
both crystalloid and colloid fluid after 
uncomplicated surgery resulted in an 
increased CI and RBF, but with no net 
effect on renal oxygen delivery using 
any of the fluids. GFR, the major de-
terminant of sodium reabsorption, 
and hence of RVO2, was increased 
using crystalloid for plasma volume 
expansion. It is evident that this in-
crease in GFR was not met by a suffi-
cient increase in RBF, since FF was in-
creased, supporting the finding of an 
increased renal oxygen extraction and 
a mismatch in renal oxygen supply/
demand using a bolus of crystalloid 
for plasma volume expansion. This 
finding is in line with an experimental 
study showing decreased renal micro-
vascular oxygenation using crystalloid 
fluid for normovolemic haemodilu-
tion, compared to colloid that main-
tained renal oxygenation [101]. The 
explanation to the mismatch in renal 
oxygen balance with crystalloid, in 
addition to hemodilution, is that renal 
blood flow is redistributed away from 
the kidneys, as demonstrated by the 
reduction in the ratio RBF/CI, which 
points at an insufficient increase in 
RBF compared to the increase in CI, 
GFR and RVO2, which was not seen 
with the colloid.
A bolus dose of colloid fluid had a 
more persistent effect on renal hemo-
dynamics than crystalloid, but did not 
improve renal function, as demon-
strated by the unchanged GFR over 
time. Hence, the sodium reabsorption 
and the oxygen consumption were 
unaffected by the bolus of colloid, and 
renal oxygenation was preserved.
The effect of the colloid solution on 
plasma volume expansion endured 
for at least 60 minutes, as demon-
strated by the persistent rise in filling 
pressures and CI. However, since the 
distribution half-time is short for crys-
talloid solutions (8-10 min) [102, 103], 
the effect of a bolus dose of Ringer’s 
solution is more transient, and the 
effect on plasma volume expansion 
declined already after 60 minutes. To 
maintain the effect on plasma volume 
expansion after a crystalloid bolus, 
it has to be repeated, with a repeated 
impairment of renal oxygenation in 
already hypovolemic patients. Anoth-
er way could be to use a larger dose of 
the crystalloid to induce a more pro-
nounced increase in CI, RBF and renal 
oxygen delivery. However, this would 
induce an increased haemodilution 
with potentially no effect on RDO2, and 
potentially an even higher RVO2 since 
the haemodilution decreases oncot-
ic pressure in the glomeruli resulting 
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in a higher GFR and hence a higher 
RVO2. This would induce a lower re-
nal oxygen supply/demand ratio and 
a worsened renal oxygenation.
5.6.2 Renal oxygen delivery by blood 
pressure targeting
RBF and GFR are maintained con-
stant despite fluctuations in MAP, 
within certain limits of MAP by renal 
autoregulatory changes in the tone 
of the afferent arterioles [104, 105]. 
At MAP levels below the lower limit 
of autoregulation, RBF and GFR be-
comes pressure-dependent and both 
therefore decrease. RDO2 is hence 
reduced and ischemic AKI may de-
velop. Hypotension has been found 
to be more common in patients who 
develop in-hospital AKI than in pa-
tients that do not [106], and MAP has 
been recommended to be kept >65 
mmHg in states of vasodilatory shock 
[107]. However, it has been found that 
a higher MAP than the recommended 
level of 65 mmHg could be necessary 
to avoid reduction in renal function in 
patients in shock, especially of septic 
origin [108]. 
Perioperative MAP has in several stud-
ies been found to have an impact on 
postoperative AKI [109, 110]. It has not 
previously been evaluated whether the 
level of MAP matters in the vasodilato-
ry shock seen in liver transplantation. 
In 2016, Mizota et al found that the 
lowest intraoperative blood pressure 
during liver transplantation was an 
independent risk factor for postopera-
tive AKI, even if the duration of hypo-
tension, i.e. MAP <50 mmHg, was very 
short and regardless of the high CI 
seen in liver recipients [111]. Splanch-
nic vasodilation and increased NO 
levels in combination with intraopera-
tive inflammatory substances released 
at reperfusion of the liver graft, results 
in the hyperdynamic vasodilated state 
of shock seen in liver recipients. The 
splanchnic vasodilation and relative 
central hypovolemia induces a release 
of vasoconstrictive substances and 
an altered renal circulation [112-115]. 
These findings are reproduced in this 
thesis, where liver graft recipients had 
a redistribution of RBF away from the 
kidneys, as demonstrated by the low-
er RBF/CI in liver recipients compared 
to the control group. One could argue 
that the redistribution of blood away 
from the kidneys could be caused by 
the vasopressor norepinephrine itself. 
This is however highly unlikely since 
RVR was unaffected by the increase 
in infusion rate of norepinephrine 
at increasing target MAP from 60 to 
75 mmHg. This has previously been 
shown in postoperative patients with 
norepinephrine-treated vasodilatory 
shock [30].  
In paper III, target MAP was randomly 
set to 60, 75 and 90 mmHg, respec-
tively, in normovolemic patients after 
liver transplantation, by changing the 
infusion rate of the vasopressor nor-
epinephrine. Since RBF and GFR both 
increased on increasing MAP from 60 
to 75 mmHg, but without any effect on 
RVR, renal autoregulation seems to be 
lost at MAP lower than 75 mmHg after 
liver transplantation. Increasing MAP 
from 75 to 90 mmHg did only induce 
an increase in RVR and no further ef-
fect on either GFR, RBF or FF. Hence, 
RVR is most likely controlled mainly 
by the autoregulatory afferent vaso-
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constriction in liver recipients and to 
a lesser exten by norepinephrine itself 
[116]. At restoring target MAP from 60 
to 75 mmHg, there was an increase in 
RDO2 due to the increase in RBF. At 
the same time, there was an increase 
in GFR, leading to an elevated RVO2. 
However, the increase in RVO2 was 
well matched by the increase in RDO2, 
leaving renal oxygenation intact de-
spite the better renal function at MAP 
75 compared to MAP 60 mmHg. 
. 
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CONCLUSION
• Postoperative plasma volume ex-
pansion with both crystalloid and 
colloid increase renal blood flow 
with no effect on renal oxygen 
delivery, this because of haemodi-
lution.
• The crystalloid-induced increase 
in GFR was associated with im-
paired renal oxygenation, which 
was not seen with a colloid fluid as 
plasma volume expander.
• After liver transplantation, vaso-
dilation of the efferent arterioles 
causes a renal vasodilation and a 
fall in GFR.
• Renal oxygen consumption is 
considerably increased early after 
liver transplantation, despite the 
lower GFR. 
• The increased renal blood flow 
seen after liver transplantation is 
not sufficient to meet the in-
creased renal metabolic demand, 
resulting in impaired renal oxy-
genation.
• Early after liver transplantation, a 
target mean arterial pressure of 75 
mmHg, compared to 60 mmHg, 
improves renal perfusion and 
function without impairing renal 
oxygenation.
• In early clinical septic shock, there 
is a fall in GFR and renal oxygen 
delivery caused by a constriction 
of afferent arterioles.
• In early clinical septic shock, sodi-
um is reabsorbed at a high oxygen 
cost, which together with reduced 
oxygen delivery impairs renal ox-
ygenation, causing renal tubular 
injury. 
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FUTURE 
PERSPECTIVES
In paper I it was shown that a bolus 
infusion of a crystalloid impairs re-
nal oxygenation. It would be inter-
esting to perform a randomised trial 
comparing volume resuscitation with 
crystalloid and a colloid, other than 
hydroxiethylstarch, on renal outcome 
in major surgery and critical illness
The use of the vasopressin-analogue 
terlipressin could be an alternative 
approach to treat systemic vasodila-
tion during and after liver transplan-
tation. Mukhtar et al found that terli-
pressin improved renal function, as 
serum levels of creatinine and cysta-
tin C significantly decreased during 
the two first postoperative days after 
liver transplantation [117]. Howev-
er, in a pharmacodynamic study on 
uncomplicated post-cardiac surgery 
patients, Bragadottir et al analyzed 
the renal effects of vasopressin and 
found that vasopressin induces a va-
soconstriction of the efferent arteri-
oles causing an increase in GFR and 
RVO2 but a decrease in renal blood 
flow [69]. Thus, vasopressin caused an 
impairment of renal oxygenation, as 
demonstrated by an increase in renal 
oxygen extraction, suggesting that the 
use of vasopressin in liver transplan-
tation might be a two-edged sword. 
The effects of vasopressin/terlipressin 
on renal perfusion, filtration and oxy-
genation in patients undergoing liver 
transplantation needs to be investi-
gated.
Since the reduction in GFR after liver 
transplantation is evident and pro-
found immediately after the opera-
tion, it would be highly interesting to 
assess renal perfusion, filtration and 
oxygenation perioperatively, measur-
ing RBF, GFR and oxygenation prior to 
and after the anhepatic phase. 
It would also be interesting to study 
the renal effects of atrial natriuretic 
peptide (ANP), both in early clinical 
sepsis and after liver transplantation. 
ANP has been shown to increase GFR, 
by afferent areriolor vasodilation, in 
acute kidney injury after cardiovas-
cular surgery. Can ANP improve re-
nal outcome in sepsis and after liver 
transplantation? 
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FORMULAE
1. The formula to calculate RBFTD, corrected to body surface area (BSA). Subscript 
denotes internal thermistor (ind=indicator measurements) or external thermistor 
(blood = blood measurements). Superscript denotes calibration (cal) or registra-
tion signal. 
2. Calculations for renal data
3. The formula to calculate RPF by infusion clearance of PAH. 
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FORMULAE ABBREVIATIONS 
Abbreviations for additional renal calculations. RVR, renal vascular resistance; 
CaO2, arterial oxygen content; CrvO2, renal vein oxygen content; RVO2, renal 
oxygen consumption; RO2Ex, renal oxygen extraction; FF, filtration fraction, 
[51CrEDTAa], arterial concentration of 51CrEDTA; [51CrEDTArv], renal vein concen-
tration of 51CrEDTA; Na+filtration, renal sodium filtration; Na+ reabsorption, renal 
sodium reabsorption; SNa, serum sodium concentration; UF, urine flow; UNa, 
urine sodium concentration; FENa, fractional excretion of sodium.
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Abstract
Background: In the present randomized study, we evaluated the differential effects of a colloid and a crystalloid ﬂuid on renal
oxygen delivery (RDO2 ), glomerular ﬁltration (GFR), renal oxygen consumption (R _VO2), and the renal oxygen supply–demand
relationship (i.e. renal oxygenation) after cardiac surgery with cardiopulmonary bypass.
Methods: Thirty patients with normal preoperative renal function, undergoing uncomplicated cardiac surgery, were studied in
the intensive care unit in the early postoperative period. Patients were randomized to receive a bolus dose of either a crystalloid
(Ringers-acetate® 20 ml kg−1, n=15) or a colloid solution (Venofundin® 10 ml kg−1, n=15). Systemic haemodynamics were
measured via a pulmonary artery catheter. Renal blood ﬂow and GFR were measured by the renal vein retrograde
thermodilution technique and by renal extraction of 51Cr-EDTA (=ﬁltration fraction). Arterial and renal vein blood sampleswere
obtained for measurements of renal oxygen delivery (RDO2 ) and R _VO2. Renal oxygenation was estimated from the renal oxygen
extraction.
Results: Despite an increase in cardiac index and renal bloodﬂowwith both ﬂuids, neither of the ﬂuids improved RDO2 , because
they both induced haemodilution. The GFR increased in the crystalloid (28%) but not in the colloid group. The crystalloid
increased the ﬁltration fraction (24%) and renal oxygen extraction (23%), indicating that the increase in GFR, the major
determinant of R _VO2, was not matched by a proportional increase in RDO2 .
Conclusions: Neither the colloid nor the crystalloid improved RDO2 whenused for postoperative plasmavolumeexpansion. The
crystalloid-induced increase in GFR was associated with impaired renal oxygenation, which was not seen with the colloid.
Clinical trial registration: NCT01729364.
Key words: colloids; crystalloids; glomerular ﬁltration rate; plasma volume expansion; postoperative treatment;
renal blood ﬂow; renal oxygen consumption and oxygenation
Acute kidney injury (AKI) after cardiac surgery with cardiopul-
monary bypass continues to be a signiﬁcant cause for morbidity
and mortality. Depending on the complexity of the procedure,
the incidence of postoperative AKI, deﬁned as an increase of
serum creatinine by >50%, ranges between 15 and 30%.1–4 Dialysis-
dependent AKI, occurring in 2–5% of cardiac surgery patients,
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carries a mortality between 50 and 80% and is associated with
highhospital costs.5–7 Furthermore, increasing evidence suggests
that aminor elevation in serum creatinine after cardiac surgery is
an independent risk factor for increased mortality and for pro-
longed stay in the intensive care unit and in hospital.6 8 9
The pathogenesis of cardiac surgery-associated AKI involves
a variety of pathways.10 Impaired renal oxygen delivery (RDO2 ),
causing ischaemic tubular cell injury, has been considered to be
one of the main mechanisms underlying postcardiac surgery
AKI.11 A decreased oxygen deliverymay be caused by haemodilu-
tion-induced anaemia and intraoperative hypotension together
with low postoperative cardiac output, in turn caused by heart
failure or hypovolaemia.3 12–14 The renal medulla, particularly
the outer portion, is on the verge of hypoxia even in normal con-
ditions. This is caused by the high utilization of oxygen of the
medullary thick ascending limb and a relative medullary hypo-
perfusion, when compared with the cortex. The outer portion
of the renal medulla is therefore particularly sensitive to im-
paired RDO2 .
15
I.V. ﬂuids, such as colloids or crystalloids, are commonly used
for treatment of postoperative hypovolaemia after cardiac or
other major surgery, to prevent or ameliorate early AKI.16 How-
ever, even though i.v. ﬂuids may increase cardiac output and
renal blood ﬂow (RBF), theywill also decrease arterial oxygen con-
tent by haemodilution,with potentially no orminor beneﬁcial net
effects on RDO2 . Indeed, recent animal studies have shown that
colloids or crystalloids do not increase RDO2 despite increases in
cardiac output and that crystalloids, in contrast to colloids, may
impair regional renal microvascular oxygenation.17 18
To our knowledge, the effects of i.v. ﬂuids on RDO2 and renal
oxygenation have not been studied in postoperative patients
after major surgery. Furthermore, perioperative data on the dif-
ferential effects of crystalloids vs colloids with respect to RBF,
RDO2 , glomerular ﬁltration rate (GFR), renal oxygen consumption
(R _VO2), and renal oxygenation, deﬁned as the renal oxygen sup-
ply–demand relationship, are lacking. We therefore performed a
randomized study to evaluate the differential renal effects of
bolus doses of a crystalloid and a colloid. In the present study,
we tested the null hypothesis that there is no difference between
a crystalloid and a colloid with respect to changes in RDO2 and
renal oxygenation after major surgery.
Methods
Patients
The study protocol was approved by the Gothenburg Regional
Ethics Committee (www.epn.se). Written informed consent was
obtained from each patient before the operation. The study was
registered in ClinicalTrials.gov, identiﬁer: NCT01729364. The in-
clusion criteriawere as follows: (i) age >18 yr; (ii) elective coronary
artery bypass surgery with cardiopulmonary bypass; (iii) pre-
operative normal serum creatinine; (iv) left ventricular ejection
≥40%; and (v) attainment of target levels of central venous pres-
sure (5–10 mm Hg), mean arterial pressure (MAP; >70 mm Hg),
and mixed venous oxygen saturation ðSvO2 ;>60%) before ran-
domization, according to our local clinical treatment protocol.
The exclusion criteria were as follows: (i) combined cardiac sur-
gery procedures; (ii) excessive postoperative bleeding (>100 ml
h−1); (iii) intra- or postoperative need for inotropic or vasoactive
support or diuretics (furosemide, mannitol); or (iv) hypotension
because of arrhythmias.
Premedication consisted of oxazepam (10 mg) and oxycodone
(10 mg). Anaesthesia was induced by fentanyl (5–10 µg kg−1) and
propofol (1–1.5mgkg−1). Before andaftercardiopulmonarybypass,
anaesthesia was maintained with sevoﬂurane (0.5–2.5%) in a 50%
O2–air mixture. During cardiopulmonary bypass, anaesthesia was
maintainedwith an i.v. infusion of propofol (2–4mg kg−1 h−1). The
pumpwas primed with acetated Ringer’s solution (1300 ml) with-
out mannitol. Normothermic, non-pulsatile cardiopulmonary by-
pass was performed at a ﬂow of 2.4 litres min−1 m−2 and a target
haematocrit of 20–25%. In the intensive care unit, the patients
were sedated with propofol (1.5–3.6 mg kg−1 h−1) and morphine
(0.5–1 mg h−1) and mechanically ventilated.
Systemic haemodynamics
Arterial blood pressure was measured continuously via a radial
or femoral artery catheter. A pulmonary artery thermodilution
catheter (Baxter Healthcare Corporation, Irvine, CA, USA) was
used for measurements of central venous pressure, pulmonary
artery and wedge pressures and cardiac output. Bolus measure-
ments of thermodilution cardiac output were performed in trip-
licate and indexed to the body surface area for cardiac index (CI).
Systemic vascular resistance index, pulmonary vascular resist-
ance index, and stroke volume index (SVI) were calculated ac-
cording to standard formulae.
Measurements of renal variables
An 8 Fr catheter (Webster laboratories, Baldwin Park, CA, USA)
was introduced into the left or right renal vein, via the right
femoral vein under ﬂuoroscopic guidance. The catheter was
placed in the central portion of the renal vein, with the position
being conﬁrmed by venography using ultra-low doses of iohexol,
5–15 mg I kg−1 (Omnipaque 300 mg I ml−1; GE Healthcare, Stock-
holm, Sweden). Renal blood ﬂow was measured in duplicate by
the continuous retrograde thermodilution technique.19–22 At
the end of each urine collection period, the bladder was rinsed
with 100 ml of sterile water. After the collection of blood and
urine blanks, an i.v. priming dose of chromiumethylenediamine-
tetraacetic acid (51Cr-EDTA; GE Healthcare, Amersham, UK) was
given, followed by an infusion at a constant rate, individualized
to body surface area and preoperative serum creatinine. Serum
51Cr-EDTA activity from arterial and renal vein blood was mea-
sured using a well counter (Wizard 3’, 1480, Automatic gamma
counter; Perkin Elma LAS, Turkuu, Finland).
Experimental procedure
The experimental procedurewas performed 4–6 h after the end of
cardiopulmonary bypass when the patients had a stable body
Editor’s key points
• Acute kidney injury is one major postoperative complica-
tion after cardiac surgery with cardiopulmonary bypass,
and it is not known whether or not there are differences
in renal oxygen delivery between plasma volume expan-
sion with crystalloid and colloid.
• In a randomized design, effects on renal oxygen delivery
and other renal factors were compared between plasma
volume expansion with crystalloid and colloid.
• Neither colloid nor crystalloid improved renal oxygen deliv-
ery, but crystalloid, but not colloid, increased the GFR with
impaired renal oxygenation.
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temperature >36°C. The patients were sedated andmechanically
ventilated during the whole experimental procedure and were
randomized to receive either a crystalloid (20 ml kg−1, Ringer-
acetate®; Fresenius Kabi, Uppsala, Sweden) or a colloid solution
(10 ml kg−1, hydroxyethylstarch 60 mg ml−1, 130/0.62, Venofun-
din®; B. B. Braun, Melsungen, Germany). After an equilibration
period of at least 60 min, two 30min urine collection control per-
iods (periods C1 and C2) were started. The investigational ﬂuid
was then administered during 20–30 min. Thermodilution mea-
surements of RBF and CI were conducted, and blood and urine
samples were obtained at 20, 40 and 60 min after the end of the
ﬂuid administration. Formulae for calculation of the various
renal variables are shown in Table 1. All renal data were normal-
ized to a body surface area of 1.73 m2.
Statistical analysis
To detect a relative difference of 25% in RDO2 or renal oxygen ex-
traction with a power of 80% and a two-sided signiﬁcance level of
0.05, at a standard deviation of 24mlmin−1 and 0.024, respective-
ly, 30 patients would be required (15 patients in each group),
based on data from a previous study.23 To compensate for drop-
outs, we aimed to include ∼40 patients. Intragroup effects of the
colloid and crystalloid solutions, respectively, were determined
by one-way  for repeated measurements. Differences be-
tween groups were compared using an analysis of covariance
() for repeated mesurements, using the mean of the two
baselinemeasurements (C1 andC2) as a covariate. This statistical
approach adjusts for baseline differences between groups. Cat-
egorical data were compared using Fisher’s exact test. A P-value
<0.05 was considered signiﬁcant. PASWStatistics 18.0 (SPSS Inc.,
Chicago, IL, USA) was used for statistical analyses. Data are pre-
sented as mean and standard deviation () of the mean.
Results
Informed consent was obtained from 39 patients the day before
surgery. The clinical trial proﬁle is shown in Figure 1. Thirty pa-
tientswere randomized after renal vein catheterization to receive
either a colloid (n=15) or a crystalloid solution (n=15). There were
no signiﬁcant differences between the two groupswith respect to
preoperative characteristics, as presented in Table 2. There were
no signiﬁcant differences between the groups at baseline (C1
and C2), before ﬂuid administration, in any of the measured or
calculated variables (Tables 3 and 4).
Table 1 Formulae for calculation of renal variables. CaO2 and CrvO2 , arterial and renal vein oxygen contents; CVP, central venous pressure;
MAP, mean arterial pressure; [Na+]s, serum sodium concentration; [Na+]u, urine sodium concentration
Variable Formula
Renal blood ﬂow (RBF) (unilateral renal vein blood ﬂow×2)+urine ﬂow
Renal plasma ﬂow (RPF) RBF×(1−haematocrit)
Filtration fraction (FF) {RPF×[51Cr-EDTA arterial]−(RPF−urine ﬂow)×[51Cr-EDTA renal vein]}/
(RPF×[51Cr-EDTA arterial])
Glomerular ﬁltration rate (GFR) FF×RPF
Renal vascular resistance (RVR) (MAP−CVP)/RBF
Arterial–renal vein (rv) oxygen content difference (RAVO2-diff ) ðCaO2 " CrvO2 Þ
Renal oxygen consumption (R _VO2) RBF×ðCaO2 " CrvO2 Þ
Renal oxygen extraction ðCaO2 " CrvO2=CaO2 Þ
Renal sodium ﬁltration GFR×[Na+]s
Renal sodium excretion Urine ﬂow×[Na+]s
Renal sodium reabsorption (GFR×[Na+]s)−(Urine ﬂow×[Na+]u)
Randomized to colloid n=15Randomized to crystalloid n=15
Unsuccessful catheterisation of the renal vein n=3
Fulfilled inclusion criteria and
informed consent obtained
(n=39)
Surgery cancelled n=2
Need for inotropic support n=2
Declined on the day of surgery n=1
Considered non-eligible by the surgeon n=1
Fig 1 Clinical trial proﬁle.
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other major surgery, to prevent or ameliorate early AKI.16 How-
ever, even though i.v. ﬂuids may increase cardiac output and
renal blood ﬂow (RBF), theywill also decrease arterial oxygen con-
tent by haemodilution,with potentially no orminor beneﬁcial net
effects on RDO2 . Indeed, recent animal studies have shown that
colloids or crystalloids do not increase RDO2 despite increases in
cardiac output and that crystalloids, in contrast to colloids, may
impair regional renal microvascular oxygenation.17 18
To our knowledge, the effects of i.v. ﬂuids on RDO2 and renal
oxygenation have not been studied in postoperative patients
after major surgery. Furthermore, perioperative data on the dif-
ferential effects of crystalloids vs colloids with respect to RBF,
RDO2 , glomerular ﬁltration rate (GFR), renal oxygen consumption
(R _VO2), and renal oxygenation, deﬁned as the renal oxygen sup-
ply–demand relationship, are lacking. We therefore performed a
randomized study to evaluate the differential renal effects of
bolus doses of a crystalloid and a colloid. In the present study,
we tested the null hypothesis that there is no difference between
a crystalloid and a colloid with respect to changes in RDO2 and
renal oxygenation after major surgery.
Methods
Patients
The study protocol was approved by the Gothenburg Regional
Ethics Committee (www.epn.se). Written informed consent was
obtained from each patient before the operation. The study was
registered in ClinicalTrials.gov, identiﬁer: NCT01729364. The in-
clusion criteriawere as follows: (i) age >18 yr; (ii) elective coronary
artery bypass surgery with cardiopulmonary bypass; (iii) pre-
operative normal serum creatinine; (iv) left ventricular ejection
≥40%; and (v) attainment of target levels of central venous pres-
sure (5–10 mm Hg), mean arterial pressure (MAP; >70 mm Hg),
and mixed venous oxygen saturation ðSvO2 ;>60%) before ran-
domization, according to our local clinical treatment protocol.
The exclusion criteria were as follows: (i) combined cardiac sur-
gery procedures; (ii) excessive postoperative bleeding (>100 ml
h−1); (iii) intra- or postoperative need for inotropic or vasoactive
support or diuretics (furosemide, mannitol); or (iv) hypotension
because of arrhythmias.
Premedication consisted of oxazepam (10 mg) and oxycodone
(10 mg). Anaesthesia was induced by fentanyl (5–10 µg kg−1) and
propofol (1–1.5mgkg−1). Before andaftercardiopulmonarybypass,
anaesthesia was maintained with sevoﬂurane (0.5–2.5%) in a 50%
O2–air mixture. During cardiopulmonary bypass, anaesthesia was
maintainedwith an i.v. infusion of propofol (2–4mg kg−1 h−1). The
pumpwas primed with acetated Ringer’s solution (1300 ml) with-
out mannitol. Normothermic, non-pulsatile cardiopulmonary by-
pass was performed at a ﬂow of 2.4 litres min−1 m−2 and a target
haematocrit of 20–25%. In the intensive care unit, the patients
were sedated with propofol (1.5–3.6 mg kg−1 h−1) and morphine
(0.5–1 mg h−1) and mechanically ventilated.
Systemic haemodynamics
Arterial blood pressure was measured continuously via a radial
or femoral artery catheter. A pulmonary artery thermodilution
catheter (Baxter Healthcare Corporation, Irvine, CA, USA) was
used for measurements of central venous pressure, pulmonary
artery and wedge pressures and cardiac output. Bolus measure-
ments of thermodilution cardiac output were performed in trip-
licate and indexed to the body surface area for cardiac index (CI).
Systemic vascular resistance index, pulmonary vascular resist-
ance index, and stroke volume index (SVI) were calculated ac-
cording to standard formulae.
Measurements of renal variables
An 8 Fr catheter (Webster laboratories, Baldwin Park, CA, USA)
was introduced into the left or right renal vein, via the right
femoral vein under ﬂuoroscopic guidance. The catheter was
placed in the central portion of the renal vein, with the position
being conﬁrmed by venography using ultra-low doses of iohexol,
5–15 mg I kg−1 (Omnipaque 300 mg I ml−1; GE Healthcare, Stock-
holm, Sweden). Renal blood ﬂow was measured in duplicate by
the continuous retrograde thermodilution technique.19–22 At
the end of each urine collection period, the bladder was rinsed
with 100 ml of sterile water. After the collection of blood and
urine blanks, an i.v. priming dose of chromiumethylenediamine-
tetraacetic acid (51Cr-EDTA; GE Healthcare, Amersham, UK) was
given, followed by an infusion at a constant rate, individualized
to body surface area and preoperative serum creatinine. Serum
51Cr-EDTA activity from arterial and renal vein blood was mea-
sured using a well counter (Wizard 3’, 1480, Automatic gamma
counter; Perkin Elma LAS, Turkuu, Finland).
Experimental procedure
The experimental procedurewas performed 4–6 h after the end of
cardiopulmonary bypass when the patients had a stable body
Editor’s key points
• Acute kidney injury is one major postoperative complica-
tion after cardiac surgery with cardiopulmonary bypass,
and it is not known whether or not there are differences
in renal oxygen delivery between plasma volume expan-
sion with crystalloid and colloid.
• In a randomized design, effects on renal oxygen delivery
and other renal factors were compared between plasma
volume expansion with crystalloid and colloid.
• Neither colloid nor crystalloid improved renal oxygen deliv-
ery, but crystalloid, but not colloid, increased the GFR with
impaired renal oxygenation.
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temperature >36°C. The patients were sedated andmechanically
ventilated during the whole experimental procedure and were
randomized to receive either a crystalloid (20 ml kg−1, Ringer-
acetate®; Fresenius Kabi, Uppsala, Sweden) or a colloid solution
(10 ml kg−1, hydroxyethylstarch 60 mg ml−1, 130/0.62, Venofun-
din®; B. B. Braun, Melsungen, Germany). After an equilibration
period of at least 60 min, two 30min urine collection control per-
iods (periods C1 and C2) were started. The investigational ﬂuid
was then administered during 20–30 min. Thermodilution mea-
surements of RBF and CI were conducted, and blood and urine
samples were obtained at 20, 40 and 60 min after the end of the
ﬂuid administration. Formulae for calculation of the various
renal variables are shown in Table 1. All renal data were normal-
ized to a body surface area of 1.73 m2.
Statistical analysis
To detect a relative difference of 25% in RDO2 or renal oxygen ex-
traction with a power of 80% and a two-sided signiﬁcance level of
0.05, at a standard deviation of 24mlmin−1 and 0.024, respective-
ly, 30 patients would be required (15 patients in each group),
based on data from a previous study.23 To compensate for drop-
outs, we aimed to include ∼40 patients. Intragroup effects of the
colloid and crystalloid solutions, respectively, were determined
by one-way  for repeated measurements. Differences be-
tween groups were compared using an analysis of covariance
() for repeated mesurements, using the mean of the two
baselinemeasurements (C1 andC2) as a covariate. This statistical
approach adjusts for baseline differences between groups. Cat-
egorical data were compared using Fisher’s exact test. A P-value
<0.05 was considered signiﬁcant. PASWStatistics 18.0 (SPSS Inc.,
Chicago, IL, USA) was used for statistical analyses. Data are pre-
sented as mean and standard deviation () of the mean.
Results
Informed consent was obtained from 39 patients the day before
surgery. The clinical trial proﬁle is shown in Figure 1. Thirty pa-
tientswere randomized after renal vein catheterization to receive
either a colloid (n=15) or a crystalloid solution (n=15). There were
no signiﬁcant differences between the two groupswith respect to
preoperative characteristics, as presented in Table 2. There were
no signiﬁcant differences between the groups at baseline (C1
and C2), before ﬂuid administration, in any of the measured or
calculated variables (Tables 3 and 4).
Table 1 Formulae for calculation of renal variables. CaO2 and CrvO2 , arterial and renal vein oxygen contents; CVP, central venous pressure;
MAP, mean arterial pressure; [Na+]s, serum sodium concentration; [Na+]u, urine sodium concentration
Variable Formula
Renal blood ﬂow (RBF) (unilateral renal vein blood ﬂow×2)+urine ﬂow
Renal plasma ﬂow (RPF) RBF×(1−haematocrit)
Filtration fraction (FF) {RPF×[51Cr-EDTA arterial]−(RPF−urine ﬂow)×[51Cr-EDTA renal vein]}/
(RPF×[51Cr-EDTA arterial])
Glomerular ﬁltration rate (GFR) FF×RPF
Renal vascular resistance (RVR) (MAP−CVP)/RBF
Arterial–renal vein (rv) oxygen content difference (RAVO2-diff ) ðCaO2 " CrvO2 Þ
Renal oxygen consumption (R _VO2) RBF×ðCaO2 " CrvO2 Þ
Renal oxygen extraction ðCaO2 " CrvO2=CaO2 Þ
Renal sodium ﬁltration GFR×[Na+]s
Renal sodium excretion Urine ﬂow×[Na+]s
Renal sodium reabsorption (GFR×[Na+]s)−(Urine ﬂow×[Na+]u)
Randomized to colloid n=15Randomized to crystalloid n=15
Unsuccessful catheterisation of the renal vein n=3
Fulfilled inclusion criteria and
informed consent obtained
(n=39)
Surgery cancelled n=2
Need for inotropic support n=2
Declined on the day of surgery n=1
Considered non-eligible by the surgeon n=1
Fig 1 Clinical trial proﬁle.
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Effects of i.v. ﬂuids on systemic haemodynamics, arterial
oxygen content, and systemic oxygen delivery (Table 3)
As expected, both ﬂuids induced haemodilution, with signiﬁcant
decreases in haematocrit and CaO2 . Therewas a peak 9% increase
in MAP at 20 min after the end of ﬂuid infusion in the crystalloid
group, after which MAP declined towards baseline. In the colloid
group, there was a consistent 12–15% increase in MAP. A 16–18%
peak increase in CI and SVI were seen after 20 min in the crystal-
loid group, followed by a decline towards baseline. In the colloid
group, there was a consistent 18–23% increase in CI and SVI. An
increase in CI of >10%was seen in 12 of 15 patients in the crystal-
loid group and 13 of 15 patients and colloid group, and 11 of 15
patients in both groups increased their CI by >15%. Left- and
right-sided ﬁlling pressures increased, systemic vascular resist-
ance index decreased, and heart rate was unaffected by the two
ﬂuids. Therewas a transient 10% increase in systemic oxygen de-
livery index in the crystalloid group at 40 min, whereas systemic
oxygen delivery index was not affected in the colloid group.
Crystalloid vs colloid
The decrease in haematocrit and arterial oxygen content was sig-
niﬁcantly greater after the ﬂuid bolus administration in the col-
loid group. The increase in MAP was not signiﬁcantly different
between groups. The increase in CI was signiﬁcantly higher in
the colloid group, while changes in SVI or heart rate did not differ
between groups. The increases in left- and right-sided ﬁlling
pressures andmean pulmonary artery pressurewere signiﬁcant-
ly higher in the colloid group during the experimental procedure.
Increases in systemic oxygen delivery index anddecreases in sys-
temic vascular resistance index after ﬂuid administration did not
differ signiﬁcantly between groups.
Effects of i.v. ﬂuids on renal variables (Table 4)
There was a transient 9% increase in RBF at 20min in the crystal-
loid group, whreas there was a more consistent 11–17% increase
in RBF in the colloid group. The ratio between RBF and CI (RBF/CI)
Table 2 Patient characteristics. Values are means (). ACE
inhibitor, angiotensin-converting enzyme inhibitor;
CPB, cardiopulmonary bypass
Characteristic Crystalloid Colloid
Number of patients (n) 15 15
Female [n (%)] 3 (14) 1 (7)
Age (yr) 68 (43–80) 66 (48–83)
Weight (kg) 78.8 (11.2) 78.3 (9.4)
Body surface area (m2) 2.08 (0.47) 1.94 (0.14)
Left ventricular ejection fraction (%) 57 (8) 57 (6)
Hypertension [n (%)] 6 (39) 11 (73)
Preoperative serum creatinine
(μmol litre−1)
80 (10) 81 (12)
Postoperative serum creatinine
(μmol litre−1)
72 (13) 76 (15)
β-Adrenergic blocker [n (%)] 11 (73) 14 (93)
ACE inhibitor [n (%)] 7 (47) 5 (33)
Calcium antagonist [n (%)] 4 (27) 3 (21)
Diuretics [n (%)] 2 (13) 2 (13)
CPB time (min) 66 (17) 75 (19)
Aortic cross-clamp time (min) 40 (17) 48 (15)
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decreasedwith the crystalloid but notwith the colloid. Renal vas-
cular resistancewas not affected in any of the groups. Bolus ﬂuid
administration did not affect RDO2 in any of the groups. The GFR
and sodium ﬁltration increased transiently with the crystalloid,
with a peak 28% increase at 40 min. In the colloid group, GFR
and sodium ﬁltration were not signiﬁcantly changed from base-
line after ﬂuid administration. In the crystalloid group, tubular
sodium reabsorption increased transiently, with a peak increase
of 23% at 40min, whereas in the colloid group tubular sodium re-
absorption did not change signiﬁcantly from baseline. The ﬁltra-
tion fraction (FF) increased transiently in the crystalloid group
(24% at 40 min), with no changes in the colloid group. Urine
ﬂow increased in both groups. The R _VO2 increased (by 16–21%)
in the crystalloid group, with no changes in the colloid group.
Renal vein oxygen saturation decreased and arterial–renal vein
oxygen content difference increased in the crystalloid group,
whereas these variables were not affected in the colloid group.
Renal oxygen extraction, a direct measure of the renal oxygen
supply–demand relationship, increased by 23% in the crystalloid
group, whereas the colloid bolus did not affect renal oxygen
extraction Figure 2.
Crystalloid vs colloid
The increase in urine ﬂowwas signiﬁcantly higher in the crystal-
loid group. The increase in FF in the crystalloid group differed sig-
niﬁcantly from the change in the colloid group. In the crystalloid
group, changes in renal vein oxygen saturation, renal oxygen ex-
traction, and arterial–renal vein oxygen content difference were
signiﬁcantly higher than in the colloid group. There was a trend
for a higher increase in R _VO2 in the crystalloid group (P=0.085)
and a higher increase in RBF in the colloid group (P=0.089).
There were no signiﬁcant intergroup differences in RDO2 , GFR,
renal vascular resistance, RBF/CI, sodium ﬁltration, or sodium
reabsorption.
T
ab
le
4
R
en
al
va
ri
ab
le
s.
V
al
u
es
ar
e
m
ea
n
(

).






,b
et
w
ee
n
-g
ro
u
p
s
an
al
ys
is
of
va
ri
an
ce
w
it
h
ba
se
li
n
e
as
a
co
va
ri
at
e;





,w
it
h
in
-g
ro
u
p
an
al
ys
is
of
va
ri
an
ce
;G
FR
,g
lo
m
er
u
la
r
ﬁ
lt
ar
ti
on
ra
te
;
R
A
V
O
2-
d
if
f,
ar
te
ri
al
–r
en
al
ve
in
ox
yg
en
co
n
te
n
t
d
if
fe
re
n
ce
;R
B
F/
C
I,
re
la
ti
on
sh
ip
be
tw
ee
n
R
B
F
an
d
ca
rd
ia
c
in
d
ex
;R
D
O
2
,r
en
al
ox
yg
en
d
el
iv
er
y;
R
B
F,
re
n
al
bl
oo
d
ﬂ
ow
;R
O
2
Ex
,r
en
al
ox
yg
en
ex
tr
ac
ti
on
;
R
_ V
O
2
,r
en
al
ox
yg
en
co
n
su
m
p
ti
on
;R
V
R
,r
en
al
va
sc
u
la
r
re
si
st
an
ce
;S
rv
O
2
,r
en
al
ve
in
ox
yg
en
sa
tu
ra
ti
on
.A
ll
re
n
al
d
at
a
w
er
e
n
or
m
al
iz
ed
to
a
bo
d
y
su
rf
ac
e
ar
ea
of
1.
73
m
2
V
ar
ia
bl
e
C
ry
st
al
lo
id
O
n
e-
w
ay





C
ol
lo
id
O
n
e-
w
ay










cr
ys
ta
llo
id
vs
co
llo
id
Ba
se
lin
e
20
m
in
40
m
in
60
m
in
P-
va
lu
e
Ba
se
lin
e
20
m
in
40
m
in
60
m
in
P-
va
lu
e
P-
va
lu
e
R
B
F
(m
lm
in
−
1
)
67
4
(1
70
)
73
8
(1
78
)
68
8
(2
26
)
67
3
(2
01
)
0.
02
5
70
6
(1
99
)
82
7
(1
64
)
78
7
(2
07
)
79
2
(1
84
)
0.
01
9
0.
08
9
R
V
R
(m
m
H
g
m
l−
1
m
in
−
1
)
0.
10
8
(0
.0
3)
0.
10
7
(0
.0
3)
0.
11
2
(0
.0
4)
0.
11
2
(0
.0
3)
0.
62
5
0.
10
4
(0
.0
4)
0.
09
3
(0
.0
2)
0.
09
8
(0
.0
3)
0.
09
8
(0
.0
3)
0.
39
4
0.
16
5
R
D
O
2
(m
lm
in
−
1 )
99
.2
(2
5.
0)
99
.7
(2
3.
0)
95
.9
(2
6.
7)
93
.1
(2
5.
0)
0.
17
6
10
2.
5
(2
4.
9)
10
5.
4
(2
7.
4)
99
.7
(3
0.
6)
10
1.
6
(2
7.
7)
0.
75
0
0.
58
2
G
FR
(m
lm
in
−
1
)
68
.6
(1
4.
3)
79
.5
(2
1.
1)
87
.5
(2
2.
7)
76
.4
(1
6.
0)
<0
.0
01
70
.9
(1
5.
3)
85
.7
(2
3.
5)
78
.3
(2
9.
0)
83
.9
(3
8.
8)
0.
29
1
0.
98
9
So
d
iu
m
ﬁ
lt
ra
ti
on
(m
m
ol
m
in
−
1
)
9.
42
(2
.0
2)
10
.8
8
(2
.9
7)
12
.0
0
(3
.2
8)
10
.4
4
(2
.2
5)
<0
.0
01
9.
69
(2
.0
3)
11
.7
2
(3
.2
7)
10
.7
3
(4
.0
5)
11
.5
2
(5
.4
1)
0.
28
8
1.
00
0
So
d
iu
m
re
ab
so
rp
ti
on
(m
m
ol
m
in
−
1
)
9.
10
(2
.0
1)
9.
63
(3
.0
0)
11
.1
8
(3
.2
1)
9.
89
(2
.1
4)
0.
00
2
9.
30
(2
.0
5)
11
.3
3
(3
.2
2)
10
.1
9
(4
.0
1)
11
.2
6
(5
.2
0)
0.
23
5
0.
57
3
Fi
tr
at
io
n
fr
ac
ti
on
0.
15
7
(0
.0
31
)
0.
16
1
(0
.0
46
)
0.
19
4
(0
.0
52
)
0.
17
4
(0
.0
45
)
<0
.0
01
0.
15
4
(0
.0
50
)
0.
14
8
(0
.0
43
)
0.
14
2
(0
.0
50
)
0.
14
6
(0
.0
50
)
0.
77
3
0.
03
0
U
ri
n
e
ﬂ
ow
(m
lm
in
−
1
)
2.
7
(1
.2
)
8.
7
(4
.9
)
6.
5
(4
.3
)
4.
1
(1
.9
)
<0
.0
01
2.
5
(1
.2
)
2.
4
(1
.3
)
3.
5
(2
.0
)
3.
9
(2
.3
)
0.
00
3
0.
00
2
R
_ V
O
2
(m
lm
in
−
1
)
9.
5
(2
.4
)
11
.1
(2
.3
)
11
.5
(2
.9
)
11
.0
(3
.4
)
<0
.0
01
10
.1
(3
.3
)
10
.6
(4
.7
)
10
.1
(3
.0
)
10
.3
(3
.0
)
0.
96
4
0.
08
5
Sr
v O
2
(%
)
88
.9
(3
.2
)
87
.2
(3
.3
)
86
.2
(3
.6
)
86
.5
(3
.9
)
<0
.0
01
88
.4
(4
.0
)
88
.0
(4
.2
)
87
.5
(4
.1
)
87
.8
(3
.8
)
0.
45
2
0.
01
9
R
O
2
Ex
0.
09
9
(0
.0
31
)
0.
11
3
(0
.0
30
)
0.
12
1
(0
.0
33
)
0.
12
0
(0
.0
39
)
<0
.0
01
0.
10
4
(0
.0
39
)
0.
10
6
(0
.0
43
)
0.
11
1
(0
.0
39
)
0.
10
9
(0
.0
39
)
0.
65
3
0.
03
2
R
A
V
O
2
-d
if
f
(m
ll
it
re
−
1
)
14
.3
(3
.2
)
15
.4
(3
.3
)
17
.3
(4
.3
)
16
.8
(5
.3
)
0.
00
4
15
.3
(5
.4
)
13
.4
(5
.1
)
13
.8
(4
.6
)
13
.8
(4
.1
)
0.
16
9
0.
00
2
R
B
F/
C
I
0.
27
4
(0
.0
54
)
0.
26
1
(0
.0
56
)
0.
24
3
(0
.0
55
)
0.
25
7
(0
.0
55
)
0.
01
2
0.
27
8
(0
.0
90
)
0.
25
8
(0
.0
55
)
0.
25
0
(0
.0
73
)
0.
25
4
(0
.0
69
)
0.
21
0
0.
90
4
14
13
12
11
10
9
8
Control 20 min
NS Colloid
Crystalloid
R
en
al
 o
xy
ge
n 
ex
tra
ct
io
n 
(%
)
Crystalloid vs. Colloid
P<0.05
P<0.001
40 min 60 min
Fig 2 Effects of a crystalloid (10 ml kg−1) and a colloid (20 ml kg−1) bolus on
renal oxygen extraction after cardiac surgery. The crystalloid increased
renal oxygen extraction (P<0.001) 20, 40 and 60 min after the bolus, in
contrast to the colloid (NS), suggesting impairment of renal oxygenation.
The change in renal oxygen extraction was signiﬁcantly (P<0.05) more
pronounced in the crystalloid group compared with the colloid group.
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Effects of i.v. ﬂuids on systemic haemodynamics, arterial
oxygen content, and systemic oxygen delivery (Table 3)
As expected, both ﬂuids induced haemodilution, with signiﬁcant
decreases in haematocrit and CaO2 . Therewas a peak 9% increase
in MAP at 20 min after the end of ﬂuid infusion in the crystalloid
group, after which MAP declined towards baseline. In the colloid
group, there was a consistent 12–15% increase in MAP. A 16–18%
peak increase in CI and SVI were seen after 20 min in the crystal-
loid group, followed by a decline towards baseline. In the colloid
group, there was a consistent 18–23% increase in CI and SVI. An
increase in CI of >10%was seen in 12 of 15 patients in the crystal-
loid group and 13 of 15 patients and colloid group, and 11 of 15
patients in both groups increased their CI by >15%. Left- and
right-sided ﬁlling pressures increased, systemic vascular resist-
ance index decreased, and heart rate was unaffected by the two
ﬂuids. Therewas a transient 10% increase in systemic oxygen de-
livery index in the crystalloid group at 40 min, whereas systemic
oxygen delivery index was not affected in the colloid group.
Crystalloid vs colloid
The decrease in haematocrit and arterial oxygen content was sig-
niﬁcantly greater after the ﬂuid bolus administration in the col-
loid group. The increase in MAP was not signiﬁcantly different
between groups. The increase in CI was signiﬁcantly higher in
the colloid group, while changes in SVI or heart rate did not differ
between groups. The increases in left- and right-sided ﬁlling
pressures andmean pulmonary artery pressurewere signiﬁcant-
ly higher in the colloid group during the experimental procedure.
Increases in systemic oxygen delivery index anddecreases in sys-
temic vascular resistance index after ﬂuid administration did not
differ signiﬁcantly between groups.
Effects of i.v. ﬂuids on renal variables (Table 4)
There was a transient 9% increase in RBF at 20min in the crystal-
loid group, whreas there was a more consistent 11–17% increase
in RBF in the colloid group. The ratio between RBF and CI (RBF/CI)
Table 2 Patient characteristics. Values are means (). ACE
inhibitor, angiotensin-converting enzyme inhibitor;
CPB, cardiopulmonary bypass
Characteristic Crystalloid Colloid
Number of patients (n) 15 15
Female [n (%)] 3 (14) 1 (7)
Age (yr) 68 (43–80) 66 (48–83)
Weight (kg) 78.8 (11.2) 78.3 (9.4)
Body surface area (m2) 2.08 (0.47) 1.94 (0.14)
Left ventricular ejection fraction (%) 57 (8) 57 (6)
Hypertension [n (%)] 6 (39) 11 (73)
Preoperative serum creatinine
(μmol litre−1)
80 (10) 81 (12)
Postoperative serum creatinine
(μmol litre−1)
72 (13) 76 (15)
β-Adrenergic blocker [n (%)] 11 (73) 14 (93)
ACE inhibitor [n (%)] 7 (47) 5 (33)
Calcium antagonist [n (%)] 4 (27) 3 (21)
Diuretics [n (%)] 2 (13) 2 (13)
CPB time (min) 66 (17) 75 (19)
Aortic cross-clamp time (min) 40 (17) 48 (15)
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decreasedwith the crystalloid but notwith the colloid. Renal vas-
cular resistancewas not affected in any of the groups. Bolus ﬂuid
administration did not affect RDO2 in any of the groups. The GFR
and sodium ﬁltration increased transiently with the crystalloid,
with a peak 28% increase at 40 min. In the colloid group, GFR
and sodium ﬁltration were not signiﬁcantly changed from base-
line after ﬂuid administration. In the crystalloid group, tubular
sodium reabsorption increased transiently, with a peak increase
of 23% at 40min, whereas in the colloid group tubular sodium re-
absorption did not change signiﬁcantly from baseline. The ﬁltra-
tion fraction (FF) increased transiently in the crystalloid group
(24% at 40 min), with no changes in the colloid group. Urine
ﬂow increased in both groups. The R _VO2 increased (by 16–21%)
in the crystalloid group, with no changes in the colloid group.
Renal vein oxygen saturation decreased and arterial–renal vein
oxygen content difference increased in the crystalloid group,
whereas these variables were not affected in the colloid group.
Renal oxygen extraction, a direct measure of the renal oxygen
supply–demand relationship, increased by 23% in the crystalloid
group, whereas the colloid bolus did not affect renal oxygen
extraction Figure 2.
Crystalloid vs colloid
The increase in urine ﬂowwas signiﬁcantly higher in the crystal-
loid group. The increase in FF in the crystalloid group differed sig-
niﬁcantly from the change in the colloid group. In the crystalloid
group, changes in renal vein oxygen saturation, renal oxygen ex-
traction, and arterial–renal vein oxygen content difference were
signiﬁcantly higher than in the colloid group. There was a trend
for a higher increase in R _VO2 in the crystalloid group (P=0.085)
and a higher increase in RBF in the colloid group (P=0.089).
There were no signiﬁcant intergroup differences in RDO2 , GFR,
renal vascular resistance, RBF/CI, sodium ﬁltration, or sodium
reabsorption.
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Fig 2 Effects of a crystalloid (10 ml kg−1) and a colloid (20 ml kg−1) bolus on
renal oxygen extraction after cardiac surgery. The crystalloid increased
renal oxygen extraction (P<0.001) 20, 40 and 60 min after the bolus, in
contrast to the colloid (NS), suggesting impairment of renal oxygenation.
The change in renal oxygen extraction was signiﬁcantly (P<0.05) more
pronounced in the crystalloid group compared with the colloid group.
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Discussion
We studied the renal effects of acute plasma volume expansion
with artiﬁcial solutions early after cardiac surgery. The main
ﬁndings were that, despite apparent increases in cardiac index
and RBF with both ﬂuids, neither of the ﬂuids increased RDO2 .
Furthermore, plasma volume expansion with the crystalloid im-
paired the renal oxygen supply–demand relationship, expressed
as a more pronounced increase in renal oxygen extraction com-
pared with the colloid.
The lack of effect on RDO2 , despite the increase in RBF with
both ﬂuids, is explained by the fact that the arterial oxygen con-
tent decreased in both groups as a result of plasma volume ex-
pansion and haemodilution. In addition, the crystalloid bolus
seemed to redistribute blood ﬂow away from the kidneys, as re-
ﬂected by the reduction in the RBF/CI ratio. Thus, the increase
in RBF was not in proportion to the increase in CI with the
crystalloid.
One important difference between the two ﬂuids was their
differential effects on the renal oxygen supply–demand relation-
ship. The R _VO2 increased in the crystalloid group, which was not
matched by a proportional increase in RDO2 , as indicated by the
increase in renal oxygen extraction. In contrast, R _VO2, RDO2 ,
and renal oxygen extraction were not affected by the colloid.
Our group has repeatedly shown in postoperative patients that
themajor determinant of R _VO2 is GFR. An increase in glomerular
sodium ﬁltration will increase the sodium reabsorption, which,
in turn, will increase R _VO2.19 20 24 Also in the present study, the
increase in glomerular sodium ﬁltration was associated with in-
creases in sodium reabsorption and R _VO2 in the crystalloid
group. In the colloid group, however, this chain of events was
not observed, as the colloid did not affect GFR.
Infusion of a bolus dose of an isotonic crystalloid, such as the
acetatedRinger’s solution used in the present study, redistributes
within 20–30 min to the interstitial ﬂuid space because of the
short (8–10 min) distribution half-life.25 26 Thus, a bolus dose of
a crystalloid induces only a transient increase in plasma volume,
as also demonstrated by a return towards baseline of haemato-
crit, cardiac ﬁlling pressures, and CI within 60 min in the present
study, in contrast to the colloid group. Thus, tomaintain the plas-
ma volume in an expanded state in the treatment of post-
operative hypovolaemia, repeated bolus doses of a crystalloid
are required, with a potential for each of the crystalloid boluses
to impair renal oxygenation in a hypovolaemic patient already
subjected to impaired RDO2 and potentially also renal medullary
ischaemia.
In the present study, we measured the renal extraction of
51Cr-EDTA, which is a direct measure of the renal FF ( i.e. the
GFR/RPF ratio). The FF increased with the crystalloid, suggesting
that the increase in GFR (and R _VO2)was notmatched by a propor-
tional increase in renal blood ﬂow. We have previously shown in
postoperative cardiac surgery patients that there is a close posi-
tive correlation (r2>0.81) between the renal FF and renal oxygen
extraction.19 20 Thus, the crystalloid-induced increase in FF sup-
ports our ﬁnding of a renal oxygen supply–demand impairment
with a crystalloid.19 20 27
Our data are in line with previous animal studies. Thus, in an
experimental study on Merino cross-ewes, it was shown that both
a crystalloid and a colloid infusion, if anything, reduced RDO2 ,
because of haemodilution, despite increased cardiac output.17
Furthermore, in a rat hypovolaemic shock model, saline for treat-
ment of hypovolaemiadidnot improveRDO2 or renalmicrovascular
PO2 .
28 In a recent experimental study, it was shown that acute nor-
movolaemic haemodilution with a crystalloid decreased renal
microvascularoxygenation in the cortex and outermedulla, in con-
trast to a colloid (hydroxethyl starch 6% 130/0.4), whichmaintained
regional renal microvascular oxygenation.18 Haemodilution with
the crystalloid was also associatedwith highest formation of tissue
oedema and highest expression of hypoxia-inducible factor-1α, in
their study.
In the present study, both ﬂuids increased cardiac index. In the
colloid group, the increase in CI was more pronounced and con-
sistent during the experimental procedure. One could therefore
argue that a larger bolus dose of the crystalloid, e.g. 30 ml kg−1,
would have induced a more pronounced increase in CI, RBF, and
renal oxygendelivery,with less or no impairment of the renal oxy-
gendemand–supply relationship.On the contrary, ahigherdoseof
the crystalloid would have induced amore pronounced haemodi-
lution, which would have counteracted a beneﬁcial increase in
RBF, with potentially no net increase in RDO2 . Furthermore, a high-
er dose of the crystalloid would decrease the oncotic pressure fur-
ther, potentially increasing GFR and R _VO2 to a greater extent than
with a lower dose of crystalloid. Thus, it is not immediately evi-
dent that a higher dose (e.g. 30 ml kg−1) of a crystalloid than the
one used in the present study would have had a less negative ef-
fect on the renal oxygen demand–supply relationship.
One limitation of the present study was that we included pa-
tients whowere considered haemodynamically stable, according
to our local postoperative treatment protocol. Thus, we did not
measure arterial pulse pressure or stroke volume variation to as-
sess ﬂuid responsiveness.28 29 The reason for this approach is
that we considered it unethical to include patients with obvious
haemodynamic signs of hypovolaemia, deﬁned by our clinical
protocol, without treating this condition during the preparation
for the experimental procedure, including time to reach a body
temperature >36°C, time needed for serum 51Cr-EDTA to reach
steady state (at least 60 min), and baseline measurements (60
min) before start of the plasma volume expansion. However,
80–90% of the patients in both groups responded to the plasma
volume by an increase in CI.29 30 We therefore strongly believe
that our results on the renal effects of colloid and crystalloid so-
lutions are valid for a group of patients undergoing major sur-
gery, responding to plasma volume expansion with an increase
in CI in the early postoperative period.
In conclusion, we evaluated the differential renal effects of a
colloid and a crystalloid early after cardiac surgery. Although
both ﬂuids increased CI and RBF, neither of the ﬂuids improved
renal oxygen delivery. The crystalloid-induced increase in GFR
was associatedwith impaired renal oxygen demand–supply rela-
tionship, not seen with the colloid. Treatment of hypovolaemia
with a bolus dose of a crystalloid therefore has the potential to
impair renal oxygenation in postoperative patients.
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Discussion
We studied the renal effects of acute plasma volume expansion
with artiﬁcial solutions early after cardiac surgery. The main
ﬁndings were that, despite apparent increases in cardiac index
and RBF with both ﬂuids, neither of the ﬂuids increased RDO2 .
Furthermore, plasma volume expansion with the crystalloid im-
paired the renal oxygen supply–demand relationship, expressed
as a more pronounced increase in renal oxygen extraction com-
pared with the colloid.
The lack of effect on RDO2 , despite the increase in RBF with
both ﬂuids, is explained by the fact that the arterial oxygen con-
tent decreased in both groups as a result of plasma volume ex-
pansion and haemodilution. In addition, the crystalloid bolus
seemed to redistribute blood ﬂow away from the kidneys, as re-
ﬂected by the reduction in the RBF/CI ratio. Thus, the increase
in RBF was not in proportion to the increase in CI with the
crystalloid.
One important difference between the two ﬂuids was their
differential effects on the renal oxygen supply–demand relation-
ship. The R _VO2 increased in the crystalloid group, which was not
matched by a proportional increase in RDO2 , as indicated by the
increase in renal oxygen extraction. In contrast, R _VO2, RDO2 ,
and renal oxygen extraction were not affected by the colloid.
Our group has repeatedly shown in postoperative patients that
themajor determinant of R _VO2 is GFR. An increase in glomerular
sodium ﬁltration will increase the sodium reabsorption, which,
in turn, will increase R _VO2.19 20 24 Also in the present study, the
increase in glomerular sodium ﬁltration was associated with in-
creases in sodium reabsorption and R _VO2 in the crystalloid
group. In the colloid group, however, this chain of events was
not observed, as the colloid did not affect GFR.
Infusion of a bolus dose of an isotonic crystalloid, such as the
acetatedRinger’s solution used in the present study, redistributes
within 20–30 min to the interstitial ﬂuid space because of the
short (8–10 min) distribution half-life.25 26 Thus, a bolus dose of
a crystalloid induces only a transient increase in plasma volume,
as also demonstrated by a return towards baseline of haemato-
crit, cardiac ﬁlling pressures, and CI within 60 min in the present
study, in contrast to the colloid group. Thus, tomaintain the plas-
ma volume in an expanded state in the treatment of post-
operative hypovolaemia, repeated bolus doses of a crystalloid
are required, with a potential for each of the crystalloid boluses
to impair renal oxygenation in a hypovolaemic patient already
subjected to impaired RDO2 and potentially also renal medullary
ischaemia.
In the present study, we measured the renal extraction of
51Cr-EDTA, which is a direct measure of the renal FF ( i.e. the
GFR/RPF ratio). The FF increased with the crystalloid, suggesting
that the increase in GFR (and R _VO2)was notmatched by a propor-
tional increase in renal blood ﬂow. We have previously shown in
postoperative cardiac surgery patients that there is a close posi-
tive correlation (r2>0.81) between the renal FF and renal oxygen
extraction.19 20 Thus, the crystalloid-induced increase in FF sup-
ports our ﬁnding of a renal oxygen supply–demand impairment
with a crystalloid.19 20 27
Our data are in line with previous animal studies. Thus, in an
experimental study on Merino cross-ewes, it was shown that both
a crystalloid and a colloid infusion, if anything, reduced RDO2 ,
because of haemodilution, despite increased cardiac output.17
Furthermore, in a rat hypovolaemic shock model, saline for treat-
ment of hypovolaemiadidnot improveRDO2 or renalmicrovascular
PO2 .
28 In a recent experimental study, it was shown that acute nor-
movolaemic haemodilution with a crystalloid decreased renal
microvascularoxygenation in the cortex and outermedulla, in con-
trast to a colloid (hydroxethyl starch 6% 130/0.4), whichmaintained
regional renal microvascular oxygenation.18 Haemodilution with
the crystalloid was also associatedwith highest formation of tissue
oedema and highest expression of hypoxia-inducible factor-1α, in
their study.
In the present study, both ﬂuids increased cardiac index. In the
colloid group, the increase in CI was more pronounced and con-
sistent during the experimental procedure. One could therefore
argue that a larger bolus dose of the crystalloid, e.g. 30 ml kg−1,
would have induced a more pronounced increase in CI, RBF, and
renal oxygendelivery,with less or no impairment of the renal oxy-
gendemand–supply relationship.On the contrary, ahigherdoseof
the crystalloid would have induced amore pronounced haemodi-
lution, which would have counteracted a beneﬁcial increase in
RBF, with potentially no net increase in RDO2 . Furthermore, a high-
er dose of the crystalloid would decrease the oncotic pressure fur-
ther, potentially increasing GFR and R _VO2 to a greater extent than
with a lower dose of crystalloid. Thus, it is not immediately evi-
dent that a higher dose (e.g. 30 ml kg−1) of a crystalloid than the
one used in the present study would have had a less negative ef-
fect on the renal oxygen demand–supply relationship.
One limitation of the present study was that we included pa-
tients whowere considered haemodynamically stable, according
to our local postoperative treatment protocol. Thus, we did not
measure arterial pulse pressure or stroke volume variation to as-
sess ﬂuid responsiveness.28 29 The reason for this approach is
that we considered it unethical to include patients with obvious
haemodynamic signs of hypovolaemia, deﬁned by our clinical
protocol, without treating this condition during the preparation
for the experimental procedure, including time to reach a body
temperature >36°C, time needed for serum 51Cr-EDTA to reach
steady state (at least 60 min), and baseline measurements (60
min) before start of the plasma volume expansion. However,
80–90% of the patients in both groups responded to the plasma
volume by an increase in CI.29 30 We therefore strongly believe
that our results on the renal effects of colloid and crystalloid so-
lutions are valid for a group of patients undergoing major sur-
gery, responding to plasma volume expansion with an increase
in CI in the early postoperative period.
In conclusion, we evaluated the differential renal effects of a
colloid and a crystalloid early after cardiac surgery. Although
both ﬂuids increased CI and RBF, neither of the ﬂuids improved
renal oxygen delivery. The crystalloid-induced increase in GFR
was associatedwith impaired renal oxygen demand–supply rela-
tionship, not seen with the colloid. Treatment of hypovolaemia
with a bolus dose of a crystalloid therefore has the potential to
impair renal oxygenation in postoperative patients.
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Background
Acute kidney injury (AKI) is a common complication
after liver transplantation, with a reported incidence of
11–57% [1–4]. Even a minimal increase in serum cre-
atinine of 0.3 mg/dl (26.4 μmol/L) is associated with
higher mortality and shorter graft survival after liver
transplantation [5, 6]. Mortality after liver transplant-
ation is reported to be 2–6% in patients not developing
AKI, compared to a 47–55% mortality in patients who
do develop AKI after liver transplantation [3, 4].
The etiology of AKI after liver transplantation is un-
known, but is most likely multifactorial. Hypotension
caused by intra-operative blood loss and reperfusion in-
jury is presumably of importance. Furthermore, renal
dysfunction may be present prior to transplantation as
seen in patients with hepatorenal syndrome (HRS). In
patients with HRS, a splanchnic vasodilatation is seen.
This vasodilation is accompanied by an activation of the
renin-angiotensin and of the sympathetic nervous system,
resulting in increased renal vascular resistance. As a result,
blood flow will be distributed away from the kidneys and
hence the kidneys will receive a decreased oxygen delivery
[7, 8]. This could be considered as a potential mechanism
causing AKI after liver transplantation.
The diagnosis of AKI is based on an increase in serum
creatinine according to Kidney Disease Improving
Global Outcomes (KDIGO) criteria [9, 10]. Patients with
hepatic failure usually have low levels of serum creatin-
ine because of a low skeletal muscle mass, a lower creat-
ine production and lower conversion of creatine to
creatinine [11, 12]. Thus, creatinine-based methods for
calculation of glomerular filtration rate (GFR) will over-
estimate measured GFR in this population.
To our knowledge, there is no data on the effects of liver
transplantation on measured GFR, renal hemodynamics
or renal oxygenation early after liver transplantation.
Thus, to improve the prevention and treatment of postop-
erative AKI, it is of great importance to get more insights
into the renal pathophysiology after liver transplantation.
Indeed, in the most recent practice-based recommenda-
tions from the American Society of Transplantation Liver
and Intestine Community of Practice, Levitsky et al. stress
that nephro-protective strategies are needed to improve
renal outcome after liver transplantation [13].
In the present study, we measured GFR, renal blood
flow, renal oxygen consumption and renal oxygenation
early after liver transplantation by using the retrograde
renal vein thermodilution technique and by measuring
the renal extraction of the filtration marker chromium
ethylenediaminetetraaceticacid (51Cr-EDTA). Patients
undergoing uneventful major cardiac surgery served as
controls. We believe that the comparison between these
two groups is relevant since both groups have been ex-
posed to major surgery, both groups have had contact
with material that is not endogenous, with a consequent
systemic inflammation. Furthermore, both groups were
sedated and mechanically ventilated during the experi-
mental procedure, which was performed early after ar-
rival in the intensive care unit (ICU). Hence, differences
between the two groups with respect to renal function can
be viewed as results-specific for liver recipients. Our pri-
mary end point was the change in measured GFR from
baseline after liver transplantation. Our null hypothesis
was that measured GFR is not affected in the immediate
postoperative period after liver transplantation.
Methods
The Gothenburg Regional Ethics Committee approved
the study protocol and written informed consent was
obtained from all patients within the 24 hours before
surgery. The group of liver-transplanted patients was
compared to a group of post-cardiac surgery patients
after uncomplicated cardiac surgery, at a numerical ratio
of 1:6. Patients in both groups were studied in the early
postoperative period in the intensive care unit during
sedation and mechanical ventilation.
Liver transplant recipients
Twelve adult patients undergoing liver transplantation
were prospectively included during the period of January
2015 to February 2016 with the following inclusion cri-
teria: (a) age >18 years and (b) measured GFR > 60 ml/
min. The exclusion criteria were: (a) intra-operative need
for veno-venous bypass, (b) clinically significant postop-
erative bleeding, (c) unsuccessful catheterization of the
renal vein, and (d) contraindication to radio-contrast
agents. In all patients, GFR was measured within
3 months prior to transplantation by the plasma clear-
ance of either 51Cr-EDTA or iohexol.
Anesthesia was induced by propofol and fentanyl or
remifentanil, and maintained with sevoflurane and either
of the opiates used for induction. Intra-operative blood
salvage was performed with the Cell Saver® 5+ device
(Haemonetics Corporation, Braintree, MA, USA). Packed
red blood cells were given to maintain hemoglobin ≥
80 g/liter and plasma and blood platelets were adminis-
tered at the discretion of the attending anesthesiologist.
Immediately before reperfusion, all patients obtained
methylprednisolone at a dose of 0.5–1 gram and mannitol
at a dose of 200–300 ml. A bolus dose of epinephrine
(0.01–0.15 mg) was administered in reperfusion-induced
hemodynamic instability. Norepinephrine was adminis-
tered intra-operatively to maintain a mean arterial pres-
sure > 65 mmHg.
On arrival to the intensive care unit (ICU), the patients
were mechanically ventilated and sedated with propofol
(2.7 ± 0.6 mg/kg/h) and either fentanyl or remifentanil.
Postoperative targets were pulse pressure variation < 12%
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and a mean arterial pressure of 70–80 mmHg. Postopera-
tive hypovolemia was treated according to routine clinical
practice with albumin (Albumin Baxalta® 200 g/l) and/or
crystalloid fluid (Ringer–Acetate®, Baxter Viaflo, Baxter
Healthcare Corporation, Irvine, CA, USA). Hypotensive
normovolemic patients were treated with norepinephrine
according to the attending intensivist.
Cardiac surgery group (control group)
Seventy-three post-cardiac surgery patients served as
controls. These patients participated in pharmacological
intervention trials performed by our research group in
2006–2014 [14–17]. The inclusion criteria were: (a)
age >18 years, (b) elective cardiac surgery with cardiopul-
monary bypass, (c) preoperative left ventricular ejection
fraction ≥ 40%, and (d) preoperative serum creatinine
within normal range. The exclusion criteria were: (a) post-
operative need for inotropic support, (b) postoperative ar-
rhythmias requiring treatment, (c) significant postoperative
bleeding, (d) unsuccessful catheterization of the renal vein,
and (e) postoperative AKI according to the AKIN criteria
[18]. The baseline renal and systemic data of these patients,
i.e. before pharmacological intervention, were used for
comparison with those of the liver-transplanted group. Pre-
operative estimated glomerular filtration rate was calcu-
lated using the Modification of Diet in Renal Disease
(MDRD) formula in all patients.
Anesthesia was induced by fentanyl and propofol. Be-
fore and after cardiopulmonary bypass, anesthesia was
maintained with sevoflurane. During cardiopulmonary
bypass, anesthesia was maintained with propofol. In the in-
tensive care unit, the patients were sedated with propofol
(3.8 ± 0.18 mg/kg/min) and morphine or fentanyl, and
mechanically ventilated. Target central venous pressure
(CVP) and target mean arterial pressure (MAP) were 5–
10 mmHg and 70–80 mmHg, respectively. Postoperative
hypovolemia was treated according to routine clinical prac-
tice with hydroxethyl starch (Venofundin, Braun, Germany)
and crystalloid fluids (Ringer–Acetate®, Baxter Viaflo).
Measurements of systemic hemodynamics
Arterial blood pressure was measured continuously via a
femoral or radial artery catheter. CVP was measured con-
tinuously via a central venous catheter inserted through the
right jugular vein. Cardiac output (CO) was measured by
the transthoracic thermodilution pulse contour technique
using the PiCCO™ device (Pulsion Ltd, Munich, Germany)
in the liver-transplanted group, and in the cardiac surgery
group by a pulmonary artery thermodilution catheter
(Baxter Healthcare Corporation, Irvine, CA, USA). CO was
measured in triplicate and indexed to the body surface area.
Systemic vascular resistance index (SVRI) and stroke vol-
ume index (SVI) were calculated according to standard
formulae. In the liver transplant recipients, cardiac index
was recorded before, during and after the anhepatic phase.
Measurements of renal variables
An 8 Fr catheter (Webster Laboratories, Baldwin Park, CA,
USA) was postoperatively introduced into the left or right
renal vein, via the right femoral vein, under fluoroscopic
guidance. The catheter was placed in the central portion of
the renal vein, the position being confirmed by venography
using ultra-low doses of iohexol, 5–15 mg I kg − 1 (Omni-
paque 300 mg I ml − 1; GE Healthcare, Stockholm,
Sweden). Renal blood flow (RBF) was measured in triplicate
by the continuous retrograde thermodilution technique
[14, 17, 19, 20]. After the collection of blood and urine
blanks, an intravenous priming dose of 51Cr-EDTA (GE
Healthcare, Amersham, UK) was given, followed by an in-
fusion at a constant rate, individualized to body surface area
and to preoperative serum creatinine. Serum 51Cr-EDTA
activity from arterial and renal vein blood was measured
using a well counter (Wizard 3’, 1480, Automatic gamma
counter; PerkinElmer LAS, Turku, Finland). Formulae for
calculation of renal variables are described in Table 1. All
renal data were normalized to a body surface area of
1.73 m2. Serum creatinine was measured in all patients
within 24 hours before surgery and on the first and second
postoperative days. In addition, serum creatinine was mea-
sured on admission to the ICU in the liver recipients.
Experimental procedure
After an equilibration period of at least 60 min, two
30-min urine collection control periods were started.
Table 1 Formulae for calculation of renal variables
Variable Formulae
Renal blood flow (RBF) (Unilateral renal vein blood flow × 2)
+ urine flow
Renal plasma flow (RPF) RBF × (1 – hematocrit)
Filtration fraction (FF) (RPF × [51Cr-EDTA arterial] –
(RPF – urine flow) × [51Cr-EDTA renal
vein])/(RPF × [51Cr-EDTA arterial])
Glomerular filtration rate (GFR) FF x RPF
Renal vascular resistance (RVR) (MAP-CVP)/RBF
Arterial-renal vein (rv) oxygen
content difference (RAVO2-diff)
(CaO2-CrvO2)
Renal oxygen consumption
(RVO2)
RBF × (CaO2-CrvO2)
Renal oxygen extraction (CaO2-CrvO2/CaO2)
Renal sodium filtration GFR × [Na+]s
Renal sodium excretion Urine flow × [Na+]s
Renal sodium reabsorption (GFR × [Na+]s) – (urine flow × [Na
+]u)
51Cr-EDTA, chromium ethylenediaminetetraaceticacid, MAP mean arterial
pressure, CVP central venous pressure, CaO2 arterial oxygen content, CrvO2
renal vein oxygen content, [Na+]s serum sodium concentration, [Na
+]u urine
sodium concentration
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Thermodilution measurements of RBF and measurements
of cardiac index (CI) were conducted at the end of each of
the urine collection periods followed by blood and urine
sampling. Infusion rates of fluids and of norepinephrine
(liver-transplanted group) were not changed during the
experimental procedure.
Statistical analysis
Data on renal and systemic hemodynamic variables from
the two 30-min measurement periods were pooled. The
primary end-point of the present study was the change
in GFR after liver transplantation compared to the
preoperatively measured GFR. To detect a fall in GFR
by 30%, ten patients were needed at a power of 0.80, a
significance level of 0.05 and a standard deviation of
20 ml/min. Continuous variables were checked for normal
distribution. Intergroup differences where compared using
independent-samples t test or Mann-Whitney U test when
appropriate. Categorical data were compared using Fish-
er’s exact test. Linear regression analyses were performed
to correlate renal oxygen consumption to renal sodium
reabsorption and GFR, respectively. PASW Statistics Ver-
sion 18.0 (SPSS Inc., Chicago, IL, USA) was used for stat-
istical analyses. Within- and inter-group repeated
measurements of serum creatinine were calculated using
mixed model in SAS (SAS version 9.3, SAS Institute Inc.,
Cary, NC, USA). An unstructured covariance structure
was assumed for the inter-group analysis.
Data are presented as mean ± SD throughout the text.
A p value < 0.05 was considered significant.
Results
Liver transplant recipients
In the liver-transplanted group, informed consent was ob-
tained from 14 patients. One patient was excluded be-
cause of postoperative bleeding and another patient was
excluded because of unsuccessful placement of the renal
vein catheter. Individual preoperative and intra-operative
data on the liver-transplanted group are shown in Tables 2
and 3, respectively. Primary sclerotic cholangitis was the
most common liver-related diagnosis, followed by cirrho-
sis due to viral infection. The mean Model For End-Stage
Liver Disease (MELD) and Child-Pugh scores were 14.0 ±
5.7 and 9.3 ± 1.7, respectively. Mean preoperative mea-
sured GFR (mGFR), estimated GFR (eGFR) and serum
creatinine were 85.5 ± 18.7 ml/min, 86.9 ± 19.8 ml/min
and 70.8 ± 13.9 μmol/l, respectively. The duration of the
surgical procedure was 5.9 ± 1.4 hours and mean intra-
operative bleeding was 2.3 ± 1.3 liters.
Liver transplant recipients versus post-cardiac surgery
(control) group
Data on the characteristics of the two study groups are
shown in Table 4. In the liver-transplanted group, the
proportion of female gender was higher, the patients
were younger, and they had a lower preoperative serum
creatinine compared to the post-cardiac surgery group.
The difference in preoperative estimated GFR between
the groups was not statistically significant. Hypertension
and treatment with angiotensin-converting enzyme in-
hibitor (ACE inhibitor) were less frequent in liver trans-
plant recipients. A greater proportion of patients in the
liver-transplanted group were treated with diuretics,
while there were no statistical differences between the
groups with respect to the use of beta-adrenergic
blockers or calcium channel antagonists.
Systemic variables (Table 5)
All liver-transplanted patients required norepinephrine
infusion at a mean dose of 0.28 ± 0.17 μg/kg/min to
maintain a MAP of between 70 and 80 mmHg. There
were no statistically significant differences between the
liver-transplanted group and the control group regarding
MAP, heart rate, CVP, serum hemoglobin or systemic
oxygen consumption index. CI (65%), SVI (69%) and sys-
temic oxygen delivery index (60%) and venous saturation
were all significantly higher (all p < 0.001), while SVRI
was significantly lower (−36%, p < 0.001), in the liver-
transplanted group compared to the control group. In
liver transplant recipients, CI increased by 33% after re-
perfusion (p < 0.01) (Table 3).
Renal variables (Figs. 1, 2, 3 and Table 6)
In the immediate postoperative period, mGFR de-
creased from 85.5 ± 18.7 to 51.5 ± 30.4 (−40%, p < 0.01)
in liver transplant recipients. This decline in mGFR
measured directly after liver transplantation was accom-
panied by a statistically significant increase in serum
creatinine by 24%, from 70.8 ± 13.9 to 87.7 ± 18.7 μmol/l
(p < 0.05) (Fig. 1).
RBF was higher (18%, p < 0.05) and renal vascular re-
sistance was lower (15%, p = 0.051) in liver transplant re-
cipients compared to the control group. The ratio
between RBF and CI (RBF/CI) was 27% lower (p < 0.001)
in the liver-transplanted compared to the control group.
GFR and filtration fraction were 27% (p < 0.05) and 40%
(p < 0.01) lower in liver transplant recipients. Renal oxy-
gen consumption was 44% higher (p < 0.001) in liver
transplant recipients despite a 19% lower renal sodium
reabsorption compared to the control group. In both
groups, there was a close correlation between renal
oxygen consumption and renal sodium reabsorption,
(control group: r2 = 0.728, p <0.001, liver recipients:
r2 = 0.587 p < 0.05), and between renal oxygen consump-
tion and GFR (control group: r2 = 0.708, p < 0.001, liver re-
cipients: r2 = 0.395, p <0.05) (Fig. 2). However, the renal
oxygen consumption per mmol/min of reabsorbed sodium
was 2.7 times higher in the liver-transplanted compared to
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the control group. This increase in renal oxygen con-
sumption was not met by a proportional increase in renal
oxygen delivery, as demonstrated by the higher renal oxy-
gen extraction in liver transplant recipients compared to
the control group (p < 0.05). Serum creatinine increased in
the liver-transplanted group by 41% (p <0.01) and 48%
(p <0.01) on the first and second postoperative day,
respectively, compared to the preoperative baseline value.
This was not seen in the control group, and as shown in
Fig. 3, there was a statistically significant difference in
serum creatinine between the groups over time. Eight pa-
tients in the liver-transplanted group (67%) developed
acute kidney injury, as defined by the KDIGO criteria,
during the two first postoperative days.
Discussion
The main finding of the present study was that there was
an early and substantial decline in renal function after
liver transplantation. In spite of this decline in GFR, and
the lower renal sodium reabsorption, renal oxygen con-
sumption was considerably elevated in liver recipients
compared to after uncomplicated cardiac surgery. Further-
more, the renal oxygen supply/demand relationship (i.e.
oxygenation) was impaired in liver transplant recipients,
as the increase in renal oxygen consumption was not met
by a proportional increase in renal oxygen delivery, despite
the hyperdynamic circulation seen in this group.
The physiological control of GFR is mediated by the
balance between the tone of the afferent and efferent ar-
terioles. A fall in GFR may be caused either by vasocon-
striction of the afferent arterioles, with reduced RBF as a
consequence, or a vasodilation of the efferent arterioles,
which will be accompanied by an increase in RBF. An
activation of the tubulo-glomerular feedback mechan-
ism, caused by tubular dysfunction, would induce an af-
ferent arteriolar vasoconstriction with a decrease in both
RBF and GFR [21, 22]. Our findings of a fall in GFR
combined with an increased RBF, is thus best explained
by vasodilation preferentially of the efferent arterioles.
Table 3 Intra-operative data of liver transplant recipients
Duration of surgery (min) 357 ± 86
Duration of anhepatic phase (min) 73 ± 30
Bleeding (ml) 2270 ± 1290
Packed red blood cells (units) 2.5 (0–4)
Platelets (units) 2.5 (0–4)
Plasma (units) 4.0 (0–6)
Fibrinogen (g) 2.0 (0–11)
Albumin (ml) 300 (0–600)
Cellsaver (ml) 400 (0–980)
Intra-operative crystalloid (L) 2.5 ± 0.9
Epinephrine, n (%) 9 (75)
Diuresis (ml/procedure hour) 118 ± 47
CI prior to anhepatic phase (l/min/m2) 3.3 ± 0.9
CI during anhepatic phase (l/min/m2) 3.9 ± 1.6
CI after reperfusion (l/min/m2) 4.4 ± 0.9
SVRI (ml/min/min2) 1413 ± 290
CVP (mmHg) 8 ± 2
Intra-operative fluid balance (ml) 665 ± 1540
Data are presented as median (min-max), mean ± SD, n = number of patients (%)
CI cardiac index, SVRI systemic vascular resistance index, CVP central
venous pressure
Table 2 Preoperative individual data, liver transplant recipients
Patient
number
Diagnosis MELD
score
Child-Pugh
score
Serum bilirubin
(mmol/l)
mGFR
(ml/min/1.73 m2)
Serum creatinine
(μmol/l)
ASA
1 Primary biliary cirrhosis 15 10 36 75 67 3
2 Hepatitis C virus, cirrhosis 17 10 32 95 109 2
3 Primary sclerosing cholanigitis 6 9 8 72 60 2
4 Primary sclerosing cholanigitis, cirrhosis 22 11 110 62 59 3
5 Hepatitis C virus, hepatocellular carcinoma, cirrhosis 8 7 10 105 74 2
6 Alpha-1 antitrypsin deficiency, cirrhosis 16 11 43 94 75 3
7 Alcoholic liver cirrhosis 24 12 150 72 62 3
8 Primary sclerosing cholanigitis, cirrhosis 13 9 60 102 73 2
9 Primary sclerosing cholanigitis, cirrhosis 9 6 32 89 76 2
10 Hepatitis C virus, hepatocellular carcinoma, cirrhosis 9 9 14 122 60 3
11 Primary sclerosing cholanigitis, hepatitis B virus 18 10 340 77 60 2
12 Hepatitis C virus, hepatocellular carcinoma, cirrhosis 11 8 24 61 75 3
Mean 14.0 9.3 71.6 85.5 70.8 2.50
SD 5.7 1.7 94.6 18.7 13.9 0.52
Data presented as mean ± SD
MELD Model For End-Stage Liver Disease, mGFR measured glomerular filtration rate, ASA American Society of Anesthesiologists
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Thermodilution measurements of RBF and measurements
of cardiac index (CI) were conducted at the end of each of
the urine collection periods followed by blood and urine
sampling. Infusion rates of fluids and of norepinephrine
(liver-transplanted group) were not changed during the
experimental procedure.
Statistical analysis
Data on renal and systemic hemodynamic variables from
the two 30-min measurement periods were pooled. The
primary end-point of the present study was the change
in GFR after liver transplantation compared to the
preoperatively measured GFR. To detect a fall in GFR
by 30%, ten patients were needed at a power of 0.80, a
significance level of 0.05 and a standard deviation of
20 ml/min. Continuous variables were checked for normal
distribution. Intergroup differences where compared using
independent-samples t test or Mann-Whitney U test when
appropriate. Categorical data were compared using Fish-
er’s exact test. Linear regression analyses were performed
to correlate renal oxygen consumption to renal sodium
reabsorption and GFR, respectively. PASW Statistics Ver-
sion 18.0 (SPSS Inc., Chicago, IL, USA) was used for stat-
istical analyses. Within- and inter-group repeated
measurements of serum creatinine were calculated using
mixed model in SAS (SAS version 9.3, SAS Institute Inc.,
Cary, NC, USA). An unstructured covariance structure
was assumed for the inter-group analysis.
Data are presented as mean ± SD throughout the text.
A p value < 0.05 was considered significant.
Results
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In the liver-transplanted group, informed consent was ob-
tained from 14 patients. One patient was excluded be-
cause of postoperative bleeding and another patient was
excluded because of unsuccessful placement of the renal
vein catheter. Individual preoperative and intra-operative
data on the liver-transplanted group are shown in Tables 2
and 3, respectively. Primary sclerotic cholangitis was the
most common liver-related diagnosis, followed by cirrho-
sis due to viral infection. The mean Model For End-Stage
Liver Disease (MELD) and Child-Pugh scores were 14.0 ±
5.7 and 9.3 ± 1.7, respectively. Mean preoperative mea-
sured GFR (mGFR), estimated GFR (eGFR) and serum
creatinine were 85.5 ± 18.7 ml/min, 86.9 ± 19.8 ml/min
and 70.8 ± 13.9 μmol/l, respectively. The duration of the
surgical procedure was 5.9 ± 1.4 hours and mean intra-
operative bleeding was 2.3 ± 1.3 liters.
Liver transplant recipients versus post-cardiac surgery
(control) group
Data on the characteristics of the two study groups are
shown in Table 4. In the liver-transplanted group, the
proportion of female gender was higher, the patients
were younger, and they had a lower preoperative serum
creatinine compared to the post-cardiac surgery group.
The difference in preoperative estimated GFR between
the groups was not statistically significant. Hypertension
and treatment with angiotensin-converting enzyme in-
hibitor (ACE inhibitor) were less frequent in liver trans-
plant recipients. A greater proportion of patients in the
liver-transplanted group were treated with diuretics,
while there were no statistical differences between the
groups with respect to the use of beta-adrenergic
blockers or calcium channel antagonists.
Systemic variables (Table 5)
All liver-transplanted patients required norepinephrine
infusion at a mean dose of 0.28 ± 0.17 μg/kg/min to
maintain a MAP of between 70 and 80 mmHg. There
were no statistically significant differences between the
liver-transplanted group and the control group regarding
MAP, heart rate, CVP, serum hemoglobin or systemic
oxygen consumption index. CI (65%), SVI (69%) and sys-
temic oxygen delivery index (60%) and venous saturation
were all significantly higher (all p < 0.001), while SVRI
was significantly lower (−36%, p < 0.001), in the liver-
transplanted group compared to the control group. In
liver transplant recipients, CI increased by 33% after re-
perfusion (p < 0.01) (Table 3).
Renal variables (Figs. 1, 2, 3 and Table 6)
In the immediate postoperative period, mGFR de-
creased from 85.5 ± 18.7 to 51.5 ± 30.4 (−40%, p < 0.01)
in liver transplant recipients. This decline in mGFR
measured directly after liver transplantation was accom-
panied by a statistically significant increase in serum
creatinine by 24%, from 70.8 ± 13.9 to 87.7 ± 18.7 μmol/l
(p < 0.05) (Fig. 1).
RBF was higher (18%, p < 0.05) and renal vascular re-
sistance was lower (15%, p = 0.051) in liver transplant re-
cipients compared to the control group. The ratio
between RBF and CI (RBF/CI) was 27% lower (p < 0.001)
in the liver-transplanted compared to the control group.
GFR and filtration fraction were 27% (p < 0.05) and 40%
(p < 0.01) lower in liver transplant recipients. Renal oxy-
gen consumption was 44% higher (p < 0.001) in liver
transplant recipients despite a 19% lower renal sodium
reabsorption compared to the control group. In both
groups, there was a close correlation between renal
oxygen consumption and renal sodium reabsorption,
(control group: r2 = 0.728, p <0.001, liver recipients:
r2 = 0.587 p < 0.05), and between renal oxygen consump-
tion and GFR (control group: r2 = 0.708, p < 0.001, liver re-
cipients: r2 = 0.395, p <0.05) (Fig. 2). However, the renal
oxygen consumption per mmol/min of reabsorbed sodium
was 2.7 times higher in the liver-transplanted compared to
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the control group. This increase in renal oxygen con-
sumption was not met by a proportional increase in renal
oxygen delivery, as demonstrated by the higher renal oxy-
gen extraction in liver transplant recipients compared to
the control group (p < 0.05). Serum creatinine increased in
the liver-transplanted group by 41% (p <0.01) and 48%
(p <0.01) on the first and second postoperative day,
respectively, compared to the preoperative baseline value.
This was not seen in the control group, and as shown in
Fig. 3, there was a statistically significant difference in
serum creatinine between the groups over time. Eight pa-
tients in the liver-transplanted group (67%) developed
acute kidney injury, as defined by the KDIGO criteria,
during the two first postoperative days.
Discussion
The main finding of the present study was that there was
an early and substantial decline in renal function after
liver transplantation. In spite of this decline in GFR, and
the lower renal sodium reabsorption, renal oxygen con-
sumption was considerably elevated in liver recipients
compared to after uncomplicated cardiac surgery. Further-
more, the renal oxygen supply/demand relationship (i.e.
oxygenation) was impaired in liver transplant recipients,
as the increase in renal oxygen consumption was not met
by a proportional increase in renal oxygen delivery, despite
the hyperdynamic circulation seen in this group.
The physiological control of GFR is mediated by the
balance between the tone of the afferent and efferent ar-
terioles. A fall in GFR may be caused either by vasocon-
striction of the afferent arterioles, with reduced RBF as a
consequence, or a vasodilation of the efferent arterioles,
which will be accompanied by an increase in RBF. An
activation of the tubulo-glomerular feedback mechan-
ism, caused by tubular dysfunction, would induce an af-
ferent arteriolar vasoconstriction with a decrease in both
RBF and GFR [21, 22]. Our findings of a fall in GFR
combined with an increased RBF, is thus best explained
by vasodilation preferentially of the efferent arterioles.
Table 3 Intra-operative data of liver transplant recipients
Duration of surgery (min) 357 ± 86
Duration of anhepatic phase (min) 73 ± 30
Bleeding (ml) 2270 ± 1290
Packed red blood cells (units) 2.5 (0–4)
Platelets (units) 2.5 (0–4)
Plasma (units) 4.0 (0–6)
Fibrinogen (g) 2.0 (0–11)
Albumin (ml) 300 (0–600)
Cellsaver (ml) 400 (0–980)
Intra-operative crystalloid (L) 2.5 ± 0.9
Epinephrine, n (%) 9 (75)
Diuresis (ml/procedure hour) 118 ± 47
CI prior to anhepatic phase (l/min/m2) 3.3 ± 0.9
CI during anhepatic phase (l/min/m2) 3.9 ± 1.6
CI after reperfusion (l/min/m2) 4.4 ± 0.9
SVRI (ml/min/min2) 1413 ± 290
CVP (mmHg) 8 ± 2
Intra-operative fluid balance (ml) 665 ± 1540
Data are presented as median (min-max), mean ± SD, n = number of patients (%)
CI cardiac index, SVRI systemic vascular resistance index, CVP central
venous pressure
Table 2 Preoperative individual data, liver transplant recipients
Patient
number
Diagnosis MELD
score
Child-Pugh
score
Serum bilirubin
(mmol/l)
mGFR
(ml/min/1.73 m2)
Serum creatinine
(μmol/l)
ASA
1 Primary biliary cirrhosis 15 10 36 75 67 3
2 Hepatitis C virus, cirrhosis 17 10 32 95 109 2
3 Primary sclerosing cholanigitis 6 9 8 72 60 2
4 Primary sclerosing cholanigitis, cirrhosis 22 11 110 62 59 3
5 Hepatitis C virus, hepatocellular carcinoma, cirrhosis 8 7 10 105 74 2
6 Alpha-1 antitrypsin deficiency, cirrhosis 16 11 43 94 75 3
7 Alcoholic liver cirrhosis 24 12 150 72 62 3
8 Primary sclerosing cholanigitis, cirrhosis 13 9 60 102 73 2
9 Primary sclerosing cholanigitis, cirrhosis 9 6 32 89 76 2
10 Hepatitis C virus, hepatocellular carcinoma, cirrhosis 9 9 14 122 60 3
11 Primary sclerosing cholanigitis, hepatitis B virus 18 10 340 77 60 2
12 Hepatitis C virus, hepatocellular carcinoma, cirrhosis 11 8 24 61 75 3
Mean 14.0 9.3 71.6 85.5 70.8 2.50
SD 5.7 1.7 94.6 18.7 13.9 0.52
Data presented as mean ± SD
MELD Model For End-Stage Liver Disease, mGFR measured glomerular filtration rate, ASA American Society of Anesthesiologists
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Another tentative explanation to the fall in GFR after
liver transplantation, as an alternative to the “vascular
abnormality” described above, would be tubular cell
dysfunction (“tubular abnormality”) manifested as a de-
crease in tubular sodium reabsorption. This would in-
crease the sodium delivery to the macula densa,
activating the tubulo-glomerular feedback mechanism
causing an afferent arteriolar vasoconstriction with a de-
crease in both RBF and GFR [21, 22]. This mechanism,
however, is unlikely to explain the fall in GFR after liver
transplantation, as renal vascular resistance in the present
study was lower compared to the control group. Further-
more, we find the early fall in GFR in this study unlikely
to be caused by shedding of tubular cells causing tubular
obstruction, as this has been described to occur only in
later phases of ischemic AKI [22].
Our group has repeatedly shown that there is a close
correlation between GFR, tubular sodium reabsorption
and renal oxygen consumption in postoperative patients
[14, 19, 23, 24]. This was also demonstrated in the
present study in patients early after liver transplantation
(Fig. 2). The major difference between liver recipients
and the control group was that renal oxygen consump-
tion was higher at a certain level of tubular sodium re-
absorption or GFR in the liver transplant group. This is
demonstrated by the upward displacement of the curves
relating renal oxygen consumption to tubular sodium re-
absorption and GFR in Fig 2. Furthermore, the renal
Table 4 Patient characteristics
Variable Control group
(n = 73)
Liver transplant recipients
(n = 12)
p value
Gender, n (% female) 8 (11) 7 (58) 0.001
Age, mean (SD) 66.6 ± 10.1 56.7 ± 10.7 0.005
Body surface area (m2) 1.96 ± 0.2 1.92 ± 0.2 0.509
Body mass index (kg/m2) 26.4 ± 3.4 21.9 ± 1.1 <0.001
Hypertension, n (%) 40 (54.8) 1 (8.3) 0.004
Diabetes, n (%) 3 (4.1) 1 (8.3) 0.462
Beta-adrenergic blocker, n (%) 58 (79.5) 7 (58.3) 0.143
ACE inhibitor, n (%) 37 (50.7) 2 (16.7) 0.033
Calcium antagonist, n (%) 12 (16.4) 0 (0) 0.201
Diuretics, n (%) 3 (4.1) 8 (66.7) <0.001
- Aldosterone antagonists, n (%) 6 (50%)
Preoperative serum creatinine (μmol/l) 82.7 ± 11.4 70.8 ± 13.9 0.001
Preoperative estimated GFR (mL/min) 84.5 ± 14.5 86.9 ± 19.8 0.690
Preoperative measured GFR (mL/min) - 85.5 ± 18.7 -
Values are means ± SD, n = number of patients (%). Estimated GFR; using MDRD (Modification of Diet in Renal Disease) formula
ACE inhibitor angiotensin-converting enzyme inhibitor, GFR glomerular filtration rate
Table 5 Systemic data in the immediate postoperative period
Variable Control group
(n = 73)
Liver transplant recipients
(n = 12)
p value
Mean arterial pressure (mmHg) 74.0 ± 8.7 75.1 ± 1.1 0.338
Cardiac index (l/min/m2) 2.6 ± 0.5 4.3 ± 1.0 <0.001
Heart rate (beats/min) 76 ± 11 73 ± 17 0.522
Stroke volume index (ml/m2) 35.4 ± 7.1 60.0 ± 12.0 <0.001
Central venous pressure (mmHg) 7.9 ± 2.5 7.4 ± 3.0 0.639
Systemic vascular resistance index (dynes x sec/cm3/m2) 2081 ± 577 1337 ± 392 <0.001
Mixed/central venous oxygen saturation (%) 72.5 ± 4.4 81.2 ± 6.7 0.001
Serum hemoglobin (g/l) 106.2 ± 13 104.7 ± 15 0.730
Systemic oxygen delivery index (ml/min/min2) 381 ± 74 608 ± 142 <0.001
Systemic oxygen consumption index (ml/min/min2) 100.1 ± 15.1 94.5 ± 19.3 0.357
Data are presented as mean ± SD
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oxygen consumption per millimole reabsorbed sodium
was 2.7 times higher in the liver-transplanted group
compared to the control group. This could either be
caused by tubular injury and an energy-inefficient tubu-
lar sodium transport, as demonstrated by our group in
patients with early ischemic AKI [24], or by an increase
in oxygen demand for basal renal metabolism. Extrapola-
tion of the regression lines in Fig. 2 to the y-axis indicates
the renal oxygen consumption in a non-filtering, non-
reabsorbing kidney, i.e. the basal renal metabolism. Thus,
the major explanation for the higher renal oxygen con-
sumption after liver transplantation, despite the lower GFR
and sodium reabsorption, seems to be an elevation of basal
renal oxygen requirements. The mechanism behind this
finding is, so far, unclear. It is not likely to be explained by
a generalized increase in organ oxygen consumption, as
the systemic oxygen consumption index did not differ be-
tween groups. One could speculate that the production
and release of reactive oxygen species (ROS) from the liver
graft, as a consequence of the ischemia/reperfusion injury
[25], may contribute to the increased renal oxygen con-
sumption, as it has been shown that oxidative stress in-
creases mitochondrial oxygen consumption [26].
The renal oxygen/supply demand relationship, i.e. renal
oxygenation, was impaired early after liver transplantation,
expressed as the higher renal oxygen extraction compared
to the control group. It is reasonable to assume that this
impairment in renal oxygenation may induce tubular injury
Fig. 1 Individual data on measured glomerular filtration rate (GFR) and serum creatinine before (preoperative) and early after liver transplantation
(intensive care unit [ICU]≤ 3 hours) (n = 12)
Fig. 2 Relationship between renal oxygen consumption (RVO2) and renal sodium reabsorption, and between renal oxygen consumption and
glomerular filtration rate (GFR), in the early postoperative period in liver recipients and after uncomplicated cardiac surgery (controls)
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crease in both RBF and GFR [21, 22]. This mechanism,
however, is unlikely to explain the fall in GFR after liver
transplantation, as renal vascular resistance in the present
study was lower compared to the control group. Further-
more, we find the early fall in GFR in this study unlikely
to be caused by shedding of tubular cells causing tubular
obstruction, as this has been described to occur only in
later phases of ischemic AKI [22].
Our group has repeatedly shown that there is a close
correlation between GFR, tubular sodium reabsorption
and renal oxygen consumption in postoperative patients
[14, 19, 23, 24]. This was also demonstrated in the
present study in patients early after liver transplantation
(Fig. 2). The major difference between liver recipients
and the control group was that renal oxygen consump-
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relating renal oxygen consumption to tubular sodium re-
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Heart rate (beats/min) 76 ± 11 73 ± 17 0.522
Stroke volume index (ml/m2) 35.4 ± 7.1 60.0 ± 12.0 <0.001
Central venous pressure (mmHg) 7.9 ± 2.5 7.4 ± 3.0 0.639
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oxygen consumption per millimole reabsorbed sodium
was 2.7 times higher in the liver-transplanted group
compared to the control group. This could either be
caused by tubular injury and an energy-inefficient tubu-
lar sodium transport, as demonstrated by our group in
patients with early ischemic AKI [24], or by an increase
in oxygen demand for basal renal metabolism. Extrapola-
tion of the regression lines in Fig. 2 to the y-axis indicates
the renal oxygen consumption in a non-filtering, non-
reabsorbing kidney, i.e. the basal renal metabolism. Thus,
the major explanation for the higher renal oxygen con-
sumption after liver transplantation, despite the lower GFR
and sodium reabsorption, seems to be an elevation of basal
renal oxygen requirements. The mechanism behind this
finding is, so far, unclear. It is not likely to be explained by
a generalized increase in organ oxygen consumption, as
the systemic oxygen consumption index did not differ be-
tween groups. One could speculate that the production
and release of reactive oxygen species (ROS) from the liver
graft, as a consequence of the ischemia/reperfusion injury
[25], may contribute to the increased renal oxygen con-
sumption, as it has been shown that oxidative stress in-
creases mitochondrial oxygen consumption [26].
The renal oxygen/supply demand relationship, i.e. renal
oxygenation, was impaired early after liver transplantation,
expressed as the higher renal oxygen extraction compared
to the control group. It is reasonable to assume that this
impairment in renal oxygenation may induce tubular injury
Fig. 1 Individual data on measured glomerular filtration rate (GFR) and serum creatinine before (preoperative) and early after liver transplantation
(intensive care unit [ICU]≤ 3 hours) (n = 12)
Fig. 2 Relationship between renal oxygen consumption (RVO2) and renal sodium reabsorption, and between renal oxygen consumption and
glomerular filtration rate (GFR), in the early postoperative period in liver recipients and after uncomplicated cardiac surgery (controls)
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in the postoperative period, particularly so in the renal me-
dulla, which is sensitive to ischemia. Medullary tissue oxy-
gen tension is low already under normal conditions,
because of the high oxygen utilization of the medullary
thick ascending limb [27]. It has been shown that tubular
injury markers, such as neutrophil gelatinase-associated
lipocalin, are released in the urine within hours after liver
transplantation and that this may predict AKI [28–30]. An
early release of tubular injury markers early after liver
transplantation could be explained by the impaired renal
oxygenation demonstrated in the present study.
In this group of patients, with advanced or moderately
advanced chronic liver disease, a hyperdynamic circula-
tion was seen, with a profound systemic vasodilation
and a high cardiac index. Such a hyperdynamic circula-
tion in patients with advanced cirrhosis has been sug-
gested to be caused by a splanchnic vasodilation [31] in
turn caused by augmented levels of nitric oxide [32].
Furthermore, there is a post-reperfusion increase in cyto-
kines and complement factors, which also contributes to
the systemic vasodilation resulting in a perioperative need
for vasopressor treatment during liver transplantation
Fig. 3 Changes in serum creatinine in liver recipients and after uncomplicated cardiac surgery (controls). **p < 0.01
Table 6 Renal data in the immediate postoperative period
Variable Control group
(n = 73)
Liver transplant recipients
(n = 12)
p value
Renal oxygen extraction 0.100 ± 0.03 0.124 ± 0.04 0.042
Urine flow (ml/min) 3.13 ± 1.7 2.54 ± 2.2 0.065
Renal blood flow (ml/min) 716 ± 209 843 ± 197 0.024
Renal blood flow/cardiac index 0.277 ± 0.08 0.202 ± 0.05 <0.001
Renal vascular resistance (mmHg/ml/min) 0.100 ± 0.03 0.085 ± 0.02 0.051
Glomerular filtration rate (ml/min) 70.9 ± 23.3 51.5 ± 30.4 0.043
Filtration fraction 0.15 ± 0.04 0.09 ± 0.06 0.006
Renal sodium filtration (mmol/min) 9.67 ± 3.2 7.63 ± 5.6 0.052
Renal sodium reabsorption (mmol/min) 9.28 ± 3.2 7. 50 ± 5.5 0.065
Fractional sodium excretion (%) 5.0 ± 4.0 2.5 ± 3.5 0.002
Renal oxygen delivery (ml/min) 103.5 ± 32.1 119.7 ± 29.7 0.048
Renal oxygen consumption (ml/min) 10.0 ± 3.2 14.4 ± 4.8 0.001
Renal oxygen consumption/renal sodium reabsorption (ml/mmol) 1.15 ± 0.3 3.13 ± 2.4 <0.001
Serum creatinine day 1 (μmol/l) 75.1 ± 13.9 99.8 ± 32.7 0.025
Data are presented as mean ± SD
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[25]. In the present study, the hyperdynamic circulation
was accompanied by a redistribution of RBF away from
the kidneys, as illustrated by the 27% lower RBF to CI ra-
tio. The systemic vasodilation in the liver-transplanted
group was treated with norepinephrine. As norepineph-
rine has been shown to decrease renal blood flow in vol-
unteers [33, 34], one could argue that this might have
mitigated an even more profound renal vasodilation and
renal hyperemia that would otherwise have occurred. We
believe that this is less likely, as we have shown that restor-
ation of mean arterial pressure from 60 to 75 mmHg by in-
creasing the dose of norepinephrine, improves renal
oxygen delivery, GFR and renal oxygenation in postopera-
tive patients with norepinephrine-dependent systemic
vasodilation and AKI [35].
An alternative approach to treat systemic vasodilation
during and after liver transplantation would be to use
the vasopressin-analogue terlipressin, which is metabo-
lized to vasopressin. In a randomized, controlled study,
Mukhtar et al. studied the effects of terlipressin versus sa-
line on splanchnic hemodynamics and postoperative renal
function in patients undergoing liver transplantation [36].
Terlipressin improved renal function, as serum levels of
creatinine and cystatin C were significantly lower in the
terlipressin group during the two first postoperative days.
Bragadottir et al. analysed in a pharmacodynamic study
the renal effects of vasopressin in uncomplicated post-
cardiac surgery patients and found that vasopressin in-
duces a vasoconstriction of the efferent arterioles causing
an increase in GFR and renal oxygen consumption but a
decrease in renal blood flow [14]. Thus, vasopressin
caused an impairment of renal oxygenation, as demon-
strated by an increase in renal oxygen extraction, suggest-
ing that the use of vasopressin in liver transplantation
might be a two-edged sword.
One limitation of the present study is the relatively
low number of included liver transplant recipients. Fur-
thermore, we did not assess whether or not there was a
structural tubular cell injury in the early postoperative
period in this group, as we did not measure tubular in-
jury markers. However, the incidence of AKI in the
present study was high (67%), when compared to previ-
ous studies on tubular injury markers after liver trans-
plantation (38–46%) [28, 29], and it is likely that release
of tubular injury markers occurred also in the present
study. The strength of the present study is that it pro-
vides new information on renal function and oxygen-
ation in the early period after liver transplantation.
Conclusions
There is a substantial decline in renal function early after
liver transplantation despite hyperdynamic circulation and
renal vasodilation. This early decline in renal function is
accompanied by an impaired renal oxygenation, as the
pronounced elevation of renal oxygen consumption is not
met by a proportional increase in renal oxygen delivery.
Key messages
After liver transplantation:
! there is an early and substantial fall in GFR caused
by a vasodilation of the efferent arterioles
! renal oxygen consumption is considerably increased
! renal oxygen delivery does not meet the increased
renal metabolic demand despite renal vasodilation
! renal oxygenation is impaired
Abbreviations
[Na+]s: Serum sodium concentration; [Na
+]u: Urine sodium concentration;
51Cr-EDTA: Chromium ethylenediaminetetraaceticacid; ACE inhibitor: Angiotensin-
converting enzyme inhibitor; AKI: Acute kidney injury; ASA: American Society of
Anesthesiologists; CaO2: Arterial oxygen content; CO: Cardiac output; CrvO2: Renal
vein oxygen content; CVP: Central venous pressure; GFR: Glomerular filtration rate;
HRS: Hepatorenal syndrome; ICU: Intensive care unit; MAP: Mean arterial pressure;
MDRD: Modification of Diet in Renal Disease; MELD: Model For End-Stage Liver
Disease; mGFR: Measured glomerular filtration rate; RBF: Renal blood flow;
SVI: Stroke volume index; SVRI: Systemic vascular resistance index
Acknowledgements
We appreciate the skilful technical assistance from Mrs. Marita Ahlqvist, the
support from the liver transplant coordinators, and from the nursing staff of
the Central Intensive Care Unit of the Sahlgrenska University Hospital,
Gothenburg, Sweden.
Funding
The study was supported by Swedish State Support for Clinical Research
(ALFGBG-75130), the Gothenburg Medical Society, the W&A Lundgren
Science Fund (SE) and the Memorial Fund of Professor L-E Gelin (SE).
Availability of data and materials
The dataset generated and/or analysed during the current study is not
publicly available due to patient-related confidentiality, but is available from
the corresponding author on reasonable request.
Authors’ contributions
JSL contributed to conception and design, patient recruitment, renal vein
catheterization and experimental procedure, compilation of data, statistical
analysis, writing and drafting of the manuscript. GB contributed to critical
intellectual review of the manuscript, and language editing. BR contributed
to conception and design, statistical advice, critical intellectual review of the
manuscript, and language editing. SER contributed to conception and design,
statistical analysis, critical intellectual review of the manuscript, language
editing, and was responsible for the approval of the final manuscript. All
authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The Gothenburg Regional Ethics Committee (Sweden) approved the study
protocol, reference number 1026-13. Written informed consent was obtained
from all patients within the 24 hours before surgery.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published
maps and institutional affiliations.
Skytte Larsson et al. Critical Care  (2017) 21:87 Page 9 of 10
in the postoperative period, particularly so in the renal me-
dulla, which is sensitive to ischemia. Medullary tissue oxy-
gen tension is low already under normal conditions,
because of the high oxygen utilization of the medullary
thick ascending limb [27]. It has been shown that tubular
injury markers, such as neutrophil gelatinase-associated
lipocalin, are released in the urine within hours after liver
transplantation and that this may predict AKI [28–30]. An
early release of tubular injury markers early after liver
transplantation could be explained by the impaired renal
oxygenation demonstrated in the present study.
In this group of patients, with advanced or moderately
advanced chronic liver disease, a hyperdynamic circula-
tion was seen, with a profound systemic vasodilation
and a high cardiac index. Such a hyperdynamic circula-
tion in patients with advanced cirrhosis has been sug-
gested to be caused by a splanchnic vasodilation [31] in
turn caused by augmented levels of nitric oxide [32].
Furthermore, there is a post-reperfusion increase in cyto-
kines and complement factors, which also contributes to
the systemic vasodilation resulting in a perioperative need
for vasopressor treatment during liver transplantation
Fig. 3 Changes in serum creatinine in liver recipients and after uncomplicated cardiac surgery (controls). **p < 0.01
Table 6 Renal data in the immediate postoperative period
Variable Control group
(n = 73)
Liver transplant recipients
(n = 12)
p value
Renal oxygen extraction 0.100 ± 0.03 0.124 ± 0.04 0.042
Urine flow (ml/min) 3.13 ± 1.7 2.54 ± 2.2 0.065
Renal blood flow (ml/min) 716 ± 209 843 ± 197 0.024
Renal blood flow/cardiac index 0.277 ± 0.08 0.202 ± 0.05 <0.001
Renal vascular resistance (mmHg/ml/min) 0.100 ± 0.03 0.085 ± 0.02 0.051
Glomerular filtration rate (ml/min) 70.9 ± 23.3 51.5 ± 30.4 0.043
Filtration fraction 0.15 ± 0.04 0.09 ± 0.06 0.006
Renal sodium filtration (mmol/min) 9.67 ± 3.2 7.63 ± 5.6 0.052
Renal sodium reabsorption (mmol/min) 9.28 ± 3.2 7. 50 ± 5.5 0.065
Fractional sodium excretion (%) 5.0 ± 4.0 2.5 ± 3.5 0.002
Renal oxygen delivery (ml/min) 103.5 ± 32.1 119.7 ± 29.7 0.048
Renal oxygen consumption (ml/min) 10.0 ± 3.2 14.4 ± 4.8 0.001
Renal oxygen consumption/renal sodium reabsorption (ml/mmol) 1.15 ± 0.3 3.13 ± 2.4 <0.001
Serum creatinine day 1 (μmol/l) 75.1 ± 13.9 99.8 ± 32.7 0.025
Data are presented as mean ± SD
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[25]. In the present study, the hyperdynamic circulation
was accompanied by a redistribution of RBF away from
the kidneys, as illustrated by the 27% lower RBF to CI ra-
tio. The systemic vasodilation in the liver-transplanted
group was treated with norepinephrine. As norepineph-
rine has been shown to decrease renal blood flow in vol-
unteers [33, 34], one could argue that this might have
mitigated an even more profound renal vasodilation and
renal hyperemia that would otherwise have occurred. We
believe that this is less likely, as we have shown that restor-
ation of mean arterial pressure from 60 to 75 mmHg by in-
creasing the dose of norepinephrine, improves renal
oxygen delivery, GFR and renal oxygenation in postopera-
tive patients with norepinephrine-dependent systemic
vasodilation and AKI [35].
An alternative approach to treat systemic vasodilation
during and after liver transplantation would be to use
the vasopressin-analogue terlipressin, which is metabo-
lized to vasopressin. In a randomized, controlled study,
Mukhtar et al. studied the effects of terlipressin versus sa-
line on splanchnic hemodynamics and postoperative renal
function in patients undergoing liver transplantation [36].
Terlipressin improved renal function, as serum levels of
creatinine and cystatin C were significantly lower in the
terlipressin group during the two first postoperative days.
Bragadottir et al. analysed in a pharmacodynamic study
the renal effects of vasopressin in uncomplicated post-
cardiac surgery patients and found that vasopressin in-
duces a vasoconstriction of the efferent arterioles causing
an increase in GFR and renal oxygen consumption but a
decrease in renal blood flow [14]. Thus, vasopressin
caused an impairment of renal oxygenation, as demon-
strated by an increase in renal oxygen extraction, suggest-
ing that the use of vasopressin in liver transplantation
might be a two-edged sword.
One limitation of the present study is the relatively
low number of included liver transplant recipients. Fur-
thermore, we did not assess whether or not there was a
structural tubular cell injury in the early postoperative
period in this group, as we did not measure tubular in-
jury markers. However, the incidence of AKI in the
present study was high (67%), when compared to previ-
ous studies on tubular injury markers after liver trans-
plantation (38–46%) [28, 29], and it is likely that release
of tubular injury markers occurred also in the present
study. The strength of the present study is that it pro-
vides new information on renal function and oxygen-
ation in the early period after liver transplantation.
Conclusions
There is a substantial decline in renal function early after
liver transplantation despite hyperdynamic circulation and
renal vasodilation. This early decline in renal function is
accompanied by an impaired renal oxygenation, as the
pronounced elevation of renal oxygen consumption is not
met by a proportional increase in renal oxygen delivery.
Key messages
After liver transplantation:
! there is an early and substantial fall in GFR caused
by a vasodilation of the efferent arterioles
! renal oxygen consumption is considerably increased
! renal oxygen delivery does not meet the increased
renal metabolic demand despite renal vasodilation
! renal oxygenation is impaired
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Abstract 
Background: Acute kidney injury is commonly seen after liver transplantation. The optimal 
perioperative target mean arterial pressure (MAP) for renal filtration, perfusion and 
oxygenation in liver recipients is not known. The effects of norepinephrine-induced changes 
in MAP on renal blood flow (RBF), oxygen delivery (RDO2), glomerular filtration rate (GFR) 
and renal oxygenation (= renal oxygen extraction, RO2Ex) were therefore studied early after 
liver transplantation.  
Methods: Ten patients with an intra- and postoperative vasopressor-dependent systemic 
vasodilation were studied early after liver transplantation during sedation and mechanical 
ventilation. To achieve target MAP levels of 60, 75 and 90 mmHg, the norepinephrine 
infusion rate was randomly and sequentially titrated. At each target MAP, data on cardiac 
index (CI), RBF and GFR were obtained by transpulmonary thermodilution (PiCCO), the 
renal vein thermodilution technique and renal extraction of chromium 
ethylenediaminetetraaceticacid (51Cr-EDTA), respectively. Renal oxygen consumption  
(RVO2) and extraction (RO2Ex) were calculated according to standard formulas.  
Results: At a target MAP of 75 mmHg, CI (13%), RBF (18%), RDO2 (24%), GFR (31%) and 
RVO2 (20%) were higher while RO2Ex was unchanged compared to a target MAP of 60 
mmHg. Increasing MAP from 75 up to 90 mmHg increased RVR by 38% but had no further 
effects on CI, RBF, RDO2 or GFR.  
Conclusions: In patients undergoing liver transplantation, RBF and GFR are pressure-
dependent at MAP levels below 75 mmHg, reflecting an exhausted renal autoregulatory 
reserve.  The optimal perioperative target MAP for renal function, perfusion and oxygenation 
in liver transplant recipients is approximately 75 mmHg.  
Keywords: liver transplantation, renal blood flow, glomerular filtration rate, renal oxygen 
consumption and oxygenation, mean arterial pressure, norepinephrine 
  
 3 
Introduction 
Acute kidney injury (AKI) is commonly seen after liver transplantation with an incidence of 
over 50% [1, 2]. Morbidity, e.g. chronic kidney disease with a lifelong need for 
haemodialysis, and mortality rates are several times higher in liver recipients developing AKI 
compared to those who do not [1-3]. Moreover, graft survival is shortened among liver 
recipients who develop AKI with vast consequences for individuals and society [4].  
Risk factors for the development of AKI after liver transplantation have been 
identified as pre-transplant renal dysfunction caused by the hepatorenal syndrome [5-9], liver 
graft dysfunction [7] and hypoperfusion caused by intra-operative blood loss [5]. The post 
reperfusion syndrome (PRS) is also a potential risk factor for postoperative AKI [10]. PRS is 
an intra-operative serious complication causing hemodynamic derangement due to severe 
systemic vasodilation combined with an increased or decreased cardiac output [11]. The 
systemic vasodilation is usually treated with norepinephrine to uphold a mean arterial 
SUHVVXUH0$3PP+J [11, 12]. Norepinephrine may on the one hand cause a renal 
vasoconstriction, as shown in healthy volunteers [12, 13]. On the other hand, leaving the 
systemic vasodilation insufficiently treated, may result in a blood pressure-dependent renal 
blood flow (RBF) since the arterial blood pressure, in this situation is left below the limit of 
the renal autoregulatory capacity. The renal effects of norepinephrine in patients undergoing 
liver transplantation are not well studied. Particularly, the optimal MAP for renal filtration, 
perfusion and oxygenation in patients undergoing liver transplantation is not known.   
 In the present investigation, we aimed to study the effects of three various target 
levels of MAP, i.e. 60, 75 and 90 mmHg, on renal function, perfusion and oxygenation early 
after liver transplantation. These target levels of MAP were randomly set and achieved by 
changes in norepinephrine infusion rates. RBF, GFR, renal oxygen consumption (RVO2) and 
renal oxygenation, were studied using the retrograde renal vein thermodilution technique and 
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by the measurement of the extraction of the renal filtration marker chromium 
ethylenediaminetetraaceticacid (51Cr-EDTA) in patients early after liver transplantation. 
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Patients and methods 
The study protocol of this prospective randomised cross-over clinical trial was approved by 
the Gothenburg Regional Ethics Committee (www.epn.se/goeteborg/) on the 30th of January 
2014 (No. 1026-13). The study was registered in ClinicalTrials.gov Identifier: NCT02455115, 
23 April 2015. All patients gave their written informed consent within 24 hours before 
surgery. In a recent descriptive article, we compared the data on renal filtration, perfusion and 
oxygenation after liver transplantation (n=12) to the results from a large population (n=73) of 
uncomplicated major cardiac surgery patients [14]. A subgroup of these liver transplant 
recipients (n=10) was subjected to an interventional procedure, in which perioperative target 
MAP was randomly changed, as described below.  
In this prospective trial, fourteen adult patients accepted for liver transplantation were 
included from January 2015 to January 2017. The inclusion criteria were: a) age >18 years, 
and b) a preoperative measured GFR (mGFR) > 60 ml/min and the exclusion criteria were: a) 
the use of veno-venous bypass intra-operatively, b) significant postoperative blood loss, c) 
failed catheterization of the renal vein, d) re-transplantation, and e) contraindication to radio-
contrast agents.  
Agents for anaesthesia induction were propofol and fentanyl/remifentanil, and 
anaesthesia was maintained by sevoflurane and an either of the opiates. Norepinephrine was 
administered intra-operatively to maintain a MAP > 65 mmHg. To reduce transfusion 
requirements, intra-operative fluid replacement was kept restrictive and central venous 
pressure (CVP) was aimed < 5 mmHg using nitroglycerine when needed [15]. The Cell 
Saver® 5+ device (Haemonetics®, USA) was used for blood salvage. Target haemoglobin 
was maintained at g/liter. Plasma and blood platelets were administered at the discretion 
of the anaesthetist in charge. Methylprednisolone at a dose of 0.5-1 gram and mannitol at a 
dose of 200-300 ml was administered to all patients before reperfusion of the transplant. In 
reperfusion-induced hemodynamic instability, epinephrine (0.01 - 0.15 mg) was administered  
 4 
by the measurement of the extraction of the renal filtration marker chromium 
ethylenediaminetetraaceticacid (51Cr-EDTA) in patients early after liver transplantation. 
  
 5 
Patients and methods 
The study protocol of this prospective randomised cross-over clinical trial was approved by 
the Gothenburg Regional Ethics Committee (www.epn.se/goeteborg/) on the 30th of January 
2014 (No. 1026-13). The study was registered in ClinicalTrials.gov Identifier: NCT02455115, 
23 April 2015. All patients gave their written informed consent within 24 hours before 
surgery. In a recent descriptive article, we compared the data on renal filtration, perfusion and 
oxygenation after liver transplantation (n=12) to the results from a large population (n=73) of 
uncomplicated major cardiac surgery patients [14]. A subgroup of these liver transplant 
recipients (n=10) was subjected to an interventional procedure, in which perioperative target 
MAP was randomly changed, as described below.  
In this prospective trial, fourteen adult patients accepted for liver transplantation were 
included from January 2015 to January 2017. The inclusion criteria were: a) age >18 years, 
and b) a preoperative measured GFR (mGFR) > 60 ml/min and the exclusion criteria were: a) 
the use of veno-venous bypass intra-operatively, b) significant postoperative blood loss, c) 
failed catheterization of the renal vein, d) re-transplantation, and e) contraindication to radio-
contrast agents.  
Agents for anaesthesia induction were propofol and fentanyl/remifentanil, and 
anaesthesia was maintained by sevoflurane and an either of the opiates. Norepinephrine was 
administered intra-operatively to maintain a MAP > 65 mmHg. To reduce transfusion 
requirements, intra-operative fluid replacement was kept restrictive and central venous 
pressure (CVP) was aimed < 5 mmHg using nitroglycerine when needed [15]. The Cell 
Saver® 5+ device (Haemonetics®, USA) was used for blood salvage. Target haemoglobin 
was maintained at g/liter. Plasma and blood platelets were administered at the discretion 
of the anaesthetist in charge. Methylprednisolone at a dose of 0.5-1 gram and mannitol at a 
dose of 200-300 ml was administered to all patients before reperfusion of the transplant. In 
reperfusion-induced hemodynamic instability, epinephrine (0.01 - 0.15 mg) was administered  
 6 
The patients were mechanically ventilated and sedated with propofol and fentanyl/ 
remifentanil in the intensive care unit. Target postoperative MAP target was 70-80 mmHg. A 
pulse pressure variation of  >12% was considered as postoperative hypovolemia and was 
treated with albumin (Albumin Baxalta® 200g/l) and/or a crystalloid (Ringer–Acetate®, 
Baxter Viaflo). Norepinephrine was used as vasoconstrictor to reach the postoperative target 
MAP in hypotensive, normovolemic, vasodilated patients.  
 
Systemic haemodynamics  
Arterial blood pressure was measured via a femoral artery catheter. A central venous catheter 
was used to measure CVP and central venous oxygen saturation (ScvO2). The PiCCO ™ 
device (Pulsion Ltd, Munich, Germany) was used to measure (in triplicate) cardiac output 
(CO) by transpulmonary thermodilution, which was indexed to the body surface area (BSA). 
Cardiac index (CI), systemic vascular resistance index (SVRI) and stroke volume index (SVI) 
were calculated according to standard formulae.  
 
Renal variables 
Postoperatively, an 8 Fr catheter (Webster laboratories, Baldwin Park, CA, USA) was 
introduced into the left or right renal vein, via punction of the right femoral vein. The central 
position of the catheter in the renal vein was confirmed by venography using ultra-low doses 
of iohexol, 5–15 mg I kgí1 2PQLSDTXHPJ,POí*(+HDOWKFDUH6WRFNKolm, Sweden). 
The continuous retrograde thermodilution technique was used to measure RBF (in triplicate). 
[16-19]. An i.v. priming dose of chromium ethylenediamine tetraacetic acid  (51Cr-EDTA) 
(GE Healthcare, Amersham, UK) was given after the collection of blood and urine blanks. 
This bolus dose was followed by constant rate infusion, individualized to BSA and to 
preoperative serum creatinine. Serum 51Cr-EDTA activity from arterial and renal vein blood 
ZDVPHDVXUHGXVLQJDZHOOFRXQWHU:L]DUG¶$XWRPDWLFJDPPDFRXQWHU3HUkin Elma 
 7 
LAS, Turkuu, Finland). Renal data were normalised to a BSA of 1.73m2. In Table 1, formulas 
for calculation of renal variables are described.  
 
Experimental protocol  
The experimental procedure was performed shortly after arrival to the intensive care unit.  
Two 30 min urine collection control periods were started at a target MAP of 75 mmHg (C1 
and C2) following a period of equilibration of at least 60 min. At the end of each 30 min 
period, urine was collected and measurements of CO and RBF were performed. Arterial, 
central and renal venous blood samples were drawn for measurements of serum 
concentrations of sodium, 51Cr-EDTA, haemoglobin and oxygen content. Using a cross-over 
design, the infusion rate of norepinephrine was changed in a random fashion to reach target 
MAP:s of 60 mmHg and 90 mmHg, respectively. Randomisation was accomplished using 
sealed envelopes in two blocks. The titration period of the norepinephrine infusion rate lasted 
for approximately 15 minutes. MAP was then kept at the new target MAP for 30 min. 
Measurements of CO, RBF and blood- and urine samples were conducted at the end of each 
30 min period. Infusion rates of fluids and drugs were unchanged during the experimental 
procedure.  
 
Statistical analysis.  
The change in GFR at a MAP of 60, 75 and 90 mmHg, respectively, was the primary end-
point of this investigation study. To detect GFR change by 30%, 9 patients were needed at a 
power of 0.80, a significance level of 0.05 and a standard deviation of the mean difference of 
paired measurements of 15 ml/min. Changes in other renal and systemic variables were 
secondary outcome variables. Data from the first (C1) and second (C2) control measurements 
were pooled. The Shapiro-Wilks analysis was used to check for normal distribution of 
continuous variables. . A repeated measures analysis of variance (ANOVA) and a least 
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significant difference (LSD) post-hoc test were used to evaluate the effects of variations in 
MAP on normally distributed data, while Friedman’s test was used followed by Wilcoxon 
summed rank test for non-parametric data. PASWStatistics 18.0 (SPSS Inc., Chicago, IL, 
USA) was used for statistical analyses. Statistical significance was indicated at a probability 
level (p value) of less than 0.05. Data is presented as mean ± standard deviation (SD).  
 9 
Results 
Fourteen patients were included in this investigation. One patient was excluded before 
measurements due to significant postoperative bleeding and another patient was excluded due 
to failed placement of the renal catheter. In two patients, catheterization and control 
measurements were completed, but the renal vein catheter was occluded after randomization, 
excluding also these patients. Thus, this study includes data from 10 patients. Data on patient 
characteristics are presented in Table 2 and 3, and intraoperative data are presented in Table 
4. 
The experimental procedure started when the patient was considered normovolemic 
by the attending intensivist, 83 ± 69 minutes after arrival to the ICU. Sedation was maintained 
by propofol 3.3 ± 0.9 mg/kg/hour and fentanyl (n=7) 0.02 ± 0.005 µg/kg/min or remifentanil 
0.12 ± 0.02 µg/kg/min (n=3) and the patients were mechanically ventilated to normocarbia at 
a FiO2 0.35 ± 0.06 and with a PEEP of 6.6 ± 1.7 cmH2O. 
 
Systemic variables (Table 5) 
The mean norepinephrine infusion rates at the target MAP:s of 60 mmHg, 75 mmHg and 90 
mmHg were 0.13 ± 0.11, 0.25 ± 0.16 and 0.38 ± 0.28 µg/kg/min, respectively. At a target 
MAP of 75 mmHg, CI (13%), SVI (13%) SVRI (14%), ScvO2 (4%), haemoglobin (4%) and 
global oxygen delivery index (DO2I) (18%) were all significantly higher than at MAP 60 
mmHg. CVP, global oxygen consumption index (VO2I) and heart rate were, however, not 
affected. The dose of norepinephrine had to be increased by 52% to increase MAP from 75 
mmHg to 90 mmHg. This caused significant increases in SVI (7%), SVRI (26%), serum 
haemoglobin (3%), and a decrease in heart rate (-10%) with no changes in CI, CVP, ScvO2, 
DOI2, VO2I or temperature.  
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haemoglobin (3%), and a decrease in heart rate (-10%) with no changes in CI, CVP, ScvO2, 
DOI2, VO2I or temperature.  
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Renal variables (Table 6) 
GFR was 31% higher at target MAP of 75 mmHg than at a target MAP of 60 mmHg. 
This GFR increase was accompanied by increases in sodium filtration (31%) and sodium 
reabsorption (29%). Increasing MAP from 60 to 75 mmHg increased RBF (18%), renal 
oxygen delivery (RDO2) (25%), and renal oxygen consumption (RVO2) (20%), but had no 
effect on renal vascular resistance (RVR), filtration fraction (FF), urine flow (UF) or renal 
oxygen extraction (RO2Ex). A further increase in MAP from 75 mmHg to 90 mmHg 
increased RVR (38%), but caused no other changes in renal variables. Six patients (60%) 
developed acute kidney injury, as defined by the KDIGO criteria [20], during the two first 
postoperative days. 
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Discussion 
In the present investigation, the effects of various target levels of MAP on GFR, RBF, RVO2 
and renal oxygenation were studied early after liver transplantation. The main findings were 
that increasing MAP from 60 mmHg to 75 mmHg caused an increase in both GFR and in 
RVO2. Renal oxygenation was preserved by the proportional increase in RDO2, leaving the 
renal oxygen extraction and hence the oxygen supply/demand relationship unaffected. No 
additional beneficial renal effects were seen when further increasing target MAP to 90 
mmHg. Thus, the perioperative MAP for optimal renal perfusion, filtration and oxygenation 
in normovolemic patients early after liver transplantation should be kept at approximately 75 
mmHg, as lower levels may be suboptimal in this respect. 
Our results are compatible with a recent investigation by Mizota et al, evaluating the 
relationship between the level of intraoperative blood pressure reduction and the risk of 
developing postoperative AKI in patients undergoing liver transplantation [21]. They found 
that the lowest intraoperative MAP was an independent predictor of AKI and that even a short 
period of severe hypotension was significantly related to the development of postoperative 
AKI. Thus, one way to evade development of postoperative AKI is to avoid hypotension, i.e. 
a MAP < 75 mmHg, by the use of an adequate dose of norepinephrine, to optimize renal 
perfusion, function and oxygenation perioperatively, in liver transplantation, as shown in this 
study. 
 Increasing renal perfusion pressure by norepinephrine increases renal vascular 
resistance (RVR) partly by a direct α-mediated vasoconstriction, but also, and to a much 
greater extent, by pressure-dependent renal autoregulation [22]. In experimental studies, it has 
been shown that the renal autoregulatory mechanism accounted for approximately 90% of the  
RVR increase when MAP was elevated by 20-40 mmHg using norepinephrine [22]. This 
renal autoregulatory mechanism controls the tone of the afferent arterioles to maintain both 
RBF and GFR virtually unchanged despite changes in MAP [23, 24]. Renal autoregulation is 
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mediated by the faster myogenic vasoconstrictory mechanism and the slower superimposed 
tubuloglomerular feed-back mechanism, both acting in concert to control the afferent 
arteriolar tone. In the present study, both RBF and GFR increased when MAP was increased 
from 60 mmHg to 75 mmHg, but there was no change in RVR. These results suggest that 
both RBF and GFR are pressure-dependent, perioperatively, at a target MAP of 
approximately 60 mmHg in liver transplants, and hence that renal autoregulation of GFR and 
RBF has been lost due to a too low pressure. On the other hand, when MAP was increased to 
90 mmHg, there was an increase in RVR without any effect on filtration fraction (i.e. the 
GFR/renal plasma flow ratio) and without any further increase in RBF or GFR. This together 
suggests that the increase in RVR to a great extent is mediated by renal autoregulation 
causing afferent arteriolar vasoconstriction, although we cannot exclude the possibility of an 
additional α-mediated renal vasoconstriction. These results are in line with our previous 
study, in which an elevation of MAP from 60 to 75 mmHg improved GFR and RDO2 in 
patients suffering from AKI and norepinephrine-treated vasodilatory shock after cardiac 
surgery [25]. 
 We have repeatedly shown in postoperative patients that the major determinant of 
RVO2 is GFR [14, 16, 17, 26]. An improved renal function, i.e. an increase in GFR, will 
enhance the filtered amount of sodium. This will increase the delivery of sodium to the 
tubules and the tubular sodium reabsorption increasing RVO2. Thus, any intervention that 
increases GFR will also increase renal oxygen demand. In this investigation, the 
norepinephrine-induced increase in MAP from 60 to 75 mmHg increased GFR by 31%, 
which induced an elevation of both tubular sodium reabsorption and RVO2. Such an increase 
in RVO2 could potentially impair renal oxygenation, provided that the increase in renal 
oxygen requirements is not accompanied by a similar increase in RDO2. This is of particular 
importance as the outer portion of the renal medulla is on the border of hypoxia under normal 
conditions, due to a relative hypoperfusion and elevated oxygen utilization of the medullary 
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thick ascending limbs when compared to the renal cortex [27]. In this investigation, RDO2 
increased by 25%, an increase that was sufficient enough to match the 20% increase in RVO2, 
resulting in a unaffected RO2Ex upon the induced changes in MAP. Thus, norepinephrine did 
not jeopardise renal oxygenation at the target MAP:s investigated in the present study, i.e. the 
renal O2 demand/supply relationship was preserved. 
 Splanchnic vasodilation caused by increased levels of nitric oxide [29] has been 
suggested to contribute to the hyperdynamic vasodilated circulation in patients with advanced 
cirrhosis [28]. An intraoperative post-reperfusion rise in cytokines and complement factors 
adds further to a systemic vasodilation, resulting in a perioperative need for vasopressor 
treatment during and after liver transplantation [11]. In the present study, the patients 
presented with a vasodilatory hyperdynamic state both intra- and postoperatively, with a high 
cardiac index and a low systemic vascular resistance resulting in a need for vasoconstrictory 
norepinephrine treatment to obtain adequate systemic perfusion pressures. One could argue 
that norepinephrine would induce a renal vasoconstriction redistributing CI from the kidneys. 
In this study, the RBF/CI UDWLRZDV§ZKLFK is somewhat lower than previously 
described in uncomplicated postoperative patients, in whom the RBF/CI ratio was 27% [19]. 
This redistribution is, however, unlikely to be explained by a norepinephrine-induced renal 
vasoconstriction, as RBF and GFR improved while RVR was unchanged when MAP was 
changed from 60 to 75 mmHg, as shown in this study. This is in line with previous results in 
postoperative patients with AKI norepinephrine-dependent systemic vasodilation [25]. 
Cardiac index increased by 8% when increasing MAP from 60 mmHg to 90 mmHg, 
most likely explained by the norepinephrine-induced, ß1-mediated increase in myocardial 
contractility. This finding is compatible with previous studies on septic [25, 30] and post-
cardiotomy vasodilatory shock patients [25, 30]. It has previously been shown that 
norepinephrine induces a decrease in plasma volume dependent on blood pressure, attributed 
to a transcapillary fluid extravasation, which will increase serum haemoglobin and arterial 
 12 
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oxygen content [31]. In the present study, both systemic and renal oxygen delivery were 
increased partly as a consequence of the norepinephrine-induced increase in serum 
haemoglobin. 
One limitation of this investigation is the low sample size, which may limit the 
generalisibility of our results. The finding of an optimal target MAP between 70-80 mmHg 
for renal function, perfusion and oxygenation needs, described here, needs to be confirmed in 
a larger study involving several centers, evaluating the role of postoperative MAP for renal 
outcome after liver transplantation.  Another limitation of the present study is the lack of a 
time-control group, resulting in a possibility that the observed changes in systemic and renal 
variables could be due to time-dependent or spontaneous fluctuations in MAP, and not to 
norepinephrine or the target MAP per se. One way to circumvent this problem was to change 
the infusion rates of norepinephrine to achieve the target MAP:s in a random fashion. 
 In conclusion, at MAP levels below 75 mmHg, renal blood flow and GFR are 
pressure-dependent, reflecting an exhausted renal autoregulatory reserve early after liver 
transplantation. These results suggest that MAP should be targeted to approximately 75 
mmHg for optimal perioperative renal filtration, perfusion and oxygenation in patients 
undergoing liver transplantation. 
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 Table 2. Patient characteristics  
Gender, n (% female) 5 (50) 
Age, mean (SD) 57 ± 12 
Height (cm) 172.0 ± 7.0 
Body surface area (m2) 1.93 ± 0.2 
Body mass index (kg/m2) 22.0 ± 1.2 
Diabetes, n (%) 1 (10) 
Beta-adrenergic blocker, n (%) 6 (60) 
ACE-inhibitor, n (%) 2 (20) 
Diuretics, n (%) 7 (70) 
 
Values are means ± SD, n = number of patients (%) 
ACE-inhibitor; angiotensin converting enzyme-inhibitor    
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Table 4. Intra-operative data of liver transplant recipients (n=10) 
 
Cold Ischaemia Time (min) 466 ± 131 
Duration of surgery (min) 363 ± 86 
Bleeding (L) 2.4 ± 1.3 
Packed red blood cells (n=8, units) 2.5 (1-4) 
Platelets (n=4, units) 2.5 (2-3.25) 
Plasma (n=6, units) 4.5 (1-6) 
Fibrinogen (n=7, g) 2.0 (1-11) 
Albumin (n=5, ml) 300 (200-600) 
Cellsaver (n=8, ml) 525 (215-980) 
Intra-operative crystalloid (L) 2.4 ± 1.0 
Epinephrine, n (%) 7 (80) 
Diuresis (ml/procedure hour) 123 ± 49 
CI prior to anhepatic phase (l/min/m2) 3.4 ± 0.9 
CI during anhepatic phase (l/min/m2) 4.1 ± 1.8 
CI after reperfusion (l/min/m2) 4.6 ± 0.9 
SVRI (ml/min/min2) 1380 ± 307 
CVP (mmHg) 7 ± 2 
Intra-operative fluid balance (ml) 583 ± 1620 
 
Data are presented as median (min-max), mean ± SD, n = number of patients (%).  
CVP; central venous pressure, SVRI; systemic vascular resistance index, CI; cardiac index 
 
Table 5. Effects of varying doses of norepinephrine on systemic variables (n=10)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data are presented as mean ± SD. 75 mmHg versus 60 mmHg *p <0.05, ** p < 0.01, *** p < 
0.001; 90 mmHg versus 75 mmHg # p <0.05, ## p < 0.01, ### p < 0.001  
SVRI, systemic vascular resistance index; ScvO2, central venous oxygen saturation 
DO2I, systemic oxygen delivery index; VO2I, systemic oxygen consumption index.  
¶, indicates a variable not normally distributed 
 
 
 
 
 60 mmHg 75 mmHg 90 mmHg 
Norepinephrine ȝJNJPLQ 0.13  ± 0.11 0.25  ± 0.16*** 0.38  ± 0.28## 
Cardiac index (l/min/m2)  3.8  ± 1.0 4.3  ± 1.1*** 4.1  ± 1.1 
Heart rate (beats/min) ¶  72 ± 15 72 ± 16 65 ± 19## 
Stroke volume index (ml/m2)  53.2  ±11.7 59.9  ± 11.6** 63.9  ± 10.9## 
Central venous pressure (mmHg)  7.1 ± 3.0 7.9  ± 2.8 8.4  ± 3.1 
SVRI (dynes x sec/cm3/m2)  1183 ± 374 1352 ± 431** 1707 ± 474### 
ScvO2 (%)  78.0  ± 6.4 81.5  ± 7.4*** 81.3  ± 7.2 
Serum haemoglobin (g/l)   102.4 ± 14.2 106.6  ± 16.2*** 109.5 ± 14.5## 
DO2I (ml/min/min2)  521 ± 122 614 ± 156*** 604 ± 150 
VO2I (ml/min/min2)  97 ± 14 92 ± 19 93 ± 19 
Body temperature 36.7  ± 0.4 36.9  ± 0.4* 36.8  ± 0.3 
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Abstract 
Objective: Current views on renal hemodynamics, function and oxygenation in clinical acute 
kidney injury (AKI) are largely based on experimental studies and clinical data are lacking. 
We therefore measured renal blood flow (RBF), glomerular filtration rate (GFR), renal 
oxygen consumption and oxygenation in patients with early septic shock. 
Design: Prospective, two-group comparative study 
Setting: General and cardiothoracic intensive care units 
Intervention: None 
Methods: Patients with norepinephrine-dependent early septic shock (n=8) were studied 
within 24 hours after arrival in the ICU and compared with post-cardiac surgery patients 
without AKI (n=58, controls). Data on systemic hemodynamics and renal variables were 
obtained during two 30-minute periods. Systemic hemodynamics were obtained by 
pulmonary artery- or transpulmonary thermodilution techniques, respectively. RBF was 
measured by the infusion clearance of para-aminohippuric acid (PAH), corrected for renal 
extraction of PAH by the use of a renal vein catheter. The filtration fraction was measured by 
renal extraction of 51Cr-EDTA. Renal oxygenation was estimated from the renal oxygen 
extraction, directly reflecting the renal oxygen supply/demand relationship.  
Results: RBF and renal oxygen delivery were significantly lower in the septic group (-19%, 
p=0.068 and -24%, p=0.037, respectively). The RBF/cardiac index ratio was significantly 
lower (-30%, p=0.003), while renal vascular resistance was higher (20%, p=0.069) the septic 
shock group. GFR (-32%, p=0.006) and renal sodium reabsorption (-29%, p=0.014) were both 
lower, in the septic group. Filtration fraction did not differ between groups., while there was 
no difference in renal oxygen consumption between groups. Renal oxygen extraction was 
significantly higher in the septic group (28%, p=0.022). In the septic group, markers of 
tubular injury were elevated.  
 3 
Conclusions: In early clinical septic shock, a reduced renal function is accompanied by an 
impaired renal oxygenation, caused by a combination of renal vasoconstriction, reduced renal 
oxygen delivery and tubular sodium reabsorption at a high oxygen cost. 
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Introduction 
Severe sepsis and septic shock continues to be a common cause of ICU admission and is 
responsible for acute kidney injury (septic AKI) in approximately 40-50% of the population 
of critically ill patients. Furthermore, septic AKI is associated with high risk of early hospital 
mortality [1-4].  
 The pathophysiology of AKI in septic shock is not well known. In 2004, Schrier and 
Wang proposed, based on experimental models, that the predominant early pathogenetic 
factor is renal vasoconstriction [5]. Thus, endotoxinemia induces a systemic vaso- and 
venodilation, causing a reflex activation of renal sympathetic activity and the renin-
angiotensin system together with an increased secretion of the renal vasoconstrictor arginine 
vasopressin. This stimulation of the neurohormonal axis will cause a renal vasoconstriction 
and renal ischemia with a predisposition to acute renal failure [5]. 
 This hypothesis was challenged by Langenberg et al who, in a conscious septic sheep 
model, found in that the endotoxinemia-induced hypotension and systemic vasodilation was 
accompanied by a high cardiac output, increased renal blood flow (RBF) and a fall in 
creatinine clearance, a surrogate for glomerular filtration rate (GFR) [6]. In that hyperdynamic 
sepsis model, the fall in creatinine clearance was explained by a renal vasodilation of 
preferentially the efferent arterioles, which will increase RBF but decrease the upstream 
glomerular filtration pressure [6].  
 Data on renal hemodynamics and GFR in clinical sepsis is scarce. Prowle et al 
measured RBF non-invasively by magnetic resonance imaging in 10 patients with established 
septic AKI (90% of the patients were on continuous renal replacement therapy) [7]. They 
found that the renal vascular bed was severely constricted with a RBF being only half of that 
seen in healthy volunteers.  
 5 
 To our knowledge there is a lack of reports on RBF, GFR and renal oxygenation in 
early clinical sepsis. In the present study, we have therefore measured renal perfusion, 
filtration and oxygenation in patients submitted to the intensive care unit (ICU) due to early 
norepinephrine-dependent septic shock requiring mechanical ventilation. RBF was measured 
using the infusion clearance technique for para-aminohippurate (PAH), corrected by renal 
extraction of PAH by a renal vein catheter. Filtration fraction was measured by renal 
extraction of chromium ethylenediamine tetraaceticacid (51Cr-EDTA). Mechanically 
ventilated and sedated post-cardiac surgery patients with no pre- or postoperative renal 
impairment served as controls. We tested the hypothesis that in early norepinephrine-
dependent clinical septic shock, a reduced GFR is accompanied with an increased RBF and 
increased renal oxygen delivery. 
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Material and methods 
The study protocol was approved by the Gothenburg Regional Ethics Committee, and written 
informed consent was obtained from the next of kin. The study was registered in 
ClinicalTrials.gov (identifier NCT02453425). Patients in septic shock were compared to a 
group of post-cardiac surgery patients early after uncomplicated cardiac surgery, at a 
numerical ratio of 1:7. Patients in both groups were studied in the intensive care unit during 
sedation and mechanical ventilation. 
  
Septic patients 
Eight septic patients were prospectively included in the study with the following inclusion 
criteria a) > 18 years of age, b) normal premorbid serum creatinine, c) norepinephrine-
dependent septic shock as defined by the International Surviving Sepsis Campaign Guidelines 
[8, 9], d) normovolemia as indicated by a pulse pressure variation < 12%, e) mechanical 
ventilation and f) inclusion within 24 hours after arrival in the ICU. The exclusion criteria 
were: a) severe circulatory instability refractory to treatment b) renal impairment due to other 
causes than septic shock, c) unsuccessful catheterization of the renal vein, and d) 
contraindication to radio-contrast agents. The patients were mechanically ventilated and 
sedated with propofol (2.23 ± 0.53mg/kg/h) and fentanyl (0.021 ± 0.014 μg/kg/min). 
Postoperative targets were pulse pressure variation < 12% and a mean arterial pressure of 70-
80 mmHg. Postoperative hypovolemia was treated according to routine clinical practice with 
albumin (Albumin Baxalta® 200g/l) and/or crystalloid fluid (Ringer–Acetate®, Baxter 
Viaflo) at the discretion of the attending intensivist.  
 
Control group 
 7 
Fifty-eight patients served as a control group. These patients had earlier been included in 
pharmacological studies performed by our study group [10-13]. Inclusion criteria for this 
group were: a) age >1 \HDUV E) HOHFWiYH FDUGiDF VXUgHU\ F) OHIW YHnWUiFXODU HMHFWiRn IUDFWiRn  
40%, and d) normal preoperative serum creatinine. The exclusion criteria were postoperative 
a) inotropic support, b) arrhythmias requiring treatment, c) significant bleeding, d) 
unsuccessful catheterization of the renal vein, and e) postoperative AKI according to the 
AKIN criteria.  The baseline renal and systemic data of these patients, i.e. before 
pharmacological intervention, were used for comparison with those of the septic shock group. 
The studies were performed postoperatively in the intensive care unit, where the patients were 
sedated with propofol (3.8 ± 0.18 mg/kg/min) and morphine (0.5-1.0 mg/hour), and 
mechanically ventilated. Target central venous pressure (CVP) and target mean arterial 
pressure (MAP) were 5-10 mmHg and 70-80 mmHg, respectively. Postoperative hypovolemia 
was treated according to routine clinical practice with hydroxethylstarch (Venofundin, Braun, 
Germany) and crystalloid fluids (Ringer–Acetate®, Baxter Viaflo).  
 
Measurements of systemic variables 
Arterial blood pressure and heart rate were continuously measured using a catheter in either 
the radial or the femoral artery. Cardiac output was measured by the transthoracic 
thermodilution pulse contour technique using the PiCCO ™ device (Pulsion Ltd, Munich, 
Germany) and by a pulmonary artery thermodilution catheter (Baxter Healthcare Corporation. 
Irvine CA) in the septic shock group, and in the cardiac surgery group, respectively. Cardiac 
index, stroke volume index, systemic oxygen delivery index, systemic oxygen consumption 
index and systemic vascular resistance index were calculated according to standard formulae. 
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Measurements of renal variables 
A 8-Fr catheter (Webster laboratories, Baldwin Park, CA, USA) was introduced via the 
femoral vein centrally into the left or right renal vein, guided by fluoroscopy. An intravenous 
priming dose of PAH (8mg/kg bodyweight) and 51Cr- EDTA (0.6 MBq/m2 BSA), (GE 
Healthcare Limited, The Grove Center, Amersham, UK), were given. This was followed by 
an infusion at a constant rate individualized to body weight and serum creatinine. Serum 
concentrations of PAH and serum 51Cr-EDTA activity from arterial and renal vein blood were 
measured using a spectrophotometer (Beckman DU 530, Life Science UV/Vis, Fullerton, CA) 
and a well counter (Wizard 300, 1480, Automatic Gamma Counter, Perkin Elma LAS, 
Turkuu, Finland), respectively. Renal plasma flow was calculated and measured using the 
infusion clearance technique as the amount of infused PAH divided by the difference in 
arterial- renal vein PAH concentrations [14]. Formulae for calculation of the various renal 
variables are described in table 1. All renal data were normalized to a BSA of 1.73 m2. 
 Urine in the septic group was assayed for N-acetyl-β-d-glucosaminidase (NAG by a 
spectrophotometric method (ABX Pentra 400, Horiba Medical, CA, USA) using a 
commercially available kit (Roche Diagnostics GmbH, Mannheim, Germany). The urinary 
NAG/creatinine ratio was calculated.  

Experimental procedure 
In both the septic and the control group, two 30-minutes urine collection periods were 
conducted after an equilibration period of at least 60 minutes. Cardiac index was measured at 
the end of each of the urine collection periods, followed by arterial, renal vein and mixed 
venous blood sampling and urine sampling for measurements of systemic and renal variables. 
The infusion rates of on-going infusions were not changed during the experimental procedure.

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Statistical analysis 
The primary end-points of this study were RBF and renal oxygen delivery (RDO2). To detect 
a 30% difference in RBF or RDO2 between the control and the septic group, 8-9 patients were 
needed in the septic group and 56-63 patients were needed in the control group at an 
enrolment ratio of 7 and a standard deviation of 250 ml/min (RBF) and 40 ml/min (RDO2) at 
a power of 0.05 and alpha of 0.8 [15]. Intra-group data on renal and systemic variables from 
the two 30- minute periods were pooled. Continuous variables were checked for normal 
distribution using Shapiro-Wilk test. Intergroup differences where compared using 
independent-samples t-test and Mann-Whitney U test when appropriate. Categorical data 
were compared using Fisher’s exact test. PASWStatistics 18.0 (SPSS Inc., Chicago, IL, USA) 
was used for statistical analyses. Data are presented as mean ± SD throughout the text. A p-
value < 0.05 was considered significant.  
  
 8 
Measurements of renal variables 
A 8-Fr catheter (Webster laboratories, Baldwin Park, CA, USA) was introduced via the 
femoral vein centrally into the left or right renal vein, guided by fluoroscopy. An intravenous 
priming dose of PAH (8mg/kg bodyweight) and 51Cr- EDTA (0.6 MBq/m2 BSA), (GE 
Healthcare Limited, The Grove Center, Amersham, UK), were given. This was followed by 
an infusion at a constant rate individualized to body weight and serum creatinine. Serum 
concentrations of PAH and serum 51Cr-EDTA activity from arterial and renal vein blood were 
measured using a spectrophotometer (Beckman DU 530, Life Science UV/Vis, Fullerton, CA) 
and a well counter (Wizard 300, 1480, Automatic Gamma Counter, Perkin Elma LAS, 
Turkuu, Finland), respectively. Renal plasma flow was calculated and measured using the 
infusion clearance technique as the amount of infused PAH divided by the difference in 
arterial- renal vein PAH concentrations [14]. Formulae for calculation of the various renal 
variables are described in table 1. All renal data were normalized to a BSA of 1.73 m2. 
 Urine in the septic group was assayed for N-acetyl-β-d-glucosaminidase (NAG by a 
spectrophotometric method (ABX Pentra 400, Horiba Medical, CA, USA) using a 
commercially available kit (Roche Diagnostics GmbH, Mannheim, Germany). The urinary 
NAG/creatinine ratio was calculated.  

Experimental procedure 
In both the septic and the control group, two 30-minutes urine collection periods were 
conducted after an equilibration period of at least 60 minutes. Cardiac index was measured at 
the end of each of the urine collection periods, followed by arterial, renal vein and mixed 
venous blood sampling and urine sampling for measurements of systemic and renal variables. 
The infusion rates of on-going infusions were not changed during the experimental procedure.

 9 
Statistical analysis 
The primary end-points of this study were RBF and renal oxygen delivery (RDO2). To detect 
a 30% difference in RBF or RDO2 between the control and the septic group, 8-9 patients were 
needed in the septic group and 56-63 patients were needed in the control group at an 
enrolment ratio of 7 and a standard deviation of 250 ml/min (RBF) and 40 ml/min (RDO2) at 
a power of 0.05 and alpha of 0.8 [15]. Intra-group data on renal and systemic variables from 
the two 30- minute periods were pooled. Continuous variables were checked for normal 
distribution using Shapiro-Wilk test. Intergroup differences where compared using 
independent-samples t-test and Mann-Whitney U test when appropriate. Categorical data 
were compared using Fisher’s exact test. PASWStatistics 18.0 (SPSS Inc., Chicago, IL, USA) 
was used for statistical analyses. Data are presented as mean ± SD throughout the text. A p-
value < 0.05 was considered significant.  
  
 10 
Results 
Patient characteristics for the septic group are presented in Table 2. Five patients had 
abdominal sepsis and three had septic pneumonia. The mean SOFA score was 7.9 ± 2.6 at the 
time of the study. The mean serum creatinine at study entry was 91 ± 22 µmol/l (range 73-139 
µmol/l). The mean dose of norepinephrine was 0.23 ± 0.17 µg/kg/min. One patient was 
treated with an infusion of furosemide (20 mg/hour).  
There was a larger portion of females in the study group than in the control group, and 
the study group had a smaller body surface area. Premorbid renal function was higher in the 
septic group, while there was no difference in age or in the prevalence of diabetes between 
groups. Hypertension, as well as, anti-hypertensive medication was more frequent in the 
control group (Table Supplemental Digital Content).  
Systemic variables (Table 3) 
The mean arterial pressure in the control group was slightly (-3.4%) but significantly lower, 
while central venous pressure was significantly higher in the septic group compared to 
control. There was a trend for a lower systemic vascular resistance index in the septic group 
(p=0.059) There were no statistically significant differences between the groups with respect 
to cardiac index, stroke volume index, heart rate, systemic oxygen delivery index, systemic 
oxygen consumption index, serum hemoglobin or arterial oxygen content. 
Renal variables (Table 4, Fig. 1) 
Serum PAH concentration from the two measurement periods did not differ significantly in 
neither of the groups, suggesting that steady state was achieved. The RBF/cardiac index ratio 
was significantly lower in the septic shock group (p=0.003). In the septic group, GFR (-32%, 
p=0.006), renal sodium filtration (-31%, p=0.008), renal sodium reabsorption (-29%, 
p=0.014) and urine flow (-52%, p=0.007) were significantly lower compared to controls. 
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There was a trend for a higher renal vascular resistance (20%, p=0.069) and a lower RBF (-
19%, p=0.068) in the septic group compared to controls. Renal oxygen delivery was 
significantly lower in the septic group (-24%, p=0.037), while there was no difference in renal 
oxygen consumption (RVO2) between the two groups. Renal oxygen extraction, a direct 
measurement of the renal oxygen supply/demand relationship, was significantly higher in the 
septic group (p=0.022). RVO2 per mmol of reabsorbed sodium was higher in the septic group 
(31%, p=0.057) compared to the control group. In the septic group, the urinary N-acetyl-β-
D-glucosaminidase (NAG) / creatinine ratio was 5.4 ± 3.4 units/ µmol creatinine (range 1.9 -
11.4).  
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There was a trend for a higher renal vascular resistance (20%, p=0.069) and a lower RBF (-
19%, p=0.068) in the septic group compared to controls. Renal oxygen delivery was 
significantly lower in the septic group (-24%, p=0.037), while there was no difference in renal 
oxygen consumption (RVO2) between the two groups. Renal oxygen extraction, a direct 
measurement of the renal oxygen supply/demand relationship, was significantly higher in the 
septic group (p=0.022). RVO2 per mmol of reabsorbed sodium was higher in the septic group 
(31%, p=0.057) compared to the control group. In the septic group, the urinary N-acetyl-β-
D-glucosaminidase (NAG) / creatinine ratio was 5.4 ± 3.4 units/ µmol creatinine (range 1.9 -
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Discussion 
In the present study, RBF, GFR and renal oxygenation were measured in an early 
norepinephrine-dependent septic shock. The main findings were that renal oxygen delivery 
was impaired caused by renal vasoconstriction and a redistribution of blood flow away from 
the kidneys when compared to controls. This redistribution of RBF in septic shock impaired 
the renal oxygen supply/demand relationship as evidenced by an increased renal oxygen 
extraction. Thus, these results do not support the concept derived from studies on large 
animals, that AKI in early septic shock is accompanied by renal vasodilation and an increase 
in RBF [6]. On the contrary, the results presented here are in line with the previously 
presented hypothesis that RBF is low due to a renal vasoconstriction resulting in a reduction 
of renal oxygen delivery [5]. 
The redistributon of RBF away from the kidneys could be explained by an increase in 
the tone of the renal afferent arterioles, as there was a decrease in both RBF and GFR in the 
present study. This explanation is supported by the finding that renal filtration fraction 
(GFR/RPF) was unchanged suggestive of a balanced decrease in both GFR and RBF. Such an 
increase of the tone of the afferent arterioles in sepsis has been demonstrated before in 
endotoxemic animals [16]. 
An increased production of nitric oxide (NO) has been demonstrated to result in a 
systemic vasodilation and hypotension in both clinical and experimental sepsis [17, 18] [19, 
20]. Hypotension in sepsis elicits a baroreflex-mediated increase in renal sympathetic nerve 
activity, as demonstrated in animal models of sepsis [21, 22] and in clinical sepsis as an 
elevated plasma norepinephrine level [23]. Thus, a NO-mediated renal vasodilation may be 
antagonised by the increase in renal sympathetic activity in sepsis. Ramchandra et al 
demonstrated, in conscious septic sheep, that the previously described renal vasodilatation [6] 
was accompanied by an increase in renal sympathetic nerve activity, which would promote 
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renal vasoconstriction [22] . They suggested that the profound increase in NO in septic shock 
will override this sympathetically-mediated renal vasoconstriction causing a net renal 
vasodilation. Based on the results of the present study, on the other hand, one could speculate 
that in clinical sepsis, the neuro-hormonal activation dominates over the release of NO, 
causing a renal distribution of RBF away from the kidneys decreasing renal oxygen delivery. 
Thus, the host response to septicemia in terms of renal hemodynamics seem to vary between 
species. 
The fall in GFR in the septic group could be explained by the increased renal 
sympathetic nerve activity, as discussed above. Activation of the renal sympathetic nerve 
activity will cause a reduction in both RBF and GFR, suggesting an effect on preferentially 
the afferent arterioles [24]. Another explanation could be an activation of the tubulo-
glomerular feedback (TGF) mechanism, caused by tubular dysfunction. This would reduce 
sodium reabsorption of individual tubules, increasing the sodium delivery to the macula 
densa, activating the TGF response, inducing afferent arteriolar vasoconstriction with a 
decrease in both RBF and GFR [5, 25]. This hypothesis is supported by the finding that renal 
extraction of PAH was significantly lower in septic shock patients, which is an indicator of 
tubular dysfunction in early clinical sepsis. We find the early fall in GFR, in this study, 
unlikely to be caused by shedding of tubular cells causing tubular obstruction[5], as 
postmortal histopathological findings in septic AKI shows limited tubular injury [26], 
suggesting that the early fall in GFR in clinical sepsis is functional rather than structural in 
nature.  
We have repeatedly shown that there is a close correlation between GFR, tubular 
sodium reabsorption and RVO2 in postoperative patients [10, 12, 14, 15]. Thus, the major 
determinant of RVO2 is the GFR. In the septic shock group, the lower GFR was accompanied 
by a lower tubular sodium reabsorption compared to controls, as expected. However, there 
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was no difference in RVO2 between groups, suggesting that in early clinical septic shock 
there is an increase in oxygen utilization for a certain level of sodium transport. This indicates 
an impaired tubular oxygen utilization, as reflected by the higher oxygen consumption per 
mmol reabsorbed sodium. Such an impairment of tubular oxygen utilization has previously 
been described by us in established AKI after cardiac surgery [15], in patients with tubular 
injury after cardiac surgery with cardiopulmonary bypass [27] and in patients with renal 
dysfunction early after liver transplantation [28]. One explanation for this impaired renal 
oxygen utilization in clinical acute renal dysfunction could be hypoxia-induced loss of 
epithelial cell-polarisation and tight junction integrity [29, 30], or reduced renal production of 
NO which will cause an increase in RVO2 [31, 32]. Finally, the impaired renal oxygen 
utilization could be explained by oxidative stress, which will increase renal mitochondrial 
oxygen consumption [33].  
N-acetyl-β-D-glucosaminidase (NAG) is an enzyme that is originating mainly from the 
proximal tubules in the kidneys. As NAG does not undergo glomerular filtration, urinary 
excretion of NAG is a marker of tubular damage [34]. We have recently shown in 
anesthetized mechanically ventilated patients with normal renal function that baseline, 
presurgical urinary NAG/creatinine is < 3 units/ µmol [27]. In the present study, mean urinary 
NAG/creatinine was found to be approximately 5 units/µmol creatinine and NAG/creatinine 
was > 3 units/µmol in 5 patients, suggesting a tubular injury in this group of patients with 
early clinical septic shock. This could be explained by renal hypoxia due to the impairment of 
the renal oxygen supply/demand relationship, as reflected by the lower renal oxygen delivery 
with a normal RVO2, also expressed as a higher renal oxygen extraction compared to controls. 
One could argue that the lower renal oxygen delivery in the septic shock group was 
caused by the fact norepinephrine was used for treatment of vasodilatory shock. We believe 
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that this is less likely, as we have shown that restoration of mean arterial pressure from 60 to 
75 mmHg by increasing the dose of norepinephrine, improves renal oxygen delivery, GFR 
and renal oxygenation in postoperative patients with norepinephrine-dependent systemic 
vasodilation and AKI [35]. 
Previous data on RBF and GFR in patients with septic shock are controversial. Brenner 
et al studied seven hyperdynamic (CI: 5.5 l/min) septic patients, all being treated with 
dopamine and found that the RBF/cardiac output (CO) ratio was reduced below 10%, 
suggesting a renal vasoconstriction [36]. Rector et al found that the RBF/CO ratio was 
essentially normal in six patients with septic shock [37] There are no data on concomitant 
medication or management of those patients in the study by Rector et al. Furthermore, none of 
those studies presented data from a non-septic mechanically ventilated and sedated control 
group with normal renal function and none demonstrated data on renal oxygenation.  
One limitation of the present study is the low number of included patients with septic 
shock. The strength of our study is that we, for the first time, measured RBF, GFR and renal 
oxygenation in the early phase of clinical septic shock in patients with premorbid normal 
renal function. Furthermore, we included a large group of control patients with 
uncompromised renal function, all being mechanically ventilated and sedated postoperatively 
in the ICU after cardiac surgery, a procedure known to induce a pronounced systemic 
inflammatory response syndrome (SIRS) [38, 39]. 
Conclusions 
We have shown that in patients with early septic shock, there is a fall in GFR and a 
redistribution of RBF away from the kidneys due to renal vasoconstriction, most likely caused 
by a constriction of afferent arterioles when compared to controls. The consequent 
impairment in renal oxygen delivery may explain early signs of tubular dysfunction/injury 
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expressed as a pathological elevation of the tubular injury marker NAG. 
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Legend 
 
Figure 1: Shows the individual data on systemic and renal oxygen delivery in patients with 
early septic shock and in uncomplicated post-cardiac surgery patients with no renal 
impairment. Both groups were sedated and mechanically ventilated in the intensive 
care unit. 
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Table 1 Formulas for calculation of renal variables 
 
Variable Formula 
Renal plasma flow (RPF) Amount of PAH infused/([PAH arterial] − [PAH renal vein]) 
Renal blood flow (RBF) RPF/ (1 − hematocrit) 
Filtration fraction (FF) (RPF × [
51Cr-EDTA arterial] – (RPF – urine flow) × [51Cr-
EDTA renal vein])/(RPF × [51Cr-EDTA arterial]) 
Glomerular filtration rate (GFR) FF x RPF 
Renal vascular resistance (RVR) (MAP-CVP)/RBF 
Arterial-renal vein (rv) oxygen content 
difference (RAVO2-diff) 
(CaO2-CrvO2) 
Renal oxygen consumption (RVO2) RBF × (CaO2-CrvO2) 
Renal oxygen extraction (CaO2-CrvO2/CaO2) 
Renal sodium filtration GFR x [Na+]S 
Renal sodium excretion Urine flow x [Na+]U 
Renal sodium reabsorption (GFR x [Na+]S) – (Urine flow x [Na+]U) 
 
MAP; mean arterial pressure, CVP; central venous pressure, CaO2 and CrvO2; arterial and 
renal vein oxygen contents, [Na+]S; serum sodium concentration, [Na+]U; urine sodium 
concentration   
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Table 2. Individual data on the septic shock patients 
 
 
 
 
CAD; coronary artery disease, PCI; percutaneous coronary intervention, COPD; chronic 
obstructive pulmonary disease, SOFA; sequential organ failure score, S-creatinine; serum 
creatinine 
 
Patient 
no. Age Sex Diagnosis Comorbidity SOFA 
Premorbid 
S-creatinine 
μmol/L 
Study entry 
S-creatinine 
μmol/L 
Norepi- 
nephrine 
µg /kg/min 
1 71 f 
Perforated 
diverticulitis 
CAD treated with 
PCI 7 60 95 0.42 
2 83 m 
Perforated 
colon 
CAD treated with 
PCI. Atrial 
fibrillation. 
6 87 90 0.15 
3 22 f Pneumonia Partus 3 weeks before 10 53 139 0.03 
4 72 f Pneumonia Pancoast tumour 6 56 77 0.55 
5 73 f Rupture of esophagus COPD 5 48 78 0.10 
6 72 m Pneumonia Stroke 9 80 97 0.16 
7 69 f Intestinal perforation 
Esophageal 
cancer 7 66 73 0.20 
8 48 f 
Intestinal 
anastomosis 
insufficiency 
Ovarial cancer 13 61 76 0.27 
Mean 
± SD 
64 
±20    
7.9 
±2.6 
64 
±13 
91 
±22 
0.23 
±0.17 
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Table 3. Systemic hemodynamics 
 
 
Variable 
Control group 
(n=58) 
Septic 
shock  
 (n=8) 
p-value 
Mean arterial pressure (mmHg) 73.2 ± 7.1 76.0 ± 1.3 0.011 
Cardiac index (l/min/m2) 2.8 ± 0.5 3.3 ± 0.6 0.502 
Heart rate (beats/min) 76 ± 11 86 ± 17 0.522 
Stroke volume index (ml/m2) 37.5 ± 7.6 39.8 ± 11.2 0.127 
Central venous pressure (mmHg) 7.8 ± 2.5 10.9 ± 3.0 0.003 
Systemic vascular resistance index  
(dynes x sec/cm3/m2) 
1943 ± 445 1630 ± 305 0.059 
Mixed/central venous oxygen saturation (%)  73.0 ± 4.7 74.8 ± 4.9 0.293 
Serum hemoglobin (g/l) 104.8 ± 12.0 98.8 ± 9.1 0.181 
Systemic oxygen delivery index (ml/min/min2) 392 ± 75 437 ± 78 0.152 
Systemic oxygen consumption index 
(ml/min/min2) 100.6 ± 14.5 99.6 ± 16.2 0.753 
Arterial oxygen content (ml O2/l) 142.9 ± 16.4  133.0 ± 10.9 0.103 
 
Values are means ± SD 
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Table 4. Renal variables 
 
Values are means ± SD 
 
Variable Control group (n=58) 
Septic shock 
(n=8) 
p-value 
Renal oxygen extraction 0.097 ± 0.027 0.124 ± 0.039 0.022 
Urine flow (ml/min) 3.84 ± 2.34 1.85 ± 1.05 0.007 
Renal blood flow (ml/min) 858 ± 261 696 ± 166 0.068 
Renal blood flow/cardiac index 0.31 ± 0.79 0.22 ± 0.67 0.003 
Renal blood flow/cardiac output 0.16 ± 0.42 0.12 ± 0.43 0.028 
Renal vascular resistance (mmHg/ml/min) 0.082 ± 0.023 0.098 ± 0.023 0.069 
Glomerular filtration rate (ml/min) 79.8 ± 24.3 54.4 ± 17.6 0.006 
Filtration fraction 0.140 ± 0.033 0.120 ± 0.052 0.306 
Renal sodium filtration (mmol/min) 11.0 ± 3.4 7.6 ± 2.5 0.008 
Renal sodium reabsorption (mmol/min) 10.5 ± 3.3 7.5 ± 2.5 0.014 
Renal oxygen delivery (ml/min) 122.3 ± 42.4 92.7 ± 23.5 0.037 
Renal oxygen consumption (ml/min) 11.4 ± 3.1 11.4 ± 4.0 0.956 
Renal oxygen consumption / renal sodium 
reabsorption (ml/mmol)  
1.12 ± 0.25 1.62 ± 0.71 0.057 
Renal extraction of para-aminohippurate 0.84 ± 0.07 0.66 ± 0.22 0.005 
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